[
  {
    "brandName": "",
    "chemicalName": "mrna-1273",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 13 Jan 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 04 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 11 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "mrna-based vaccine",
    "numSites": "2",
    "otherPartners": "cepi",
    "phase": "1",
    "preferredName": "mrna-1273",
    "productId": 1,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Seattle",
        "country": "US",
        "lat": 47.6169397,
        "lng": -122.329572,
        "locationId": "a6018262eeb2425434539c72bd2bc1cf527bca54",
        "name": "1730 Minor Ave, Seattle, WA 98101, USA",
        "state": "WA"
      },
      {
        "city": "Atlanta",
        "country": "US",
        "lat": 33.7934917,
        "lng": -84.3195325,
        "locationId": "a20a7fbfc641e0fed17496f7f38d14ea4ba6c6a3",
        "name": "1405 E Clifton Rd NE, Atlanta, GA 30322, USA",
        "state": "GA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "375ad6c4b12a03acefcf5e9b052423279351910a",
        "sponsorName": "Moderna"
      },
      {
        "sponsorId": "69301ed353817a1eb80b77b32f82e5809965a871",
        "sponsorName": "National Institute of Allergy and Infectious Diseases"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": "nct04283461"
  },
  {
    "brandName": "",
    "chemicalName": "novavax vaccine",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "not totally clear that it is prophylactic vaccine. p1 expected late spring",
    "numSites": "",
    "otherPartners": "cepi",
    "phase": "",
    "preferredName": "novavax vaccine",
    "productId": 2,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "605f6647f1bdd3849bac0626225a6effc774a373",
        "sponsorName": "Novavax Inc"
      },
      {
        "sponsorId": "f4d20a236175ba7e1926d1e68974b9e499bd94ed",
        "sponsorName": "Emergent BioSolutions Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "bnt-162",
    "conditionOrDisease": "",
    "countries": ["germany"],
    "countryCodes": ["deu"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "expect clinical testing in late april. note this drug is also being developed in china with fosun pharma. assumed this is in discovery as no explicit statements aboit preclinical found",
    "numSites": "",
    "otherPartners": "polymun",
    "phase": "",
    "preferredName": "bnt162",
    "productId": 3,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7c4d34cd18acefd9b97f8b918fe356fec61f94d6",
        "sponsorName": "Pfizer Inc"
      },
      {
        "sponsorId": "633c14412c5bdb1e419eeef95aef4fe8eb93e2a1",
        "sponsorName": "BioNTech SE"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "imperial college london vaccine",
    "conditionOrDisease": "",
    "countries": ["united kingdon"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "expect clinical testing in summer",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "imperial college london vaccine",
    "productId": 4,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "cellectraÂ®",
    "chemicalName": "ino-4800",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 23 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "us dod,bill and melinda gates foundation,coalition for epidemic prepardness innovations funding",
    "phase": "1",
    "preferredName": "ino-4800",
    "productId": 5,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": null,
        "country": "US",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "4fbd6454566c6f303ca18ea84340ce056b96f257",
        "name": "United States",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a28cb988e230163b5e185750856269de4f3cd2eb",
        "sponsorName": "Inovio Pharmaceuticals Inc"
      },
      {
        "sponsorId": "2534fc505ec4a7e9f4871746ebd7fe5a84b18af8",
        "sponsorName": "Beijing Advaccine Biotechnology"
      },
      {
        "sponsorId": "09820e27323251c097da890722d6b1060e453555",
        "sponsorName": "US Department of Defense"
      },
      {
        "sponsorId": "8b02e4cb59e0603882788f6b09eece49a6f530e2",
        "sponsorName": "Ology Bioservices Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "ad26 sars-cov-2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["belgium"],
    "countryCodes": ["bel"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "gene therapies",
    "notes": "expect clinical testing no later than fall 2020",
    "numSites": "",
    "otherPartners": "barda",
    "phase": "",
    "preferredName": "ad26 sars-cov-2",
    "productId": 6,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "sanofi vaccine",
    "conditionOrDisease": "",
    "countries": ["france"],
    "countryCodes": ["fra"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "they are repurposing vaccines that have been preclinically tested for sars - hence i have put the current status as preclinical",
    "numSites": "",
    "otherPartners": "barda",
    "phase": "",
    "preferredName": "sanofi vaccine",
    "productId": 7,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      },
      {
        "sponsorId": "e0bdadccf43d8757f432e13f07484a9d84e509c7",
        "sponsorName": "BARDA"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "regeneron therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "plan to start human trials in summer 2020. technique was previously used to develop successful regn-eb3 ebola treatment.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "regeneron therapeutic",
    "productId": 8,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      },
      {
        "sponsorId": "fc75c1a3f384fb950104d48eeee9665cc126614f",
        "sponsorName": "HHS"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "vaxart vaccine",
    "chemicalName": "vaxart vaccine",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "oral tablet. recombinant vaccine. plan to initiate phase i trial in second half of 2020.",
    "numSites": "",
    "otherPartners": "emergent",
    "phase": "",
    "preferredName": "vaxart vaccine",
    "productId": 9,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "80a6767f041a7aef5269023e2f54d91aa27066da",
        "sponsorName": "Vaxart"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "university of queensland vaccine",
    "conditionOrDisease": "",
    "countries": ["australia"],
    "countryCodes": ["aus"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "plans for clinical trials in july in queensland.",
    "numSites": "",
    "otherPartners": "cepi,the queensland government,paul ramsay foundation,a2 milk company",
    "phase": "",
    "preferredName": "university of queensland vaccine",
    "productId": 10,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "83489a1277ddc5cf37050ab7342ac914748abdc2",
        "sponsorName": "University of Queensland"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "vido-intervac vaccine candidate",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "canadian federal government",
    "phase": "",
    "preferredName": "vido-intervac vaccine candidate",
    "productId": 11,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "52a54b2f0746508531714d16ee2993cb5ff764a5",
        "sponsorName": "International Vaccine Centre"
      },
      {
        "sponsorId": "7ffe768f0f9cf49a08e526fad894319b1b874d64",
        "sponsorName": "University of Saskatchewan"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "chadox1 ncov-19",
    "conditionOrDisease": "coronavirus",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "university of oxford",
    "phase": "1/2",
    "preferredName": "chadox1 ncov-19",
    "productId": 12,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b91bf90d7d04e343ba36d6ff216e09bcbdf60f8f",
        "sponsorName": "Jenner Institute"
      },
      {
        "sponsorId": "d1cf38e4f7d70b602814433c015565b664ba5fa5",
        "sponsorName": "Oxford Vaccine Group"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "niv pune vaccine candidate",
    "conditionOrDisease": "",
    "countries": ["india"],
    "countryCodes": ["ind"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "niv pune vaccine candidate",
    "productId": 13,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "db62a75311d8473967f358928e8460e901771f76",
        "sponsorName": "National Institute of VirologyPune"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "animal testing",
    "numSites": "",
    "otherPartners": "stermirna therapeutics co. ltd",
    "phase": "",
    "preferredName": "chinese_center_for_disease_control_and_prevention_tongji_university_school_of_medicine_stermirna_therapeutics_co_ltd-14",
    "productId": 14,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "52d02c14b6240aabfbdc4ded5640e554e55e2ca1",
        "sponsorName": "Chinese Center for Disease Control and Prevention"
      },
      {
        "sponsorId": "5f73dfa644e6480f6632298372551fe30f6bfc70",
        "sponsorName": "Tongji University School of Medicine"
      },
      {
        "sponsorId": "3020404bf63cebc77d8c10a2cc920657b5249ee2",
        "sponsorName": "Stermirna Therapeutics Co Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "university of hong kong vaccine",
    "chemicalName": "delns1-sars-cov2-rbd laiv",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "whole-pathogen vaccines",
    "notes": "live-attenuated vaccine. plans for clinical trials in july. proof of concept testing done using mers-cov and various animal models.",
    "numSites": "",
    "otherPartners": "cepi,xiamen university,changchun-baike,hualan-bio,beijing wantai,sinovac,cnbg",
    "phase": "",
    "preferredName": "delns1-sars-cov2-rbd laiv",
    "productId": 15,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6b014b07406a291e8e325b2a212ac65562a16644",
        "sponsorName": "University of Hong Kong"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["germany"],
    "countryCodes": ["deu"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "not named yet,2 products currently undergoing animal studies,plan to start a clinical trial in early summer",
    "numSites": "",
    "otherPartners": "cepi",
    "phase": "",
    "preferredName": "curevac_ag-16",
    "productId": 16,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "40795cb229b892237d8be44830cd652481d40676",
        "sponsorName": "CureVac AG"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ad5-ncov",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "gene therapies",
    "notes": "vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express sars-cov-2 spike protein,immunogenic action,current study is assessing evaluate the safety reactogenicity and immunogenicity,active but not recruiting",
    "numSites": "1",
    "otherPartners": "institute of biotechnology-academy of military medical sciences-pla of china,jiangsu province centers for disease control and prevention,hubei provincial center for disease control and prevention,tongji hospital",
    "phase": "1",
    "preferredName": "ad5-ncov",
    "productId": 17,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "55e07a379cb17727226339407a902ef5bc142106",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ae6d6a42f1f04b04f866b7d03b344389efca16ee",
        "sponsorName": "CanSino Biologics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04313127"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "using existing vaccine platform called gv-mva-vlp,3 candidates have been identified,animal trials soon to begin",
    "numSites": "",
    "otherPartners": "bravovax",
    "phase": "",
    "preferredName": "geovax_labs_inc-18",
    "productId": 18,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f5413cebc2f1a8871f47600364147dc47dbb9ad1",
        "sponsorName": "GeoVax Labs Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ino-4700 - appears to not be for 2019-ncov",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ino-4700 - appears to not be for 2019-ncov",
    "productId": 19,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a28cb988e230163b5e185750856269de4f3cd2eb",
        "sponsorName": "Inovio Pharmaceuticals Inc"
      },
      {
        "sponsorId": "a16b70b82bdd9b5e61c50e750862a8851ee80507",
        "sponsorName": "GeneOne Life Science"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "medicago vaccine",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "medicago vaccine",
    "productId": 20,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e59212c9eed9f476dcb441a9645267e5e6b915c2",
        "sponsorName": "Medicago"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "adcovid (based on nasovax)",
    "chemicalName": "nasovax analog (not currently specified)",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "gene therapies",
    "notes": "this is a repurposing of the nasovax technology (recombinant intranasal) for a covid-19 vaccine,it should be noted that the provided source on atimmune's nasovax-based covid-19 vaccine was published on february 28. since then there has been no news on the vaccine until march 30 which is when a new article was published stating that altimmune will collaborate with uab to develop adcovid. because adcovid possesses the same characteristics as the nasovax analog (recombinant vaccine - single-dose - and intranasal) i believe that this entry should be reclassified as adcovid. nasovax is still currently in a phase 2a trial so i have opted to classify adcovid as a repurposed-not approved product. currently working on preclinical animal studies and characterization of vaccine immunogenicity,aims to receive ind approval and enable phase 1 by q3 2020",
    "numSites": "",
    "otherPartners": "university of alabama at birmingham (uab)",
    "phase": "",
    "preferredName": "nasovax analog (not currently specified)",
    "productId": 21,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e97fb449c577795bfb9ae1692146c17455a06ef8",
        "sponsorName": "Altimmune"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "ibv",
    "chemicalName": "avian coronavirus infectious bronchitis virus (ibv) vaccine",
    "conditionOrDisease": "",
    "countries": ["israel"],
    "countryCodes": ["isr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "whole-pathogen vaccines",
    "notes": "adaption of avian coronavirus infectious bronchitis virus vaccine for human use. this is an adaptation of the ibv vaccine (against poultry coronavirus) for use in humans against covid-19,ibv vaccine was based on a protein expression vector and the covid vaccine will likely work in a similar manner,the israeli ministries plan to accelerate the approval process to bring the vaccine to the market asap,migal believes the vaccine could enter phase 1 by june 1,it is still in the final stages of development due to delays in receiving the genetic construct,migal has begun trials in mice",
    "numSites": "",
    "otherPartners": "israel innovation authority,health ministry and the headquarters of the national digital israel initiative",
    "phase": "",
    "preferredName": "avian coronavirus infectious bronchitis virus (ibv) vaccine",
    "productId": 22,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "83dd887c3fd8789867722d2edd6b259ee645f1a3",
        "sponsorName": "MIGAL Research Institute"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "tnx-1800",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "modified horsepox virus designed to express the sars-cov-2 spike protein,currently in the pre-clinical stage of development and tonix expects preliminary data from animal experiments in q3 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tnx-1800",
    "productId": 23,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "40e82256fff7abb570316aa4f46cf693fc0c6c98",
        "sponsorName": "Tonix Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "pds_biotechnology_corp-449",
    "productId": 449,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3a55329a850b005a641bf3bda030265211c6969",
        "sponsorName": "PDS Biotechnology Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "s-trimer",
    "chemicalName": "recombinant subunit vaccine",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "glaxosmithkline",
    "phase": "",
    "preferredName": "recombinant subunit vaccine",
    "productId": 24,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ad3e27aa56a9275005c084d1c2ca3c71cc945a1",
        "sponsorName": "Clover Biopharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "linear dna vaccine",
    "conditionOrDisease": "",
    "countries": ["united states", "rome - italy"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "pcr produced linear dna vaccine",
    "numSites": "",
    "otherPartners": "applied dna sciences,takis biotech",
    "phase": "",
    "preferredName": "linear dna vaccine",
    "productId": 25,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "35a1314de34e0181bb072a8ab28865c9f1cdecc1",
        "sponsorName": "Applied DNA Sciences"
      },
      {
        "sponsorId": "3d80bed6c0a0fd89072a0112ae97d02303dc1b5e",
        "sponsorName": "Takis Biotech"
      },
      {
        "sponsorId": "ea1f0842312281e699947cd442445fd782ddde1c",
        "sponsorName": "Linearx Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "nanoflu",
    "chemicalName": "full length s trimers/nanoparticle + matrix m",
    "conditionOrDisease": "seasonal flu/influenza",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "recombinant quadrivalent seasonal influenza vaccine using hemagglutinin (ha) protein nanoparticles",
    "numSites": "19",
    "otherPartners": "novavax,emergent biosolutions inc,cepi",
    "phase": "3",
    "preferredName": "nanoflu",
    "productId": 26,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b83afd40b4f01cc1236b6df8d6a2476e04cb0bac",
        "sponsorName": "Novavax"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "predictive oncology vaccine ai platform",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "unknown",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "unknown",
    "notes": "note the platform is for drugs and vaccines",
    "numSites": "",
    "otherPartners": "soluble therapeutics",
    "phase": "",
    "preferredName": "predictive oncology vaccine ai platform",
    "productId": 27,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5e5fd3a94173dbc6792d6963099af3d35fffc59a",
        "sponsorName": "Predictive Oncology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "integral_molecular__not_developing_vaccine_or_drug-28",
    "productId": 28,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1d80e80fd8d52ab6db14ba080480f1482b091f85",
        "sponsorName": "Integral Molecular  NOT DEVELOPING VACCINE OR DRUG"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "aj vaccines",
    "chemicalName": "s protein vaccine",
    "conditionOrDisease": "",
    "countries": ["denmark"],
    "countryCodes": ["dnk"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "the vaccine being developed is an s protein vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "s_protein_vaccine",
    "productId": 29,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f3d84a99a68fdd7ad327bbc8ce41458fc29dec50",
        "sponsorName": "AJ Vaccines"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccines",
    "trialId": ""
  },
  {
    "brandName": "gs-5734",
    "chemicalName": "remdesivir",
    "conditionOrDisease": "covid 19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 15 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "other trials undertaken by niad-usa,inserm-france,china japanese friendship hospital,no of study is increasing rapidly",
    "numSites": "41",
    "otherPartners": "gilead sciences",
    "phase": "3",
    "preferredName": "remdesivir",
    "productId": 30,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cbb34f9aed92e21ff89501b842a385faabf9c8c6",
        "sponsorName": "Gilead Sciences Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "kaletra,aluvia",
    "chemicalName": "lopinavir,ritonavir",
    "conditionOrDisease": "2019-ncov",
    "countries": ["multiple"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. some studies are published: https://www.nejm.org/doi/pdf/10.1056/nejmoa2001282?articletools=true,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. note that for the highest study there were multiple phase 4 so i picked the largest one that had alrady started recruiting",
    "numSites": "1",
    "otherPartners": "abbvie",
    "phase": "4",
    "preferredName": "lopinavir,ritonavir",
    "productId": 31,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "13d59996aa51adcd58d0147ed49d522c15c0b9ae",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "69e116d4f9df799550df0e74438d37589994fb45",
        "sponsorName": "AbbVie"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "kevzara",
    "chemicalName": "sarilumab",
    "conditionOrDisease": "covid-19",
    "countries": ["unites states"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "57",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "sarilumab",
    "productId": 32,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      },
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "plaquenil",
    "chemicalName": "hydroxychloroquine",
    "conditionOrDisease": "covid 19",
    "countries": ["na"],
    "countryCodes": ["nam"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "not listed",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "hydroxychloroquine",
    "productId": 33,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a5091ee00972baec20a88b0bfc29cf8df11fc10e",
        "sponsorName": "Sanofi SA"
      },
      {
        "sponsorId": "11f8e68d5ce8289f7c1254157f73a6429006ed8c",
        "sponsorName": "Amneal Pharmaceuticals INc"
      },
      {
        "sponsorId": "a951d8e8824303ff34be3adad3b714181ce40092",
        "sponsorName": "Rising Pharma Holdings Inc"
      },
      {
        "sponsorId": "d49e1350f4c21eef623eb4e22b9709b13ac08f82",
        "sponsorName": "University of Minnesota"
      },
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      },
      {
        "sponsorId": "c6596b3fee7a992d790e288b27e50edfb07b5974",
        "sponsorName": "IHUMÃ©diterranÃ©e Infection"
      },
      {
        "sponsorId": "de07adc682970664b17a2475d74c5691cd707ef6",
        "sponsorName": "Sandoz Inc"
      },
      {
        "sponsorId": "67da3aa3718d35ed721af558ab42d840a58dfdbe",
        "sponsorName": "Bayer AG"
      },
      {
        "sponsorId": "00a23d14d5c43daa469abd0a9c6a20c98de6e086",
        "sponsorName": "University of Washington"
      },
      {
        "sponsorId": "d0b12c5f18dc027ada9bc28c72459c2e0d798809",
        "sponsorName": "PatientCenterede Outcomes Research Institute"
      },
      {
        "sponsorId": "03fdeb1f847122b01435c2cc44a82112b2f1e5c9",
        "sponsorName": "World Health Organization"
      },
      {
        "sponsorId": "f87860860d12518378b68c8b4c2d0d61407eac5a",
        "sponsorName": "New York State Department of Health"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "tjm2",
    "chemicalName": "tj003234",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 18 Mar 2019 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "antibody against gm-csf. previously passed a phase 1 trial. inds submitted for phase ii clinical trials in china usa and south korea.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tj003234",
    "productId": 34,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4d5fc82efed329adf6897a54f395828e900a3a4d",
        "sponsorName": "IMab Biopharma"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "at-100",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "recombinant surfactant protein developed to treat bronchopulmonary dysplatia. no timeline for clinical trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "at-100",
    "productId": 35,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cce5891ec7c3582e4abbb8a5a1675065288b051b",
        "sponsorName": "Airway Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "tzls-501",
    "conditionOrDisease": "",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "tiziana life sciences,novimmune",
    "phase": "",
    "preferredName": "tzls-501",
    "productId": 36,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2a18b405cfddff30dc89c827294ce141e1078ed6",
        "sponsorName": "Tiziana Life Sciences"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "oya1",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "oyagen",
    "phase": "",
    "preferredName": "oya1",
    "productId": 37,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "09c1011fb00f7f2c97e9b4ebc1373e23f10f3703",
        "sponsorName": "OyaGen"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "bpi-002",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "also being considered as a vaccine adjuvant to stimulate long term immunity,very little information is available on development stages - a patent has been filed for it by the company but it is not clear what that translates to,information in column t was seen on just one website",
    "numSites": "",
    "otherPartners": "beyondspring inc",
    "phase": "",
    "preferredName": "bpi-002",
    "productId": 38,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bdc58d6b3c51adacec8fd2e5f71d1d5d71046d8d",
        "sponsorName": "BeyondSpring Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "np-120 (ifenprodil)",
    "conditionOrDisease": "idiopathic pulmonary fibrosis",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 19 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "therapeutic approach - receptor antagonist,drug originally evaluated for treatment of idiopathic pulmonary fibrosis",
    "numSites": "",
    "otherPartners": "cascade chemistry",
    "phase": "2",
    "preferredName": "np-120 (ifenprodil)",
    "productId": 39,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4ec6ff9fa7840783f9d6a9a99ce82cc52a732239",
        "sponsorName": "Algernon Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "apn01",
    "conditionOrDisease": "covid-19",
    "countries": ["austria"],
    "countryCodes": ["aut"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "9",
    "otherPartners": "austrian government",
    "phase": "2",
    "preferredName": "apn01",
    "productId": 40,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Innsbruck",
        "country": "AT",
        "lat": 47.2692124,
        "lng": 11.4041024,
        "locationId": "3b3c933b786906ba7d9e18d54a9faf1d7f7ef27a",
        "name": "Innsbruck, Austria",
        "state": "Tyrol"
      },
      {
        "city": "Vienna",
        "country": "AT",
        "lat": 48.2081743,
        "lng": 16.3738189,
        "locationId": "6d6ab2914a1128322effa7d1980016caf27914c7",
        "name": "Vienna, Austria",
        "state": "Vienna"
      },
      {
        "city": "Vienna",
        "country": "AT",
        "lat": 48.2081743,
        "lng": 16.3738189,
        "locationId": "6d6ab2914a1128322effa7d1980016caf27914c7",
        "name": "Vienna, Austria",
        "state": "Vienna"
      },
      {
        "city": "Copenhagen",
        "country": "DK",
        "lat": 55.6760968,
        "lng": 12.5683372,
        "locationId": "86f72934b80db72866e586c2214d3c67d685b3f5",
        "name": "Copenhagen, Denmark",
        "state": null
      },
      {
        "city": null,
        "country": "DK",
        "lat": 55.736943,
        "lng": 12.4215514,
        "locationId": "35ae21472c3f1162111d025710c76111a5a238b3",
        "name": "Herlev Municipality, Denmark",
        "state": null
      },
      {
        "city": "HillerÃ¸d",
        "country": "DK",
        "lat": 55.927909,
        "lng": 12.300806,
        "locationId": "25d537faa42d795d05e69592cf4a5c94e94c55fb",
        "name": "3400 HillerÃ¸d, Denmark",
        "state": null
      },
      {
        "city": "Hvidovre",
        "country": "DK",
        "lat": 55.64252200000001,
        "lng": 12.4753859,
        "locationId": "5957843170ba4696a42cc098bcabe084e0768db4",
        "name": "2650 Hvidovre, Denmark",
        "state": null
      },
      {
        "city": "Hamburg",
        "country": "DE",
        "lat": 53.5510846,
        "lng": 9.9936819,
        "locationId": "dc0bb352aed3c7ba0d64f6fccc80d28f4a5e4fe9",
        "name": "Hamburg, Germany",
        "state": "HH"
      },
      {
        "city": "Munich",
        "country": "DE",
        "lat": 48.1351253,
        "lng": 11.5819805,
        "locationId": "5c3028fefab9d217dec01dfaae4f9f941e7dcc78",
        "name": "Munich, Germany",
        "state": "BY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6f60b15593583caa5a157b68e379e898ed540bfe",
        "sponsorName": "University of British Columbia"
      },
      {
        "sponsorId": "135275cdf7dd39808bf7b9ddb4115db4750d3cdc",
        "sponsorName": "APEIRON Biologics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04335136"
  },
  {
    "brandName": "brilacidin",
    "chemicalName": "brilacidin tetrahydrochloride",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "innovation pharamaceuticals",
    "phase": "",
    "preferredName": "brilacidin tetrahydrochloride",
    "productId": 41,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d74b3bc88aff79062ddc7572f048d10a2f1b7254",
        "sponsorName": "Innovation Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "pro-140",
    "chemicalName": "leronlimab",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "patient treatment underway via emergency ind,phase 2 trial protocol filed",
    "numSites": "",
    "otherPartners": "redchip companies",
    "phase": "",
    "preferredName": "leronlimab",
    "productId": 42,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a5c509d28e5944d0d7121691e82a49f47e20f7ef",
        "sponsorName": "CytoDyn"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "btx-025",
    "chemicalName": "novel viral inhibitor",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "novel galectin inhibitor for use in covid-19. currently pre-clinical.",
    "numSites": "",
    "otherPartners": "bioxytran",
    "phase": "",
    "preferredName": "novel viral inhibitor",
    "productId": 43,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6e5983b2fe019c343dfaeb0ad2e7419f3dfaa118",
        "sponsorName": "BIOXYTRAN"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "actemra",
    "conditionOrDisease": "severe covid-19 pneumonia",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "first approved anti-il-6 receptor biologic available in both intravenous (iv) and subcutaneous (sc) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (ra).",
    "numSites": "not disclosed",
    "otherPartners": "roche",
    "phase": "3",
    "preferredName": "actemra",
    "productId": 44,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Independence",
        "country": "US",
        "lat": 37.2268697,
        "lng": -95.74036489999999,
        "locationId": "b57905eaba2d52aca7e6f84155cab9074e1490ea",
        "name": "2700 W Main St, Independence, KS 67301, USA",
        "state": "KS"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "galidesivir",
    "chemicalName": "bcx4430",
    "conditionOrDisease": "yellow fever",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "neucleoside analogue for yellow fever broad spectrum.",
    "numSites": "not disclosed",
    "otherPartners": "niaid,barda-nih",
    "phase": "1",
    "preferredName": "bcx4430",
    "productId": 45,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0b4eda6dd2c2599e8ad9c5c9117893d90ae570f4",
        "sponsorName": "Biocryst Pharma"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "regn3048-3051",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "there is conflicting information. i found a trial that used these drugs for mers suggesting it is reporpused-not approved but here it says they are starting a first in human trial: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/",
    "numSites": "",
    "otherPartners": "national institute of allergy and infectious diseases (niaid)",
    "phase": "1",
    "preferredName": "regn3048-3051",
    "productId": 46,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "cannot identify study"
  },
  {
    "brandName": "",
    "chemicalName": "sng001",
    "conditionOrDisease": "covid-19",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "inhaled forumation of beta-1a interferon",
    "numSites": "20",
    "otherPartners": "public funding through shares",
    "phase": "2",
    "preferredName": "sng001",
    "productId": 47,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "GB",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "a57b0c3cc65858327313fd551f25d352d5ce5768",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "844645398c47a20691e7b88009bf4a28ca9e0a56",
        "sponsorName": "Synairgen Research"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "amnioboost",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "",
    "numSites": "1",
    "otherPartners": "lattice biologics",
    "phase": "1",
    "preferredName": "amnioboost",
    "productId": 48,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Seattle",
        "country": "US",
        "lat": 47.6062095,
        "lng": -122.3320708,
        "locationId": "12f0390a608c98a7783bde49799b823a98b19a2d",
        "name": "Seattle, WA, USA",
        "state": "WA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3269ba5b3b1fa17511555e6336cff3ddd90b84b2",
        "sponsorName": "Lattice Biologics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "unknown",
    "notes": "direct acting antiviral",
    "numSites": "",
    "otherPartners": "enanta pharmaceuticals",
    "phase": "",
    "preferredName": "enanta_pharmaceuticals-49",
    "productId": 49,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7bf6d2f389a2e6a86e1d696dcc1c2052ef9a9eae",
        "sponsorName": "Enanta Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "vaxart",
    "chemicalName": "vaast",
    "conditionOrDisease": "covid-19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 19 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sun, 19 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "recombinant vaccines",
    "notes": "oral vaccine,recombinant adenovirus expressing ha,non-replicating viral vector",
    "numSites": "",
    "otherPartners": "emergent biosolutions,vaxart",
    "phase": "1",
    "preferredName": "vaast",
    "productId": 50,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cd5be69c518689ef12547e8559a4ff1c7ebed1d1",
        "sponsorName": "Emergent BioSolutions"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "adenoviral vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "adenoviral_vector_vaccine",
    "productId": 450,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b79c8bf08e2131d6f17af795021cda7e20aa3f7",
        "sponsorName": "Reithera Srl"
      },
      {
        "sponsorId": "ed3ecc44d1a89a98ad8d14b1eba036c34af14330",
        "sponsorName": "Keukocare AG"
      },
      {
        "sponsorId": "c6d3d92f1e1dc0abb834bfa3a90e55ad9bbaf8d3",
        "sponsorName": "Univercells SA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "leaps covid-19",
    "conditionOrDisease": "covid-19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "immunotherapy",
    "numSites": "",
    "otherPartners": "cel-sci,university of georgiaâs (ugaâs) center for vaccines",
    "phase": "1",
    "preferredName": "leaps covid-19",
    "productId": 51,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7146a8671f847f80a0c4c99c0466916089840d58",
        "sponsorName": "CELSCI"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "tak-888",
    "chemicalName": "anti-sars-cov-2 polyclonal hyperimmune globulin (h-ig)",
    "conditionOrDisease": "covid-19",
    "countries": ["japan"],
    "countryCodes": ["jpn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 03 Jun 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "a plasma-derived therapy",
    "numSites": "",
    "otherPartners": "takeda pharmaceutical company",
    "phase": "1",
    "preferredName": "anti-sars-cov-2 polyclonal hyperimmune globulin (h-ig)",
    "productId": 52,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ab95e09c1c41756dc8b947ebd1fa0e087a23da6c",
        "sponsorName": "Takeda Pharmaceutical Company"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "azithromycin,hydroxychloroquine",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "pfizer",
    "phase": "",
    "preferredName": "azithromycin-hydroxychloroquine combination",
    "productId": 53,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      },
      {
        "sponsorId": "fd203d1438cfd911102049306e6081fba3f89b87",
        "sponsorName": "Intermountain Healthcare"
      },
      {
        "sponsorId": "e8c2d02eac49d122b3733cdbc1e0009caae5b4c7",
        "sponsorName": "University of Utah Health"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ot-101",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "appears to still be in vitro testing",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ot-101",
    "productId": 54,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "839146f1d67c1b00a841adde72a3555186ed2ee2",
        "sponsorName": "Mateon Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "remdesivir - duplicate?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "remdesivir",
    "productId": 55,
    "repurposed": "repurposed",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "597be3ec42623eb2b339b165717d84c7c3137601",
        "sponsorName": "Columbia University"
      }
    ],
    "status": "",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "southwest research institute screening platform",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "unknown",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 19 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "texas biomedical research institute",
    "phase": "",
    "preferredName": "southwest_research_institute_screening_platform",
    "productId": 56,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "24d9d6c7cef2fb07a9bf63de1e32e0d49e73466f",
        "sponsorName": "Southwest Research Institute"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "nanoviricides therapeutic",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nanoviricides_therapeutic",
    "productId": 57,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ce9215688edb9650cbc3b3d92876af43dd53d52b",
        "sponsorName": "NanoViricides"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "vir-7831",
    "chemicalName": "modified anti-sars-cov-2 antibodies",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "2 different modifications of one single clone of antibody originally developed against sars-cov-1,shown to act as both vaccine and therapeutic",
    "numSites": "",
    "otherPartners": "wuxi biologics,biogen",
    "phase": "",
    "preferredName": "modified anti-sars-cov-2 antibodies",
    "productId": 58,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c32fa743ed510db10e7c97fd975d2a2a5700a4a",
        "sponsorName": "Vir Biotechnology Inc"
      },
      {
        "sponsorId": "7b6f419a075a9d4cfc1742367fdc3d11cc35f994",
        "sponsorName": "Biogen Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "sirna against  sars-cov-1/2",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "350 candidates undergoing in vitro test",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sirna against  sars-cov-1/2",
    "productId": 59,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165",
        "sponsorName": "Alnylam"
      },
      {
        "sponsorId": "ec6e5f3e381b52ffa801d3826f90ffc80615c431",
        "sponsorName": "Vir Biotechnology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "sirna against  sars-cov-2",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "150 candidates under in vitro test",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sirna against  sars-cov-2",
    "productId": 60,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4d4713f1054b2bc9d367a86155cb363519d5ad5",
        "sponsorName": "Sirnaomics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "antibodies",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "monoclonal antibodies,500 antibody sequences isolated 03/12/2020",
    "numSites": "",
    "otherPartners": "vaccine research centre - niaid",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 61,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3e548eb19a8c76ea5f8eeabdbc8086a91e469af",
        "sponsorName": "AbCellera Biologics"
      },
      {
        "sponsorId": "3415f73b4bae4701d6612a2aa318423dc3c571b2",
        "sponsorName": "Eli Lilly and Company"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "bdb-001",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "anti-c5a antibody,phase 2 trial number 2020l0003",
    "numSites": "",
    "otherPartners": "staidson (beijing) biopharmaceuticals co. ltd,inflarx",
    "phase": "2",
    "preferredName": "bdb-001",
    "productId": 62,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ff5ce7f46efeff43870c4a88459cedf1e13cc9c1",
        "sponsorName": "Beijing Defengrei Biotechnology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "sylvant",
    "chemicalName": "siltuximab",
    "conditionOrDisease": "covid-19",
    "countries": ["england"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "clinical trial nct04322188 started but phase unknown",
    "numSites": "1",
    "otherPartners": "ergomed",
    "phase": "unknown",
    "preferredName": "siltuximab",
    "productId": 63,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Bergamo",
        "country": "IT",
        "lat": 45.68707329999999,
        "lng": 9.639130699999999,
        "locationId": "8495fcc3ac06291f7ee9fbc358f8f213eed6a207",
        "name": "Piazza OMS, 1, 24127 Bergamo BG, Italy",
        "state": "Lombardia"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "887084fb166ace787dba446286c132705fbea1b3",
        "sponsorName": "EUSA Pharma"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "47d11",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "monoclonal antibodies",
    "numSites": "",
    "otherPartners": "mount sinai,utrecht university,eurasmus mc",
    "phase": "",
    "preferredName": "47d11",
    "productId": 64,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4e2f58ce0e723737336ad8f95d829829f4eca5cd",
        "sponsorName": "Harbour Biomed"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "polytope mab therapy",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "monoclonal antibodies",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "polytope mab therapy",
    "productId": 65,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7670240cc18d7cdc6c4cdc1e43d130218caa45c4",
        "sponsorName": "ImmunoPrecise Antibodies Ltd"
      },
      {
        "sponsorId": "6eab2ef2c61e3007604b07fb544709610e671afa",
        "sponsorName": "EVQLV"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ifx-1",
    "conditionOrDisease": "covid19",
    "countries": ["germany"],
    "countryCodes": ["deu"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 31 Mar 2000 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "monoclonal antibodies",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "ifx-1",
    "productId": 66,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "e983bf277d7e2b931f94f5559b7a6df679283a36",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8b37254ccb340a35bc492a85125002e78f979b1e",
        "sponsorName": "InflaRx"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "aplidin",
    "chemicalName": "plitidepsin",
    "conditionOrDisease": "covid 19",
    "countries": ["spain"],
    "countryCodes": ["esp"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "anti-melanoma agent",
    "numSites": "",
    "otherPartners": "csic",
    "phase": "2",
    "preferredName": "plitidepsin",
    "productId": 67,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Spanish Fork",
        "country": "US",
        "lat": 40.1335888,
        "lng": -111.6381703,
        "locationId": "e3dba356432b019c3ee8e1a7e408b9f93e19375b",
        "name": "E Market Pl Dr, Spanish Fork, UT 84660, USA",
        "state": "UT"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ec5f02cd738afe63b04534d0cc394af54573dc39",
        "sponsorName": "Pharmamar"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-immunosupressive",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ganovo,ritonavir",
    "conditionOrDisease": "covid19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 25 Jan 2000 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "study patients discharged",
    "numSites": "",
    "otherPartners": "shaoxing government",
    "phase": "2",
    "preferredName": "ganovo,ritonavir",
    "productId": 68,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3799735fca71d687b33e157b0589e09999052c4f",
        "sponsorName": "Ascletis Pharma"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "protease inhibitor",
    "trialId": ""
  },
  {
    "brandName": "lunar-cov19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 27 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "mrna vaccine. they color code where in the pipeline their drugs are. someone who can tell shades of blue apart better than me should double check their current status.",
    "numSites": "",
    "otherPartners": "duke-national university of singapore",
    "phase": "",
    "preferredName": "lunar-cov19",
    "productId": 69,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "20dfe597bbef86e0b9719260a7c300a5b0df15ae",
        "sponsorName": "Arcturus"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "avigan,favilavir",
    "chemicalName": "favipiravir",
    "conditionOrDisease": "covid-19",
    "countries": ["japan"],
    "countryCodes": ["jpn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "japan has stockpile of 2 million.",
    "numSites": "11",
    "otherPartners": "",
    "phase": "not applicable",
    "preferredName": "favipiravir",
    "productId": 70,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "3c07d62423fd1737f99c228839fafd2c3eec27b9",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Beijing",
        "country": "CN",
        "lat": 39.90419989999999,
        "lng": 116.4073963,
        "locationId": "05ea721da769b738c9757c26ee48db2a13926082",
        "name": "Beijing, China",
        "state": "Beijing"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "34d00fafed342348290ae426b7563ce4af7e2726",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "c635518286cbe313699f1e5929055bbcd5875fe5",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "46330a7ae1548937388b861eda320a15b45df839",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "dff7392ea2b052bd827fa337df279eb790ad5ad6",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "2b9397570f6b7b70c2956c949ba638bea7e3e6dc",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, é¶æ½­è·¯1å·",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "53a718d1a35afc9b6866488b2350dbf5f7006234",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.4917469,
        "lng": 114.1732702,
        "locationId": "a19d476b4b4cdc5bc4ad8810c3aaf1f51babe9af",
        "name": "58 Shenlong Ave, Caidian Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "16d1b5ecd5151676200a02b7c5eaee103f84e9a6",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "2d05357a44a80c3b4f973993829b53c513dbfed1",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d3f2295022832956ff09046194ed9b4ab9077636",
        "sponsorName": "Fujifilm"
      },
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "zydus cadila - live attenuated vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["india"],
    "countryCodes": ["ind"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 05 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "whole-pathogen vaccines",
    "notes": "uses a measles vector. they also are working on a dna vaccine.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "zydus_cadila__live_attenuated_vaccine",
    "productId": 71,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "sinovac vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "whole-pathogen vaccines",
    "notes": "inactivated vaccine. based on a sars platform. very little direct information.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sinovac_vaccine",
    "productId": 72,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "93bef25f8dc322ecb56eae9b00dfed2b3169a709",
        "sponsorName": "Sinovac"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "inactivated vaccine",
    "chemicalName": "delete",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 73,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e1992462e6978a6ef1bdee8a86f7d513222c1ad6",
        "sponsorName": "Beijing Institute of Biological Products"
      },
      {
        "sponsorId": "ad6a16130480e1a77d5ffb88a5752fdae6685597",
        "sponsorName": "Wuhan Institute of Biological Products"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "codagenix live-attenuated vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 13 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "whole-pathogen vaccines",
    "notes": "live-attenuated vaccine. country might need to be switched to india later. targeting september for human trials and 2022 for release.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "codagenix_liveattenuated_vaccine",
    "productId": 74,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4f658739e6abe56363d5f2d9559538ae578e3aad",
        "sponsorName": "Codagenix"
      },
      {
        "sponsorId": "adee3b214297c2f83d459d75e4e295cde4fd187c",
        "sponsorName": "Serum Institute of India"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 75,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "42dc4894fcc96aa20e701b0f9bbb2fb79c1f0279",
        "sponsorName": "DZIF  German Center for Infection Research"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "greffex vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 11 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "they lack funding to start animal trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "greffex_vaccine",
    "productId": 76,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c01129b833a3f153fc0408879e5a2bb4bf21b9b",
        "sponsorName": "Greffex"
      }
    ],
    "status": "on hold",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "adaptvac vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["denmark"],
    "countryCodes": ["dnk"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 09 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "consortium of danish companies and universities. one of the universities will likely be the sponsor when they go to clinical trials.",
    "numSites": "",
    "otherPartners": "prevent-ncov consortium",
    "phase": "",
    "preferredName": "adaptvac_vaccine",
    "productId": 77,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b3dd9ec1147ddf57383d3eda6cd2d861e37911df",
        "sponsorName": "AdaptVac"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaccine",
    "productId": 78,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "433f99ff8c5ca5efa43e610e5d05b69e4f37d5ef",
        "sponsorName": "ExpreS2ion Biotechnologies ApS"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "usamriid vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "usamriid_vaccine",
    "productId": 79,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "455288f646569f2165f9af95d690d300bbd182a8",
        "sponsorName": "WRAIR"
      },
      {
        "sponsorId": "301d4da21e654a4dac3ab28cf3feba940a10bc5f",
        "sponsorName": "USAMRIID"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "vaxhit",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["israel"],
    "countryCodes": ["isr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "utilized single peptide technology,",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaxhit",
    "productId": 80,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6326cfa8bba7bb5f22c4c0c558835079ac7fc122",
        "sponsorName": "Vaxil Bio Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "flowvax covid 19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "approach - biodegradable microsphere peptide vaccine targeting sars-cov-2 nucleocapsid,t-cell vaccine,expected to be used for pre- and post-exposure prophylaxis,currently being tested on nonhuman primates",
    "numSites": "",
    "otherPartners": "university of texas medical branch at galveston",
    "phase": "",
    "preferredName": "flowvax_covid_19",
    "productId": 81,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "306b4a5ca7bafa2c8cb1637d2068fec4dcf4c872",
        "sponsorName": "Flow Pharma"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "unbranded h-ig therapeutic,tak-888",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["japan"],
    "countryCodes": ["jpn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "takeda started development as tak-888. several groups working on immunoglobulin strategies are now working together. they need plasma donors.",
    "numSites": "",
    "otherPartners": "biotest,bio products laboratory,octa pharma,lfb,csl behrig",
    "phase": "",
    "preferredName": "unbranded_hig_therapeutic_tak888",
    "productId": 119,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "31759effba9dd9037b4a5b2a4e1bf87cb0e4042b",
        "sponsorName": "Takeda"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "dna vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "dna_vaccine",
    "productId": 451,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "092bd155058a125cab87c808b5adaf8207b382dd",
        "sponsorName": "Scancell Holdings plc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "epv-cov19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "peptide-based epitope driven vaccine candidate,expected to stimulate protective t-cell response,expected to protect against severe disease rather than protect against infection,specifically targeted at healthcare workers,availability of no-cost licenses for the vaccine recipe for developing world countries who have gmp facilities for production of the vaccine,phase 1 trial expected to begin in 3 months",
    "numSites": "",
    "otherPartners": "generex biotechnology,gaia vaccine foundation",
    "phase": "",
    "preferredName": "epvcov19",
    "productId": 82,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bd27e9eeb1bca08ea29864fa4bd2121d5abb6345",
        "sponsorName": "EpiVax Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "this seems to be separate from the partnership between epivax and generex,also seems to be in pre-discovery phase as no specific mechanism has been identified",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "epivax_university_of_georgia-83",
    "productId": 83,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2b2068ecd13962f5098c0b0cd04aaf01f7c38c14",
        "sponsorName": "EpiVax"
      },
      {
        "sponsorId": "e4bf2c53813e4971a809acf75b015ef7d10cbebc",
        "sponsorName": "University of Georgia"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "covid 19 vaccine",
    "chemicalName": "gp96-mediated vaccine",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "mechanism of action - gp96 + viral antigens",
    "numSites": "",
    "otherPartners": "university of miami",
    "phase": "",
    "preferredName": "gp96mediated_vaccine",
    "productId": 84,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "69a6b23cf97fddaef2d35262b69a690f029417f4",
        "sponsorName": "Heat Biologics Inc"
      },
      {
        "sponsorId": "0fc2d17219cc99046bce21a2c41bc8215617c73d",
        "sponsorName": "University of Miami"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "t-cell therapies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "t-cell therapy,baylor college of medicine is also pushing for testing of a vaccine developed against sars-cov-1 in 2016 - not much information about this",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tcell_therapies",
    "productId": 85,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "41801411fe7d66b24eae2e0411ee409f9ad29507",
        "sponsorName": "Baylor College of Medicine"
      },
      {
        "sponsorId": "e6c4cbd24fa49f8c604388e030a0790d277ad9a6",
        "sponsorName": "AlloVir"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "ibio-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "virus-like particle,developed using fastpharming technology,patent filed in march 2020",
    "numSites": "",
    "otherPartners": "texas a&m university system laboratories",
    "phase": "",
    "preferredName": "ibio200",
    "productId": 86,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "505b07d6981f93ee187513e197589f4c16f04b35",
        "sponsorName": "iBio Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "international vaccine institute of south korea",
    "phase": "",
    "preferredName": "vidointervac__university_of_saskatchewan-87",
    "productId": 87,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "922e9730a7311def2db9cd56cf99adc4ac2f16a6",
        "sponsorName": "VIDOInterVac  University of Saskatchewan"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 88,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "102fe9bb3724bbad454162ce2f31318baff6facb",
        "sponsorName": "OncoGen"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mv vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["france"],
    "countryCodes": ["fra"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "molecule type - dna based vaccine,based on the use of measles vaccine as a vector",
    "numSites": "",
    "otherPartners": "themis bioscience gmbh,university of pittsburg - center for vaccine research,cepi",
    "phase": "",
    "preferredName": "mv_vaccine",
    "productId": 89,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a2a15d79e1f0b774dbc631aeed3b73af7f225cfe",
        "sponsorName": "Institute Pasteur"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "rnacure 2019-ncov vaccine candidate",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "rnacure biopharma",
    "phase": "",
    "preferredName": "rnacure_2019ncov_vaccine_candidate",
    "productId": 90,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      },
      {
        "sponsorId": "aa6799f660cd49b264d3e155560878bb15e8b804",
        "sponsorName": "Shanghai JiatTong University"
      },
      {
        "sponsorId": "f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0",
        "sponsorName": "RNACure Biopharma"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "stermina 2019-ncov vaccine candidate",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "stermina therapeutics",
    "phase": "",
    "preferredName": "stermina_2019ncov_vaccine_candidate",
    "productId": 91,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "20e19a20e9874c07beba2c307650020c6a63535b",
        "sponsorName": "China CDC"
      },
      {
        "sponsorId": "0a82122244646304c943aa942a96ad3ace268562",
        "sponsorName": "Tongji University"
      },
      {
        "sponsorId": "30508a3774a3fd8aeb4cf75885e2ee9011d8514f",
        "sponsorName": "Stermina"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "opencorona 2019-ncov vaccine candidate",
    "conditionOrDisease": "",
    "countries": ["sweden"],
    "countryCodes": ["swe"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "horizon 2020",
    "phase": "",
    "preferredName": "opencorona_2019ncov_vaccine_candidate",
    "productId": 92,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a26c2ef25366b153b9c8bb0d553426bbab80d427",
        "sponsorName": "Karolinska Institute"
      },
      {
        "sponsorId": "4b38f0c3421f6f67e79a27c6fd64a3930c0c2627",
        "sponsorName": "CobraBiologics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "reithera 2019-ncov vaccine candidate",
    "conditionOrDisease": "",
    "countries": ["italy"],
    "countryCodes": ["ita"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "reithera_2019ncov_vaccine_candidate",
    "productId": 93,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6887e6de5a46033245e0bcb4f49450dcbadd7441",
        "sponsorName": "ReiThera"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "bionet 2019-ncov vaccine candidate",
    "conditionOrDisease": "",
    "countries": ["thaialnd"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "bionet_2019ncov_vaccine_candidate",
    "productId": 94,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a4be0a2fbeb04dd3db2a97fc2f68a2388bb723b",
        "sponsorName": "BioNet Asia"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "immunoprecise 2019-ncov mab candidate",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "immunoprecise_2019ncov_mab_candidate",
    "productId": 95,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c287fbb2eede11927b6a7b38de9c5e7b1e04b966",
        "sponsorName": "ImmunoPrecise"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "ivomec",
    "chemicalName": "ivermectin",
    "conditionOrDisease": "",
    "countries": ["australia"],
    "countryCodes": ["aus"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ivermectin",
    "productId": 96,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e8af2a52a069a3c9d2e7076dbd1450dcac577b76",
        "sponsorName": "Doherty Institute"
      },
      {
        "sponsorId": "5f1bf89bc842335651ec9768cc0377edaff0185e",
        "sponsorName": "Monash University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "vaccine/therapeutics",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "nih",
    "phase": "",
    "preferredName": "vaccinetherapeutics",
    "productId": 97,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b4a99af9eec1a8f807ede0e67dd5e8d77867b245",
        "sponsorName": "Tulane University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "vaxcelerate vaccine,hoth voltron 2019-ncov vaccine candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "hoth,voltron",
    "phase": "",
    "preferredName": "vaxcelerate_vaccine_hoth_voltron_2019ncov_vaccine_candidate",
    "productId": 98,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a0e1dd25259a873fb5bbf352459b984c718be493",
        "sponsorName": "Hoth Therapeutics"
      },
      {
        "sponsorId": "465edc414eb3f341233a89dca1b03de024926e45",
        "sponsorName": "Voltron Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "covid-19 s-trimer",
    "conditionOrDisease": "",
    "countries": ["united states", "china"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "dynavax,clover",
    "phase": "",
    "preferredName": "covid19_strimer",
    "productId": 99,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8b4d210c885dc58c6711e526b8b4bd37c6acfd55",
        "sponsorName": "Dynavax"
      },
      {
        "sponsorId": "98d391f3ea6e38dce05de1f6df1b3d708f268eff",
        "sponsorName": "Clover"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "sti-6991",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sti6991",
    "productId": 100,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4f038c1fd0e4c52d93147fc334849bc67394496",
        "sponsorName": "Sorrento Therapeutics"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vtp-500",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vtp500",
    "productId": 101,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3539cc93ae38ac97613e91267777269795073379",
        "sponsorName": "Vaccitech"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sanofi_translate_bio-102",
    "productId": 102,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      },
      {
        "sponsorId": "1ddb247542fcbc349fe829611d29e6ded2b999e7",
        "sponsorName": "Translate Bio"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "nebulized ampion",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nebulized_ampion",
    "productId": 103,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "02881a510323f0cd43a11e035e7be1138b026116",
        "sponsorName": "Ampio Pharmaceuticals"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "piclidenoson",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "piclidenoson",
    "productId": 104,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ea7e102c17c41b12f5ea330cafbdf8e967c6742",
        "sponsorName": "CanFite BioPharma Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "gilenya",
    "chemicalName": "fingolimod",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fingolimod",
    "productId": 105,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d774a499f97544cfed35dafa3d82a1e11e3b643e",
        "sponsorName": "First Affiliated Hospital"
      },
      {
        "sponsorId": "a47ed0af8e79c0d5e04834a88fa5c0fa3a019663",
        "sponsorName": "Novartis AG"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "bdb-1",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "bdb1",
    "productId": 106,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecc0feedb452374f3f35ae9224fd597c82fca6a1",
        "sponsorName": "InflaRx NV"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ryoncil",
    "chemicalName": "remestemcel-l",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "remestemcell",
    "productId": 107,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4959407d4633b3c9180469947d99a947263aeb9",
        "sponsorName": "Mesoblast Limited"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "actemvra",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tocilizumab",
    "productId": 108,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cc672ac08b0d9e540145295250d172650b81b78c",
        "sponsorName": "Rogers Corporation"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "diammonium",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "diammonium",
    "productId": 109,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "828d3ce717e4188e36142a37dde46c7150e54532",
        "sponsorName": "Sino Biopharmaceuticals"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "dantonic",
    "chemicalName": "t89",
    "conditionOrDisease": "newly diagnosed covid-19 patients with oxygen saturation > 90%",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "t89 is an industrialized botanical drug formula developed from traditional chinese medicine. it is a mixture of multiple plant extracts and other excipients. it is to be tested for increasing blood o2 saturation in the ongoing clinical trial registered in us. the trial was approved but not yet recruiting.",
    "numSites": "not specified",
    "otherPartners": "tasly pharmaceuticals",
    "phase": "not applicable",
    "preferredName": "t89",
    "productId": 110,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "8f9a00aec6e4f5cd001e619183bceb10d96e50da",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0dda51f9c95a47c39d878234d93d16d7902c83f1",
        "sponsorName": "Tasly Pharmaceuticals"
      },
      {
        "sponsorId": "3a0d49eb534018ed04f1ba984529ab2611135695",
        "sponsorName": "Arbor Pharmaceuticals Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04285190"
  },
  {
    "brandName": "",
    "chemicalName": "monoclonal antibodies",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 111,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "156a9d5b5c0452de6985da63b61ee8521a939741",
        "sponsorName": "AstraZeneca PLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "monoclonal antibodies",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "they have 300 candidates now will narrow down to fewer candidates",
    "numSites": "",
    "otherPartners": "celltrion",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 112,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "625c2965f7108c1ad1edf37eef366aad6b28fbd8",
        "sponsorName": "Celltrion"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "monoclonal antibodies",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "iibr will use the manufacturing platform of dyadic to produce their monoclonal antibody candidate",
    "numSites": "",
    "otherPartners": "iibr,dyadic",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 113,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bc5f1b8a05634976386ebb4a0eb43f430166cf2f",
        "sponsorName": "Israel Institute for Biological Research IIBR"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "kpl-301",
    "chemicalName": "mavrilimumab",
    "conditionOrDisease": "documented covid-19 pneumonia",
    "countries": ["italy", "us"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "the drug had up to phase-2 trial for other indications. successfully used in covid-19 pts in italy (did not find the exact trial description).",
    "numSites": "1",
    "otherPartners": "kiniksa pharmaceuticals,virginia commonwealth university",
    "phase": "phase 2",
    "preferredName": "mavrilimumab",
    "productId": 114,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Richmond",
        "country": "US",
        "lat": 37.5407246,
        "lng": -77.4360481,
        "locationId": "0465e734085f945eda3fbeedc06c5c5b9b7c115f",
        "name": "Richmond, VA, USA",
        "state": "VA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f0b7d34b0d2bf183e3127d2f2ae6859f2e0c2303",
        "sponsorName": "Kiniksa Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "vir-7831",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 22 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "also testing vir-7832. they are going to skip phase i and go directly to phase ii in the summer. targeting early 2021 for commercial manufacturing.",
    "numSites": "",
    "otherPartners": "generation bio,samsung biologics,xencor,wuxi biologics",
    "phase": "",
    "preferredName": "vir7831",
    "productId": 115,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dc00d3517e3f13a2cb70d81bbab7f9d0514888f3",
        "sponsorName": "Vir"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 116,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dc00d3517e3f13a2cb70d81bbab7f9d0514888f3",
        "sponsorName": "Vir"
      },
      {
        "sponsorId": "93b3b8946f754bf8d8937c425327d7e3188585ac",
        "sponsorName": "WuXi Biologics"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 117,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dc00d3517e3f13a2cb70d81bbab7f9d0514888f3",
        "sponsorName": "Vir"
      },
      {
        "sponsorId": "e2d696e69bf7af5a9d75dc0e458af621a10d78ba",
        "sponsorName": "Xencor"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vir sirna therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 04 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "they have 2 different sirna treatments under development. this column is for the one that targets the virus. their other treatment targets host factors.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vir_sirna_therapeutic",
    "productId": 118,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dc00d3517e3f13a2cb70d81bbab7f9d0514888f3",
        "sponsorName": "Vir"
      },
      {
        "sponsorId": "2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165",
        "sponsorName": "Alnylam"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "triazavirin",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "originally developed in russia for influenza.",
    "numSites": "4",
    "otherPartners": "",
    "phase": "phase 3",
    "preferredName": "triazavirin",
    "productId": 155,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.766278,
        "lng": 126.64794,
        "locationId": "5d28a31c7bd5063aff9a4ef8a0ba56a97349af46",
        "name": "23 Youzheng St, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.696577,
        "lng": 126.616301,
        "locationId": "8945d13696425c8a875c1a9d1564a394660b17be",
        "name": "246 Xuefu Rd, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China, 150086",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.7003851,
        "lng": 126.6202132,
        "locationId": "b649876b615b666cccbe675b1c1da0b0bbea5eac",
        "name": "157 Baojian Rd, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.752385,
        "lng": 126.6020651,
        "locationId": "bab5cbc193c499433eb4174fde21b14bd0088c7a",
        "name": "204 Hayao Rd, Daoli Qu, Haerbin Shi, Heilongjiang Sheng, China",
        "state": "Heilongjiang Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "74eb28bb89c6d76ecbdcbb4b00449a43dd0efd98",
        "sponsorName": "Health commission of Heilongjiang province"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": "chictr2000030001"
  },
  {
    "brandName": "plasma immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 26 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "convalescent plasma",
    "numSites": "",
    "otherPartners": "cerus corporation,california department of public health,university of california,irvineâs vaccine development research laboratory,vitalant research institute,california national primate research center,enable biosciences",
    "phase": "discovery",
    "preferredName": "plasma_immunoglobulins",
    "productId": 120,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fe619f6a989eee7d5e22b0c5a964b30deeb615db",
        "sponsorName": "CERS actually spelt Cerus Corporation"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "plasma immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "convalescent plasma",
    "numSites": "",
    "otherPartners": "grifols,barda,fda",
    "phase": "discovery",
    "preferredName": "plasma_immunoglobulins",
    "productId": 121,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "893c4bdb7386d6aa83dda414cb161d199a4e191f",
        "sponsorName": "Grifols"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "plasma immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "convalescent plasma program. ongoing. no dates given.",
    "numSites": "6",
    "otherPartners": "mayo clinic",
    "phase": "on market",
    "preferredName": "plasma_immunoglobulins",
    "productId": 122,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7899953,
        "lng": -73.9527248,
        "locationId": "4334073b9ce79140b650a9b625cce27013c1e2e4",
        "name": "1468 Madison Ave, New York, NY 10029, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.769405,
        "lng": -73.9862357,
        "locationId": "e29b980f9cc8508873e04d2556b93cb2b42001a5",
        "name": "1000 10th Ave, New York, NY 10019, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.8052591,
        "lng": -73.96117029999999,
        "locationId": "96e92b1f11d45f623f56d8ef2a5f7d167935b70d",
        "name": "1111 Amsterdam Ave, New York, NY 10025, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7341691,
        "lng": -73.9826815,
        "locationId": "008df50720ae125c6e646c1e3628ead4835d4ca1",
        "name": "317 E 17th St, New York, NY 10003, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "US",
        "lat": 40.76804190000001,
        "lng": -73.9247844,
        "locationId": "b1bfde4f9a9f925f24bd3763ede884b805b76913",
        "name": "3019 Crescent Street at, 30th Rd, Queens, NY 11102, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "US",
        "lat": 40.6187604,
        "lng": -73.94282380000001,
        "locationId": "da26c94471b8cbba875a962b8455b1914bf66817",
        "name": "3201 Kings Hwy, Brooklyn, NY 11234, USA",
        "state": "NY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "67cc1b58cfec53c29d2af191d961276e32239c1b",
        "sponsorName": "Mount Sinai Health System"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "plasma immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "convalescent plasma program. ongoing. no dates given.",
    "numSites": "3",
    "otherPartners": "china national biotec group",
    "phase": "phase ii eqvlt study completed. randomised control trial recommended.",
    "preferredName": "plasma_immunoglobulins",
    "productId": 123,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "8f846eacc4adba34e9bfdbff984791cee9d5a4bc",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, é¶æ½­è·¯1å·",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.375552,
        "lng": 114.320726,
        "locationId": "21c92e34f9b33428a58e17885d70036c2989fe96",
        "name": "Jiangxia District, Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.3500539,
        "lng": 114.328985,
        "locationId": "7b6576ae12cfba609168964ed5c0096adf32a532",
        "name": "116 Jiangxia Ave, Jiangxia Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de649c1e3ec322020be03d52590a6461de6d1a6a",
        "sponsorName": "China National Biotec"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "ards in covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "vasoactive intestinal polypeptide which inhibits inflammatory cytokines causing ards",
    "numSites": "4",
    "otherPartners": "neurorx",
    "phase": "phase iii",
    "preferredName": "neurrx_relief_therapeutics-124",
    "productId": 124,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Miami",
        "country": "US",
        "lat": 25.7904064,
        "lng": -80.21199279999999,
        "locationId": "cc40f9d619426f7d01479c31ba9ad9e4c1f5c3a9",
        "name": "1600 NW 10th Ave #1140, Miami, FL 33136, USA",
        "state": "FL"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7422466,
        "lng": -73.9743033,
        "locationId": "a6270af190239f1d484d8a0e1e5358d3b444b51b",
        "name": "560 1st Avenue, New York, NY 10016, USA",
        "state": "NY"
      },
      {
        "city": "Philadelphia",
        "country": "US",
        "lat": 39.9495623,
        "lng": -75.1580318,
        "locationId": "afb3854b15daac654265ec1d46edfc6789f72cf4",
        "name": "111 S 11th St, Philadelphia, PA 19107, USA",
        "state": "PA"
      },
      {
        "city": "Haifa",
        "country": "IL",
        "lat": 32.8329785,
        "lng": 34.9857062,
        "locationId": "0c389bff72080433bc8b061dd167d06a65749e97",
        "name": "HaAliya HaShniya St 8, Haifa, 3109601, Israel",
        "state": "Haifa District"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8c18a287de447a9a8dfa13df486ebd28237a8878",
        "sponsorName": "NeurRx"
      },
      {
        "sponsorId": "a30d64bea24fb02aa2230fa1359a99643a0fc3a3",
        "sponsorName": "Relief Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04311697"
  },
  {
    "brandName": "covidtrap",
    "chemicalName": "sti-4398",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "designed to block the sars-cov-2 virus from binding and infecting respiratory epithelial cells - which is expected to effectively interrupt the viral life cycle",
    "numSites": "",
    "otherPartners": "sorrento theraputics",
    "phase": "pre-clinical testing",
    "preferredName": "sti4398",
    "productId": 125,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dd736e19d9cf47b8b0d9049c8729f5f8c706b691",
        "sponsorName": "Sorrento Therapeutics inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "university_of_life-126",
    "productId": 126,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3a828ae8c0095976a9e4da7d0e3c7bfdddeb87ac",
        "sponsorName": "University of Life"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "inopulse",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 25 Jul 2016 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "inhaled nitric oxide at phase 2 for  for copd - ild - sarcoidosis",
    "numSites": "",
    "otherPartners": "bellerophon therapeutics",
    "phase": "phase 2,currently pursuing expanded access program clearance in usa,currently applying for phase iii trial",
    "preferredName": "inopulse",
    "productId": 127,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7efcbd9db54765e1aeaf893d6a3ed78f9d70a195",
        "sponsorName": "Bellepheron Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "cytosorb",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["germany"],
    "countryCodes": ["deu"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 10 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "miller school of medicine university of miami medical center - florida - united states,robert i grossman school of medicine nyu langone medical center new york united states,thomas jefferson university hospital philadelphia pennsylvania united states,rambam health care campus haifa israel",
    "numSites": "",
    "otherPartners": "cytosorb",
    "phase": "emergency use - not under trial",
    "preferredName": "cytosorb",
    "productId": 128,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d550d39fbfcc114bb9424feb7ee3922ee7889355",
        "sponsorName": "CytoSorbents Corporation"
      }
    ],
    "status": "on market",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "snx-5542",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "snx5542",
    "productId": 129,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "282eaef03c22bad7cc8a8fd8da311711425b1a20",
        "sponsorName": "Esanex"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mytesi",
    "chemicalName": "crofelemer",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "antidiarrheal for those on anti-retroviral therapy - used in hiv patients - permission sought from fda for use in covid patients",
    "numSites": "",
    "otherPartners": "jaguar health",
    "phase": "",
    "preferredName": "crofelemer",
    "productId": 130,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c7563c3b7fe4829bad22fa8782140bff9d34561f",
        "sponsorName": "Jaguar Health"
      }
    ],
    "status": "failed",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find therapeutic use,only antibody test for covid?",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "leibniz_institute-131",
    "productId": 131,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8e15d495d6fb7018df95d75779b82dcd926be20f",
        "sponsorName": "Leibniz Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find any therapeutic drug/vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "allergan-132",
    "productId": 132,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "81ce487fc0d3a5b4c58a218b8adceb96a044468f",
        "sponsorName": "Allergan"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "cd24fc",
    "conditionOrDisease": "covid-19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "first-in-class recombinant fusion protein (biologic)",
    "numSites": "1",
    "otherPartners": "oncoimmune",
    "phase": "3",
    "preferredName": "cd24fc",
    "productId": 133,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Baltimore",
        "country": "US",
        "lat": 39.2892017,
        "lng": -76.6257057,
        "locationId": "60cacde8298e7bd21f4ff28cd44311755851f783",
        "name": "620 W Lexington St, Baltimore, MD 21201, USA",
        "state": "MD"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "01bbc68194bde084f23cb9df2a7ae7d59d15b54f",
        "sponsorName": "OncoImmune"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "pul-042 inhalation solution",
    "conditionOrDisease": "covid-19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 19 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "2 clinical trials: one for short term immunisation,also one for reducing severity (link below for latter)",
    "numSites": "not listed",
    "otherPartners": "pulmotect",
    "phase": "2",
    "preferredName": "pul042_inhalation_solution",
    "productId": 134,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Houston",
        "country": "US",
        "lat": 29.7106626,
        "lng": -95.399568,
        "locationId": "b4f15db0675d756b8132a890f2f68d5ca777c4c1",
        "name": "6565 Fannin St, Houston, TX 77030, USA",
        "state": "TX"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1eab813cb618e383ce0ca0e7f81c6684b50fdddc",
        "sponsorName": "Pulmotect"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "kaletra",
    "chemicalName": "lopinavir,ritonavir",
    "conditionOrDisease": "covid-19",
    "countries": ["korea"],
    "countryCodes": ["prk"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 11 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "phase 2 rct of hiv protease inhibitors versus hydroxychloroquine",
    "numSites": "not listed",
    "otherPartners": "asan medical center",
    "phase": "2",
    "preferredName": "lopinavir_ritonavir",
    "productId": 135,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": null,
        "country": "KR",
        "lat": 37.526922,
        "lng": 127.108381,
        "locationId": "e47744f33ecd40c285a0023935b5d4f911cbb2dc",
        "name": "88 Olympic-ro 43-gil, Pungnap 2(i)-dong, Songpa-gu, Seoul, South Korea",
        "state": "Seoul"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "46995ecc0a38eb8057922b33c458f0c5a641c004",
        "sponsorName": "Asan Medical Center"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find therapeutic drug/vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "digestive_disease_research_institute-136",
    "productId": 136,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4df36b5a59c84e2083f2bc2c1d75bda25e29f290",
        "sponsorName": "Digestive Disease Research Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "doi yohei is the dr leading the clinical trial for avigan in japan - this drug is already listed (id 72)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 137,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "055d27dd32192f82e546e2324220d44b2377d3e2",
        "sponsorName": "Doi Yohei"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "hydroxychloroquine,zithromax",
    "chemicalName": "hydroxychloroquine,azithromycin",
    "conditionOrDisease": "",
    "countries": ["france"],
    "countryCodes": ["fra"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "much of the documentation is in french. studies have been conducted (interventional) and results presented in \"papers\" - however no official trials per se",
    "numSites": "",
    "otherPartners": "ihu mÃ©diterranÃ©e infection",
    "phase": "",
    "preferredName": "hydroxychloroquine_azithromycin",
    "productId": 138,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f504a9b418cd0c0f06bc0337180c16761e95b8b1",
        "sponsorName": "Fondation Mediterranee Infection"
      },
      {
        "sponsorId": "7c4d34cd18acefd9b97f8b918fe356fec61f94d6",
        "sponsorName": "Pfizer Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["france"],
    "countryCodes": ["fra"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "clinical trials - stage unknown - to test 4 therapes: remdesevir,hydroxychloroquine,lopinavir and rotinavir,plus ifn-beta",
    "numSites": "",
    "otherPartners": "national insitute for health and medical research",
    "phase": "",
    "preferredName": "inserm-139",
    "productId": 139,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0e1ea407af0902261db76719a57a5c127ea53bfe",
        "sponsorName": "INSERM"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "nitric oxide",
    "conditionOrDisease": "covid-19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "4 current/upcoming trials - to assess use of nitric oxide for treating covid patients - and also potentially preventing the disease",
    "numSites": "2",
    "otherPartners": "massachusetts general hospital",
    "phase": "2",
    "preferredName": "nitric_oxide",
    "productId": 140,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Boston",
        "country": "US",
        "lat": 42.3626109,
        "lng": -71.067566,
        "locationId": "26cac4ec1afc8a69ac47d4f0593a44e3b5780b46",
        "name": "55 Fruit St, Boston, MA 02114, USA",
        "state": "MA"
      },
      {
        "city": "Xi'an",
        "country": "CN",
        "lat": 34.2706897,
        "lng": 108.9880179,
        "locationId": "9bfa4732abffe577744b788704b81f018a8871d1",
        "name": "Kangfu Road Shangquan, Xincheng District, Xi'an, Xi'an, Shaanxi, China",
        "state": "Shaanxi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8a365c9b40d6477fb64fadbb35d6bac33dafb436",
        "sponsorName": "Massachusetts General Hospital"
      },
      {
        "sponsorId": "df85596f7d7dbeb2a2e8c43c35f6f8fa02b44690",
        "sponsorName": "Mallincrodt plc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "roacterma",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "covid-19 pneumonia",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "phase 3 approved",
    "numSites": "",
    "otherPartners": "roche and barda",
    "phase": "2",
    "preferredName": "tocilizumab",
    "productId": 141,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ca60c923f9bd40c651529c4a7b5a6972829d31d",
        "sponsorName": "National Cancer Institute"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete",
    "conditionOrDisease": "covid -19",
    "countries": ["mexico"],
    "countryCodes": ["mex"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "sanofi",
    "phase": "3",
    "preferredName": "delete",
    "productId": 142,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36b7ee51bc8a5fb34d5cf19f3495367204341eb6",
        "sponsorName": "National Institute or Respiratory Diseases  Mexico"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "tamiflu",
    "chemicalName": "`oseltamivir",
    "conditionOrDisease": "covid-19,sars cov-2",
    "countries": ["thailand"],
    "countryCodes": ["tha"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "rajavithi hospital",
    "phase": "3",
    "preferredName": "oseltamivir",
    "productId": 143,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6929a0f7701affd68fc35e0bb16ed03f8cfbfee6",
        "sponsorName": "Rajavithi Hospital"
      },
      {
        "sponsorId": "ef7f40a7a4970541f7271499b9755b383671309d",
        "sponsorName": "Roche AG"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "delete?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 144,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "eb058ec8d1b15050f17777e54392b41479ffda20",
        "sponsorName": "Shahid Beheshti Univeristy of Medical Sciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "interferon beta",
    "conditionOrDisease": "covid-19",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "interferon_beta",
    "productId": 145,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0d3266afcc25af5b518f15e74146cd88dd963d48",
        "sponsorName": "Synairgen Research Limited"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "delete?",
    "chemicalName": "sofosbuvir,ledipasvir",
    "conditionOrDisease": "",
    "countries": ["iran"],
    "countryCodes": ["irn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sofosbuvir_ledipasvir",
    "productId": 146,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3d91d8a2763ff7a2305e9571ce331344f8db21d8",
        "sponsorName": "Tehran University of Medical Sciences"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "delete?",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 147,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e34ee0fed8a1cf2adcf0af137c8c46865212e52c",
        "sponsorName": "Tokue Yutaka"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "delete?",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 148,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2edadb0a368326e19a38c17e17aa31d37ca94581",
        "sponsorName": "Beijing Chaoyang Hospital"
      },
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "delete?",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "delete",
    "productId": 149,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "321cfa99e2d96ffd805132b7d743b6bce706e380",
        "sponsorName": "Beijing Youan Hospital"
      },
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "carrimycin",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "11",
    "otherPartners": "beijing youan hospital",
    "phase": "4",
    "preferredName": "carrimycin",
    "productId": 150,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cmab806",
    "chemicalName": "interleukin-6 monoclonal antibody",
    "conditionOrDisease": "cytokine release syndrome of new coronavirus pneumonia (covid-19)",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "study goes to may 31st",
    "numSites": "1",
    "otherPartners": "",
    "phase": "phase 2",
    "preferredName": "interleukin6_monoclonal_antibody",
    "productId": 151,
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "98bef52e91c5a4ccc0aa5b419dd2e1a531d0ee9d",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c1d2cca1e1c545b115cedcb4a88a86dfc5cc4c0",
        "sponsorName": "JinYu BioTechnology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": "chictr2000030196"
  },
  {
    "brandName": "castem",
    "chemicalName": "mesenchymal stem cells",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "phase 2",
    "preferredName": "mesenchymal_stem_cells",
    "productId": 152,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.497745,
        "lng": 114.47528,
        "locationId": "7b0d120450c171f6cd6ca4868f5e47879812e969",
        "name": "Guanggu 3rd Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "a74833f3438f0aec7b3c20ea0b5386e00d2f7ef4",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e13a47c3805a5ea782acbdd30bf4d9672426da11",
        "sponsorName": "Beijing 302 Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04288102"
  },
  {
    "brandName": "",
    "chemicalName": "nkg2d-ace2 car-nk cells",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 21 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 21 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "phase i/ii trial",
    "numSites": "1",
    "otherPartners": "chongqing sidemu biotechnology",
    "phase": "phase 2",
    "preferredName": "nkg2dace2_carnk_cells",
    "productId": 153,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 29.5749191,
        "lng": 106.4218862,
        "locationId": "82468bf36375052608ee29368db46203aa48526f",
        "name": "Lingyun Rd, Shapingba Qu, Chongqing Shi, China",
        "state": "Chongqing Shi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "45c8692c794fd50c930fb0b97c607465d7d554b9",
        "sponsorName": "Chongqing Public Health Medical Center"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04324996"
  },
  {
    "brandName": "",
    "chemicalName": "long-acting interferon alpha-2a (135ug),ribavirin",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "5",
    "otherPartners": "",
    "phase": "phase 2",
    "preferredName": "longacting_interferon_alpha2a_135ug_ribavirin",
    "productId": 154,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Foshan Shi",
        "country": "CN",
        "lat": 22.8500072,
        "lng": 113.2578008,
        "locationId": "76eb279641a9a077776e8378c5f562ee00cb1ef5",
        "name": "Yungui 7th St, Shunde Qu, Foshan Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Shenzhen Shi",
        "country": "CN",
        "lat": 22.54483,
        "lng": 114.095787,
        "locationId": "41d0aaf1027196befa268f3b31f31f4328b562ae",
        "name": "2 Zhenhua Rd, Futian Qu, Shenzhen Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Dongguan",
        "country": "CN",
        "lat": 23.020673,
        "lng": 113.751799,
        "locationId": "f51b56947439216ae055f5c4d11e3fbeefd03f9f",
        "name": "Dongguan, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Jiangmen Shi",
        "country": "CN",
        "lat": 22.605688,
        "lng": 113.115602,
        "locationId": "f75f48e2427eb4801e19f4afb6f123d3f1384522",
        "name": "China, Guangdong Sheng, Jiangmen Shi, Pengjiang Qu, åè¡æµ·æè¡23å·",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Foshan Shi",
        "country": "CN",
        "lat": 22.960003,
        "lng": 112.978451,
        "locationId": "020fb6bba3f5827565d569abccedde4018f68113",
        "name": "China, Guangdong Sheng, Foshan Shi, Nanhai Qu, Qiaojin Hwy, æ¨µéè·¯",
        "state": "Guangdong Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0aa5baf3a5bfcd9bd34bc49ddd68b3369a8bd29f",
        "sponsorName": "Foshan First Peoples Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": "chictr2000030922"
  },
  {
    "brandName": "",
    "chemicalName": "azvudine",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "http://www.chictr.org.cn/showprojen.aspx?proj=50507",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "azvudine",
    "productId": 156,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "590809afc11f993a1d02526632882469be2ae713",
        "sponsorName": "Henan Provincial Peoples Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "esbriet",
    "chemicalName": "pirfenidone",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "pirfenidone",
    "productId": 157,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "abf659ef96c4f7cef8ec83e1e16ec37d171098bb",
        "sponsorName": "Huilan Zhang"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "chloroquine",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "https://clinicaltrials.gov/ct2/show/nct04282902?term=pirfenidone&cond=coronavirus&draw=2&rank=1",
    "preferredName": "chloroquine",
    "productId": 158,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "617b848747bc14a2a9fc203852ab5529565cab2a",
        "sponsorName": "Hwa Mei Hospital"
      },
      {
        "sponsorId": "ac1ac20ca0b9ec951428fe364c421040f1f4829b",
        "sponsorName": "University of Chinese Academy of Sciences"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "xuebijing",
    "chemicalName": "xuebijing",
    "conditionOrDisease": "novel coronavirus pneumonia",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 19 May 2004 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "traditional chinese medicine,5-herb combination",
    "numSites": "1",
    "otherPartners": "n/a",
    "phase": "1",
    "preferredName": "xuebijing",
    "productId": 159,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Jingzhou Shi",
        "country": "CN",
        "lat": 30.30907899999999,
        "lng": 112.259189,
        "locationId": "5ed12eb2a7b9f7f64d2da4c8ac4a0e5b45714dca",
        "name": "8 Hangkong Rd, Shashi Qu, Jingzhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de88121edbf4cca2b6df882b71a3a79995714b11",
        "sponsorName": "Jingzhou First Peoples Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "chictr2000030388"
  },
  {
    "brandName": "",
    "chemicalName": "methylprednisolone",
    "conditionOrDisease": "acute respiratory failure",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 24 Oct 1957 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Jan 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "zhongda hospital,renmin hospital of wuhan university",
    "phase": "2",
    "preferredName": "methylprednisolone",
    "productId": 160,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "0a05bf3e09a72ea4c349127b9ce0c2e406ff1cac",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "10172e384c8eaa0f469f305f6d2b50b0eabb14f5",
        "sponsorName": "Peking Union Medical College Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04244591"
  },
  {
    "brandName": "",
    "chemicalName": "favipiravir,tocilizumab",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "favipiravir - small molecule,tocilizumab - protein based,anti-viral and monoclonal antibody combination",
    "numSites": "9",
    "otherPartners": "n/a",
    "phase": "0",
    "preferredName": "favipiravir_tocilizumab",
    "productId": 161,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "611d61beb83cd65a882586081e19f48da246ef9d",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "168c14553206b3c69785fda3db7bccc98367c33f",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "4438c811df8946a3e2fb6359f1898de9b67180ec",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.33156,
        "lng": 114.690679,
        "locationId": "5699fa66900cac9c5e6b6788ffed3096e358be42",
        "name": "China, Hubei Sheng, Ezhou Shi, Liangzihu Qu, 239çé",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "bc04246a97f892025417c4a06f9073c72868fa88",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "804b3e0c3520f469c08233cbcae2c35e97b8c3ec",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, é¶æ½­è·¯1å·",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "6dc26677c3ecfa48564134cc1e509ed090ef9cb8",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.576258,
        "lng": 114.289076,
        "locationId": "f7cf4bddbf3d42cbbabcbe954754cac264b3381e",
        "name": "Hualou Street, Jianghan District, Wuhan, China",
        "state": null
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "1c209e02d1f56e3a39628da0964fd50734c03aed",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "6ad959a9586216433fcbcb291316bec99ecb4214",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04310228"
  },
  {
    "brandName": "azvudine",
    "chemicalName": "ro-0622",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "n/a",
    "phase": "0",
    "preferredName": "ro0622",
    "productId": 162,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Xinyang",
        "country": "CN",
        "lat": 32.014808,
        "lng": 114.906546,
        "locationId": "918952a1f02fd413b12411861b34a10209ac2f4e",
        "name": "Guangshan County, Xinyang, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b38a8623a43ac6813f56ef17b83f2ca2a213237",
        "sponsorName": "Peoples Hospital of Guangshan County"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": "chictr2000029853"
  },
  {
    "brandName": "noscovid",
    "chemicalName": "noscapine",
    "conditionOrDisease": "covid-19",
    "countries": ["iran"],
    "countryCodes": ["irn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 17 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "n/a",
    "phase": "2",
    "preferredName": "noscapine",
    "productId": 163,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Qazvin",
        "country": "IR",
        "lat": 36.3245163,
        "lng": 49.9972276,
        "locationId": "1b6abd2c5a8342d402f7b8d0c6a9d25775d72f30",
        "name": "Qazvin, ØØ Ø§Ø³ØªØ§Ù ÙØ²ÙÛÙ ÙØ²ÙÛÙ ÙÛÙÙØ¯Ø± Ú©ÙÛ Ø§ÙÙÛÙ Ø Ø¨ÙÙØ§Ø± 22 Ø¨ÙÙÙØ Tavon Square, Iran",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2c3dce78e2656e4bdf014ec95f1f244efcb85b05",
        "sponsorName": "Qazvin University of Medical Sciences"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "irct20160625028622n1"
  },
  {
    "brandName": "avastin",
    "chemicalName": "bevacizumab",
    "conditionOrDisease": "covid-19 pneumonia",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 26 Feb 2004 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "renmin hospital of wuhan university,ialy moriggia pelascini gravedona hospital s.p.a,wuhan university,jiangbei union hospital of huazhong university of science and technology,shandong provincial chest hospital",
    "phase": "not stated",
    "preferredName": "bevacizumab",
    "productId": 164,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Jinan Shi",
        "country": "CN",
        "lat": 36.655439,
        "lng": 117.018034,
        "locationId": "c10d03a44bbecad53a631e50f33ddcf2d8babb8b",
        "name": "107 Wenhua W Rd, Lixia Qu, Jinan Shi, Shandong Sheng, China",
        "state": "Shandong Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5097a8114e431ac8ebcbd82cdf94884e315a5cba",
        "sponsorName": "Qilu Hospital of Shandong University"
      },
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "nct04305106"
  },
  {
    "brandName": "delete?",
    "chemicalName": "leflunomide",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "leflunomide",
    "productId": 165,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14a2146233138c07a64e0baef6cc949f64c7af25",
        "sponsorName": "Renmin Hospital of Wuhan University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "bisolvon",
    "chemicalName": "bromhexine hydrochloride",
    "conditionOrDisease": "covid-19 pneumonia",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "wanbangde pharmaceutical group co. ltd.",
    "phase": "not stated",
    "preferredName": "bromhexine_hydrochloride",
    "productId": 166,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wenzhou Shi",
        "country": "CN",
        "lat": 28.006211,
        "lng": 120.67225,
        "locationId": "77ae0ec32355b94de6e8136bd005254284b1918e",
        "name": "109 Xueyuan W Rd, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng, China",
        "state": "Zhejiang Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "87b385be246abb1a4c3e0d7f6bbe23e811156173",
        "sponsorName": "Second Affiliated Hospital of Wenzhou Medical University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04273763"
  },
  {
    "brandName": "avigan",
    "chemicalName": "interferon beta,favipiravir",
    "conditionOrDisease": "covid-19",
    "countries": ["iran"],
    "countryCodes": ["irn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 27 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "used to treat influenza",
    "numSites": "1",
    "otherPartners": "chemrar,rdif",
    "phase": "3",
    "preferredName": "interferon_beta_favipiravir",
    "productId": 167,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "JP",
        "lat": 36.204824,
        "lng": 138.252924,
        "locationId": "4d7f366d3d44c0327b5bac6fbcf1323bfe38d088",
        "name": "Japan",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b58861dc99cd85f531c98907e3577fe93964d0f3",
        "sponsorName": "Shahid Beheshti University of Medical Sciences"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "prezista",
    "chemicalName": "darunavir,cibicistat",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "treat pneumonia",
    "numSites": "1",
    "otherPartners": "johnson and johnson",
    "phase": "3",
    "preferredName": "darunavir_cibicistat",
    "productId": 168,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Shanghai",
        "country": "CN",
        "lat": 31.230416,
        "lng": 121.473701,
        "locationId": "8003511806a121dc3e888b0bbdf2c905dc2e9b21",
        "name": "Shanghai, China",
        "state": "Shanghai"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral - protease inhibitor",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "pd1,thymosin,camrelizumab",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "cancer therapy",
    "numSites": "",
    "otherPartners": "nihr",
    "phase": "2",
    "preferredName": "pd1_thymosin_camrelizumab",
    "productId": 169,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9ba50a6c509f14bcba0e2116a0a021e05e985ae6",
        "sponsorName": "Southeast University  China"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "meplazumab",
    "conditionOrDisease": "covid-19",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "treat pneumonia",
    "numSites": "1",
    "otherPartners": "national science and technology major project",
    "phase": "2",
    "preferredName": "meplazumab",
    "productId": 170,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Huizhou",
        "country": "CN",
        "lat": 22.94223,
        "lng": 114.29824,
        "locationId": "c9023a657b5ef76b93f4b255126175ba459e0cf6",
        "name": "Tangdu, Huiyang District, Huizhou, Guangdong Province, China",
        "state": "Guangdong Province"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "90580332dd2c5e7458dc3f0dc0ba01024427917e",
        "sponsorName": "TangDu Hospital"
      },
      {
        "sponsorId": "2453464d7d85243db737220519ad6c684bfec004",
        "sponsorName": "Jingsu Pacific Meinuoke Biopharmaceutical Co"
      },
      {
        "sponsorId": "fd9f01621385a9d2c18ef56159f02c2acd10e0e0",
        "sponsorName": "Fourth Military Medical University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "gilenya",
    "chemicalName": "fingolimod",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 22 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "treats ms",
    "numSites": "1",
    "otherPartners": "nihr",
    "phase": "2",
    "preferredName": "fingolimod",
    "productId": 171,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Fuzhou",
        "country": "CN",
        "lat": 26.074478,
        "lng": 119.296482,
        "locationId": "bbdb55a35aec091011c1945ea9dacc5ac59c9d1b",
        "name": "Fuzhou, Fujian, China",
        "state": "Fujian"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "beea472f9414420dd2ba494bd1b0dbf60d0df7a7",
        "sponsorName": "The First Affiliated Hospital of Fujian Medical University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "avigan",
    "chemicalName": "asco9f,ritonavir,favipiravir",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "hiv protease inhibitor",
    "numSites": "1",
    "otherPartners": "self funding,national natural science foundation of china",
    "phase": "2",
    "preferredName": "asco9f_ritonavir_favipiravir",
    "productId": 172,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "271006796f2ff6cc9f94d739d54e2b03240929f0",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs- hiv protease inhibitor",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "nitric oxide (g)",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "2",
    "otherPartners": "private",
    "phase": "2",
    "preferredName": "nitric_oxide_g",
    "productId": 173,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "e8220f8e8f30f40a5335eb3d4cf41e956f848400",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c8523547da03b9b3e757de3bc960672aa18072e3",
        "sponsorName": "Xijing Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "vitamin c,sodium ascorbate",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "prevent cytokine induced damage to lungs",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "vitamin_c_sodium_ascorbate",
    "productId": 174,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "fe59e29302618ef72fa896edf10e5ce7dccc61cc",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "97762ba3b2e3dd4f574d358f75498097f2645ed4",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4aa837dcf498f3cc77b727f1990dd1d645311b0b",
        "sponsorName": "ZhiYong Peng"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antioxidant",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ivermectin",
    "conditionOrDisease": "",
    "countries": ["australia"],
    "countryCodes": ["aus"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 04 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "monash biomedicine discovery institute,peter doherty institute for infection and immunity,",
    "phase": "",
    "preferredName": "ivermectin",
    "productId": 175,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a6fe5f8f84da1d7b22c45630250e4e2f8089321f",
        "sponsorName": "Peter Doherty Institute for Infection and Immunity"
      },
      {
        "sponsorId": "3082a5fece956a5b8c18d78151ccaa493e0b1b01",
        "sponsorName": "Medical Research Future Fund"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "cynk-001",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 29 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "sorrento therapeutics inc.",
    "phase": "phase i",
    "preferredName": "antibody",
    "productId": 176,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Galveston",
        "country": "US",
        "lat": 29.312325,
        "lng": -94.773173,
        "locationId": "bea223ecbdc0795e15e7c29c4ae5d21638a3ee8d",
        "name": "301 University Blvd, Galveston, TX 77555, USA",
        "state": "TX"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "db21bb858ca06c7530b53487f0dd905696244c54",
        "sponsorName": "Celularity Inc"
      },
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "sti-4920,cmab020",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "bispecific ace-mab fusion protein",
    "numSites": "",
    "otherPartners": "sorrento therapeutics inc.,mabpharm limited",
    "phase": "pre-clinical testing",
    "preferredName": "antibody",
    "productId": 177,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      },
      {
        "sponsorId": "c9c165926c1b9b7b8832e8afef24f2834d6e595c",
        "sponsorName": "Mabpharm Limited"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "gene mabâ¢",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "uses gene mabâ¢ platform for ab delivery",
    "numSites": "",
    "otherPartners": "sorrento therapeutics inc.",
    "phase": "discovery",
    "preferredName": "antibody",
    "productId": 178,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "99401ebed0fa84553f3dab49ec5651d6e16ebb72",
        "sponsorName": "SmartPharm Therapeutics Inc"
      },
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["south korea"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sun, 19 Apr 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 19 Sep 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "celltrion  korea centers for disease control and prevention",
    "phase": "pre-clinical testing",
    "preferredName": "antibody",
    "productId": 179,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "625c2965f7108c1ad1edf37eef366aad6b28fbd8",
        "sponsorName": "Celltrion"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "anti-corona immunoglobulin (igg)",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["israel"],
    "countryCodes": ["isr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 03 Nov 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "plasma of recovered people w ab is used in patients",
    "numSites": "",
    "otherPartners": "kamada",
    "phase": "pre-clinical testing",
    "preferredName": "antibody",
    "productId": 180,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5929da2b33c19978e9dd493734a7e92160428081",
        "sponsorName": "Kamada Ltd"
      },
      {
        "sponsorId": "3e412b7cf7607d2c373441c8651e88306e8012b0",
        "sponsorName": "Kedrion Biopharma Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "centivax",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 19 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 19 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 19 Aug 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "centivax",
    "phase": "pre-clinical testing",
    "preferredName": "antibody",
    "productId": 181,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bcb8d1f52e45cce0b2413d1c2485755444633dbb",
        "sponsorName": "Swiftscale Biologics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["netherlands"],
    "countryCodes": ["nld"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 03 Oct 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "erasmus mc",
    "phase": "pre-clinical testing",
    "preferredName": "antibody",
    "productId": 182,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fe367a0d5ee946a16335321f006255c41d4c8e7b",
        "sponsorName": "Erasmus MC"
      },
      {
        "sponsorId": "e5479b2036f6950930cca1811fbcb4957595d9cd",
        "sponsorName": "Utrecth University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "prezcobix",
    "chemicalName": "(darunavir,hiv-1 protease inhibitor/cobicistat,cyp3a inhibitor)",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 31 Aug 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 30 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "janssen pharmaceutical companies,shanghai public health clinical center",
    "phase": "phase i",
    "preferredName": "darunavir__hiv1_protease_inhibitorcobicistat__cyp3a_inhibitor",
    "productId": 183,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      },
      {
        "sponsorId": "7745b01b52b6f1cf88a706afd1b056e344c46e24",
        "sponsorName": "Zhongnan Hospital of Wuhan University"
      },
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "arbidol",
    "chemicalName": "umifenovir",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 07 Jan 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 02 Jul 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "membrane fusion inhibitor",
    "numSites": "",
    "otherPartners": "chinaâs ruijin hospital",
    "phase": "phase iv",
    "preferredName": "umifenovir",
    "productId": 184,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "deef1b7181395ef02ad3b7cd894fb64716ba0215",
        "sponsorName": "Pharmstandard"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "xofluza",
    "chemicalName": "baloxavir marboxil",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 02 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 31 May 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "polymerase acidic endonuclease inhibitor",
    "numSites": "",
    "otherPartners": "the first hospital affiliated to zhejiang university's medical school,roche",
    "phase": "phase i",
    "preferredName": "baloxavir_marboxil",
    "productId": 185,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      },
      {
        "sponsorId": "50a9bfad2cbb96596fb34d34cdfbd349c1a4fbbc",
        "sponsorName": "The First Hospital Affiliated to Zhejiang Universitys Medical School"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "plx cell product",
    "chemicalName": "placenta-based cells",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "placenta-based cell therapy",
    "numSites": "",
    "otherPartners": "pluristem therapeutics,bih center for regenerative therapy,berlin center for advanced therapies",
    "phase": "phase i",
    "preferredName": "placentabased_cells",
    "productId": 186,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Brookline",
        "country": "US",
        "lat": 42.3326456,
        "lng": -71.1150656,
        "locationId": "beea7c0b1e1e47f800c4bbab74b16e7a62a49749",
        "name": "1 Brookline Pl # 123, Brookline, MA 02445, USA",
        "state": "MA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2b9a512817547dd6eca9ae64392478de4df5ea55",
        "sponsorName": "Pluristem Therapeutics"
      },
      {
        "sponsorId": "14df6ecd68ad3a991782c40f386042236234019a",
        "sponsorName": "BIH Center for Regenerative Therapy"
      },
      {
        "sponsorId": "3c023d5d2630d83ff1f51fee219f0e0dec252a08",
        "sponsorName": "Berlin Center for Advanced Therapies"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "thalidomide",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 16 Jul 1998 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "an approved drug with noted immunosuppressive and anti-angiogenic activity,used for a number of immunological and inflammatory disorders,clinical trials aim to see if these properties of thalidomide can be used to prevent or treat covid-19 induced lung injury instead of functioning as a direct antiviral,note that there is a second study with the same sponsors and utilizing thalidomide as well - but that includes the use of low does hormones as well and only enrolls 40 participants,discovery start - nda approval - and on the market are completed with respect to thalidomide itself without taking into account its prospective use in treating covid-19",
    "numSites": "undisclosed",
    "otherPartners": "second affliated hospital of wenzhou medical university,wenzou central hospital",
    "phase": "2",
    "preferredName": "thalidomide",
    "productId": 187,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4337c2a735b1c82b0b730abbf6b584dd7f97e512",
        "sponsorName": "The First Affiliated Hospital of Wenzhou Medical University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04273529,nct04273581"
  },
  {
    "brandName": "arb",
    "chemicalName": "losartan",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 14 Apr 1995 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "approved drug used to treat hypertension by functioning as an angiotensin ii receptor blocker,study intends to track covid-19 patients' risk status in the icu using the sequential organ failure assessment (sofa) respiratory score following treatment with losartan or a placebo",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "losartan",
    "productId": 188,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.9722301,
        "lng": -93.2615932,
        "locationId": "1ad95ac103a0c5ccf4cf950b536b79acc5d0cd8b",
        "name": "730 S 8th St, Minneapolis, MN 55415, USA",
        "state": "MN"
      },
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.9711356,
        "lng": -93.2311679,
        "locationId": "e0fde6273f6c30f3b59cae50303c6c77cbf61f70",
        "name": "500 SE Harvard St, Minneapolis, MN 55455, USA",
        "state": "MN"
      },
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.97399,
        "lng": -93.2277285,
        "locationId": "9d6b622185088b9c6655b133c4fc7f1526993472",
        "name": "Minneapolis, MN 55455, USA",
        "state": "MN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d49e1350f4c21eef623eb4e22b9709b13ac08f82",
        "sponsorName": "University of Minnesota"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04311177,nct04312009"
  },
  {
    "brandName": "",
    "chemicalName": "sildenafil citrate",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 09 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 19 May 1998 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "approved drug used to treat pulmonary arterial hypertension,angina,and erectile dysfunction,study evaluates rate of disease remission,rate of entering the critical stage,and time of entering the critical stage after treatment with sildenafil citrate",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "sildenafil_citrate",
    "productId": 189,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "70519e36b027fabffe022762ad9ba746ca0563ad",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04304313"
  },
  {
    "brandName": "",
    "chemicalName": "a lipic acid",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "a_lipic_acid",
    "productId": 190,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d8a6fb8782589eff1784a987131a3510fd1991ff",
        "sponsorName": "Zhongshan Hospital"
      },
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "chloroquine phosphate",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chloroquine_phosphate",
    "productId": 191,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2d7ffefe148247749f6402c5edc286a5095cc88a",
        "sponsorName": "Jingzhou Central Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "ebastine,lopinavir,interferon a",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ebastine_lopinavir_interferon_a",
    "productId": 192,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a61efee7bdf9baf309997f1ccf652ee02887c52",
        "sponsorName": "Wuhan Red Cross Hospital"
      },
      {
        "sponsorId": "1be6e3f3520226675b831cc738fab10a9812c4fd",
        "sponsorName": "Minanyang Central Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "danoprevir,ritonavir,interferon",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 19 Jun 2018 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "danoprevir is an oral hepatitis c virus protease inhibitor approved in china in june 2018,used in a phase 4 trial that began 02/17/2020 to observe its effects on the rate of composite adverse outcomes and time to recovery among other measures",
    "numSites": "1",
    "otherPartners": "ascletis pharmaceutials co. ltd.",
    "phase": "4",
    "preferredName": "danoprevir_ritonavir_interferon",
    "productId": 193,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Nanchang",
        "country": "CN",
        "lat": 28.682892,
        "lng": 115.858197,
        "locationId": "a88a11cef39b39fc6508e4d32108c5d0d0f3e432",
        "name": "Nanchang, Jiangxi, China",
        "state": "Jiangxi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bdb545b6c04a880d9d0382f48b816fee837c1330",
        "sponsorName": "The Ninth Hospital of Nanchang"
      },
      {
        "sponsorId": "e1bafffd3c4ccdf8eaf5841a8838a032654edc76",
        "sponsorName": "Ascletis Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04291729"
  },
  {
    "brandName": "",
    "chemicalName": "mesenchymal stem cells",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "mscs have been shown to exert antiinflammatory and immunoregulatory functions - promote regeneration of damaged tissues - and inhibit tissue fibrosis,trial aims to explore msc's potential to treat covid-19 patients",
    "numSites": "1",
    "otherPartners": "puren hospital affliated to wuhan university of science and technology,shanghai university,qingdao co-orient watson biotechnology group co. ltd,basic medical sciences - chinese academy of medical sciences",
    "phase": "1",
    "preferredName": "mesenchymal_stem_cells",
    "productId": 194,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "f102d77d501493dde5b0e0eb54ce716530b1b03f",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba",
        "sponsorName": "Chinese Academy of Medical Sciences"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04339660"
  },
  {
    "brandName": "",
    "chemicalName": "bevacizuman biosimilar",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 26 Feb 2004 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "approved anti-vegf (vascular endothelial growth factor) treatment widely used in clinical oncotherapy,it is a humanized monoclonal antibody,good potential in being repurposed for covid treatment because vegf levels are higher in covid patients compared to healthy controls and vegf is considered the most potent vascular permeability inducers and can lead to acute lung injury and ards,qilu hospital is sponsoring two different trials for bevacizumab - one is a hybrid phase 2-3 trial and the other has a not applicable phase",
    "numSites": "3,1",
    "otherPartners": "renmin hospital of wuhan university,ialy morigga pelascini gravedona hospital s.p.a,wuhan university,jiangbei union hospital of huazhong university of science and technology,shandong provincial chest hospital",
    "phase": "3 and 2,n/a",
    "preferredName": "bevacizuman_biosimilar",
    "productId": 195,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "b4482dc0e5c5f018166544c4c238d7dcdc11227c",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Jinan",
        "country": "CN",
        "lat": 36.6512,
        "lng": 117.120095,
        "locationId": "d5a8fb4002b7fa21f4fbc1f547ed746747d16000",
        "name": "Jinan, Shandong, China",
        "state": "Shandong"
      },
      {
        "city": "Gravedona ed Uniti",
        "country": "IT",
        "lat": 46.1485418,
        "lng": 9.3085677,
        "locationId": "f6d7911fa93de5956abf32a515d74ddd2d96ad12",
        "name": "22015 Gravedona ed Uniti, Province of Como, Italy",
        "state": "Lombardy"
      },
      {
        "city": "Jinan",
        "country": "CN",
        "lat": 36.6512,
        "lng": 117.120095,
        "locationId": "d5a8fb4002b7fa21f4fbc1f547ed746747d16000",
        "name": "Jinan, Shandong, China",
        "state": "Shandong"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5097a8114e431ac8ebcbd82cdf94884e315a5cba",
        "sponsorName": "Qilu Hospital of Shandong University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "nct04275414,nct04305106"
  },
  {
    "brandName": "",
    "chemicalName": "recombinant ace2",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "study to investigate if there is efficacy signal that warrants a large phase 2b trial or harm that suggests trial should not be done,study in question has a not applicable phase,status is withdrawn as of 03/17/2020 (which is why many cells were left blank)",
    "numSites": "1",
    "otherPartners": "",
    "phase": "n/a",
    "preferredName": "recombinant_ace2",
    "productId": 196,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Guangzhou",
        "country": "CN",
        "lat": 23.12911,
        "lng": 113.264385,
        "locationId": "616d5326a681eec1774e290b5d8149aca680aa13",
        "name": "Guangzhou, Guangdong Province, China",
        "state": "Guangdong Province"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ea78fbfadca996d3b3279e672883c8476ffd78cf",
        "sponsorName": "The First Affiliated Hospital of Guangzhou Medical University"
      }
    ],
    "status": "on hold",
    "therapeuticApproach": "other",
    "trialId": "nct04287686"
  },
  {
    "brandName": "",
    "chemicalName": "washed micrbiota transplantation",
    "conditionOrDisease": "condition",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 05 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "molecule type - microbiota. the recent study on using washed microbiota transplantation (wmt) as rescue therapy in critically ill patients with aad demonstrated the important clinical benefits and safety of wmt. additionally the recent animal study provided direct evidence supporting that antibiotics could decrease gut microbiota and the lung stromal interferon signature and facilitate early influenza virus replication in lung epithelia. importantly the above antibiotics caused negative effects can be reversed by fecal microbiota transplantation (fmt) which suggested that fmt might be able to induce a significant improvement in the respiratory virus infection.",
    "numSites": "1",
    "otherPartners": "the second hospital of nanjing medical university",
    "phase": "experimental",
    "preferredName": "washed_micrbiota_transplantation",
    "productId": 197,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Nanjing Shi",
        "country": "CN",
        "lat": 32.043846,
        "lng": 118.774763,
        "locationId": "eb6cb36658813f7e8a8b90f691f6b2ff2098d0d3",
        "name": "140 Hanzhong Rd, Gulou Qu, Nanjing Shi, Jiangsu Sheng, China, 210029",
        "state": "Jiangsu Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3452304684b286fca6c4db5bb90b92026a7d077b",
        "sponsorName": "The Second Hospital of Nanjing Medical University"
      }
    ],
    "status": "on hold",
    "therapeuticApproach": "",
    "trialId": "nct04251767"
  },
  {
    "brandName": "persantine",
    "chemicalName": "dipyridamole",
    "conditionOrDisease": "condition",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "type - vasodilator",
    "numSites": "6",
    "otherPartners": "major regional immunity cultivation project - 91742109",
    "phase": "4",
    "preferredName": "dipyridamole",
    "productId": 198,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Guangzhou Shi",
        "country": "CN",
        "lat": 23.100146,
        "lng": 113.288641,
        "locationId": "fa1361df1dfcde68acb14cb16e1d4ecd25532661",
        "name": "1 Kangda Rd, Bin Jiang Lu, Haizhu Qu, Guangzhou Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.53535699999999,
        "lng": 114.299525,
        "locationId": "9ee0c1fde532529932f2f1e35f8dc5e22cd86794",
        "name": "Wuchang District, Wuhan, China",
        "state": null
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.583826,
        "lng": 114.273585,
        "locationId": "4ff22b2050432ef8ec1e757395aca935caea187c",
        "name": "Jiefang Ave, Xi Bei Hu, Jianghan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.88255699999999,
        "lng": 114.375743,
        "locationId": "c0966ac52a518b7b6e32a8ed8addbf22a6f64e1c",
        "name": "Huangpi District, Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Xiaogan",
        "country": "CN",
        "lat": 31.561164,
        "lng": 114.127022,
        "locationId": "188d2d303c800840d83e684a57a0d3921ea7e35f",
        "name": "Dawu County, Hubei, Xiaogan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wenzhou",
        "country": "CN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "e188f786c7dee2c0822bcf93710feb32c00eba3b",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ea78fbfadca996d3b3279e672883c8476ffd78cf",
        "sponsorName": "The First Affiliated Hospital of Guangzhou Medical University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": "chictr2000030055"
  },
  {
    "brandName": "",
    "chemicalName": "bromhexine hydrochloride,arbidol umifenovir,favipiravir,interferon a2b",
    "conditionOrDisease": "condition",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "on going recruitment",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "bromhexine_hydrochloride_arbidol_umifenovir_favipiravir_interferon_a2b",
    "productId": 199,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wenzhou Shi",
        "country": "CN",
        "lat": 28.006211,
        "lng": 120.67225,
        "locationId": "367a04f8484eac49d051059d30259471f67e1cd0",
        "name": "109 Xueyuan W Rd, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng, China",
        "state": "Zhejiang Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1a54d298d5b18d923897d81e7dd0a48df5240f94",
        "sponsorName": "The Second Affiliated Hospital of Wenzhou Medical University"
      },
      {
        "sponsorId": "9b98ab2f7f83afd2e87f907a0f64dbc3220477b6",
        "sponsorName": "WanBangDe Pharmaceutical Group"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": "nct04273763"
  },
  {
    "brandName": "",
    "chemicalName": "dihydroartemisinin,piperaquine,arbidol umifenovir,interferon a",
    "conditionOrDisease": "condition",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "cancelled by investigator",
    "numSites": "4",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "dihydroartemisinin_piperaquine_arbidol_umifenovir_interferon_a",
    "productId": 200,
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Independence",
        "country": "US",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "8e3d5c9bc72dedc56b4aa211892e36ca39528688",
        "name": "Independence, KS 67301, USA",
        "state": "KS"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "38fcdd512a2ead59bfa4dcd3a88380a2cc4f6fe4",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.599041,
        "lng": 114.301165,
        "locationId": "fcd31e15686386f5966c05ceb921f84a6fa9b9e8",
        "name": "China, Hubei Sheng, Wuhan Shi, Jiangan Qu, ä¸é³è·¯",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "534a6f8e0e60ade16ff786af299a23f4763a68ac",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b2025696e611deea59bde95a78322849a7a75f10",
        "sponsorName": "The First Affiliated Hospital of Nanchang University"
      }
    ],
    "status": "failed",
    "therapeuticApproach": "antiviral drugs-not specified,anti-malarial",
    "trialId": "chictr2000030082"
  },
  {
    "brandName": "intravenous immunoglobulin",
    "chemicalName": "human immunoglobulin (ph4)",
    "conditionOrDisease": "pneumonia",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "tongji hospital of tongji medical college,huazhong university of science and technology",
    "phase": "2",
    "preferredName": "human_immunoglobulin_ph4",
    "productId": 201,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "430f3309288e69c27036079c72b0538d46f897a2",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "10172e384c8eaa0f469f305f6d2b50b0eabb14f5",
        "sponsorName": "Peking Union Medical College Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04261426"
  },
  {
    "brandName": "roactemra",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 08 Jan 2010 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "being used in above trial",
    "numSites": "9",
    "otherPartners": "n/a",
    "phase": "0",
    "preferredName": "tocilizumab",
    "productId": 202,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "f7951f6ec6adee6c1b371ff1f60eacee7d801b28",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "6459bc63cbd37ab9f1b832200745d85d6ede8d78",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "5053ecd2b42f371f07211a2f005dd65911e34632",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.33156,
        "lng": 114.690679,
        "locationId": "dad71fcd37c65a26f76c2afa8b9d9ee76d5285ad",
        "name": "China, Hubei Sheng, Ezhou Shi, Liangzihu Qu, 239çé",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "afc9af69864692b580cb4d13f07bac04297fd0b3",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "802ebdab641542b156f4a996045a34005f49d0ea",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, é¶æ½­è·¯1å·",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "4c9fc80b3e00f3b2a6a097bf4e2caec62c189bd2",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.576258,
        "lng": 114.289076,
        "locationId": "85b97e9c56432eac403821d19f10459d6c33a305",
        "name": "Hualou Street, Jianghan District, Wuhan, China",
        "state": null
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "ec6ea049940ea4f56dd685bc9de2a0e1330cdc28",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "61b796a11a286085a1500bab09ded97bbeeb7c0c",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      },
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "nct04310228"
  },
  {
    "brandName": "anulohuaxian",
    "chemicalName": "anulohuaxian",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "other",
    "notes": "traditional chinese medicine",
    "numSites": "8",
    "otherPartners": "n/a",
    "phase": "0",
    "preferredName": "anulohuaxian",
    "productId": 203,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Fuyang Shi",
        "country": "CN",
        "lat": 33.164296,
        "lng": 115.628262,
        "locationId": "6976f8ec2dd4b2e7b213d50f4bff1a0e863a8617",
        "name": "Wenming Rd, Taihe Xian, Fuyang Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.33156,
        "lng": 114.690679,
        "locationId": "06c0fccf81d1934bcb8aa37a90d162b5d7b4c979",
        "name": "China, Hubei Sheng, Ezhou Shi, Liangzihu Qu, 239çé",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "cd2650965da74f1e565312a7a4b576c9b7e8d2bb",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "3373073c0028330f5a37c4039f9f58e85e011ab5",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, é¶æ½­è·¯1å·",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "8683f24112818727740a7f176fbdf042b6c1fabb",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.576258,
        "lng": 114.289076,
        "locationId": "bf2b9c0fcc0e78476f0fadcca81085292c41b191",
        "name": "Hualou Street, Jianghan District, Wuhan, China",
        "state": null
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "ef7cffd12241c3187e53738f9bf2d240ff3e0be4",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "c4ab789c386a670ee05d4eef18a5069a28d367c4",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wenzhou",
        "country": "CN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "a2ed1b62346ff251b0edfebaac12c6cf4558605b",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": "nct04334265"
  },
  {
    "brandName": "avigan",
    "chemicalName": "favipiravir",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 19 May 2014 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "for patients who's nucleic acids have changed from negative to positive",
    "numSites": "8",
    "otherPartners": "n/a",
    "phase": "0",
    "preferredName": "favipiravir",
    "productId": 204,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Fuyang Shi",
        "country": "CN",
        "lat": 33.164296,
        "lng": 115.628262,
        "locationId": "a5de6343cbec3dd0a704f07c637d2a00a2781263",
        "name": "Wenming Rd, Taihe Xian, Fuyang Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Ezhou",
        "country": "CN",
        "lat": 30.39194,
        "lng": 114.894843,
        "locationId": "2362077c2840505f6682793bb8da4207f1177ec3",
        "name": "Ezhou, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.33156,
        "lng": 114.690679,
        "locationId": "b8d96488754cfe6252262bbd1811b4f2ea26c57e",
        "name": "China, Hubei Sheng, Ezhou Shi, Liangzihu Qu, 239çé",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "6d9b46aaca34a0a69245d8e3003520aaa5d9813c",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "d9d638c726c16ff84916b89f3759993926c78c33",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, é¶æ½­è·¯1å·",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "d0aefb69a29f62e538573ad239da68d0ac9f4401",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "1950faad1fb3589d28c772c93b889e192b66a6f6",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wenzhou",
        "country": "CN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "91cd73a623fb67aae321dc49845ed898e952bb0e",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": "nct04333589"
  },
  {
    "brandName": "",
    "chemicalName": "allogeneic human dental pulp stem cells",
    "conditionOrDisease": "covid-19 pneumonia",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "1",
    "otherPartners": "beijing sh bio-tech corporation - beijing - china,utooth biological technology co. ltd. - hubei - china",
    "phase": "1",
    "preferredName": "allogeneic_human_dental_pulp_stem_cells",
    "productId": 205,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.53535699999999,
        "lng": 114.299525,
        "locationId": "5f3bf686f7fabe1adcd5213d397b21f6801b57c4",
        "name": "Wuchang District, Wuhan, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14a2146233138c07a64e0baef6cc949f64c7af25",
        "sponsorName": "Renmin Hospital of Wuhan University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04336254"
  },
  {
    "brandName": "ibio-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "being repurposed to treat idiopathic pulmonary fibrosis,previously granted orphan drug designation for treatment of systemic sclerosis investigated to systemic scleroderma",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ibio100",
    "productId": 206,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "505b07d6981f93ee187513e197589f4c16f04b35",
        "sponsorName": "iBio Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "chloroquine,azithromycin",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chloroquine_azithromycin",
    "productId": 207,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9f993454bdb55447c232ff4e925773960b482c3a",
        "sponsorName": "Population Health Research"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "favipiravir,baloxavir marboxil",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "favipiravir_baloxavir_marboxil",
    "productId": 208,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a81e304214bfeeb11d72efbec071b026a7bec070",
        "sponsorName": "First Hospital Affiliated"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "darunavir & cobicistat",
    "conditionOrDisease": "covid 19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "darunavir is an established antiretroviral for hiv combined with cobicistat to increase systemic penetration,currently being evaluated for safety and efficacy for covid 19 pneumonia,johnson & johnson made an announcement about the lack of evidence of efficacy of this combination on 03/16/2020 based on the trial listed",
    "numSites": "2",
    "otherPartners": "gilead,janssen,johnson&johnson",
    "phase": "3",
    "preferredName": "darunavir__cobicistat",
    "productId": 209,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 30.791749,
        "lng": 121.341627,
        "locationId": "a7aaf83ddabbcd172cb4c11942031695b43faf08",
        "name": "2901 Caolang Hwy, Jinshan Qu, Shanghai Shi, China",
        "state": "Shanghai Shi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      },
      {
        "sponsorId": "0ff0405e4544cd120687a915ea369ae1dac78dca",
        "sponsorName": "Johnsons  Johnson"
      },
      {
        "sponsorId": "8cd26a383793b281ef40085df75c92792db1b43d",
        "sponsorName": "Gilead"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": "nct04252274"
  },
  {
    "brandName": "jakafi,jakavi",
    "chemicalName": "ruxolitinib",
    "conditionOrDisease": "covid 19",
    "countries": ["switzerland"],
    "countryCodes": ["che"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "being evaluated for treatment of covid 19 associated cytokine storm",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ruxolitinib",
    "productId": 210,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      },
      {
        "sponsorId": "28de4f9051af1771961895dd1ee280ee55497988",
        "sponsorName": "Incyte Corporation"
      },
      {
        "sponsorId": "a47ed0af8e79c0d5e04834a88fa5c0fa3a019663",
        "sponsorName": "Novartis AG"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": "nct04355793"
  },
  {
    "brandName": "peginterferon lambda-1a",
    "chemicalName": "peginterferon lambda-1a",
    "conditionOrDisease": "covid 19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "peginterferon_lambda1a",
    "productId": 211,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "683d20f6c6f23f9c1e0851b35e3f725262584fe3",
        "sponsorName": "Stanford University"
      },
      {
        "sponsorId": "4b56e1109e3c62392ddb122d219ce7bd5514472d",
        "sponsorName": "Eiger Biopharmaceuticals Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04331899"
  },
  {
    "brandName": "lv-smenp-dc",
    "chemicalName": "",
    "conditionOrDisease": "covid 19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "vaccine to treat and prevent severe covid-19 pneumonia,innovative covid19 minigenes engineered based on multiple viral genes using an efficient lentiviral vector system to express viral proteins and immune modulatory genes to modify dendritic cells and to activate t cells",
    "numSites": "3",
    "otherPartners": "shenzhen third people's hospital,shenzhen second people's hospital",
    "phase": "2",
    "preferredName": "lvsmenpdc",
    "productId": 212,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Shenzhen",
        "country": "CN",
        "lat": 22.543096,
        "lng": 114.057865,
        "locationId": "350f2de599a574f36b4886230c52d5e4047b65ff",
        "name": "Shenzhen, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Shenzhen",
        "country": "CN",
        "lat": 22.635796,
        "lng": 114.130144,
        "locationId": "cf88257bce5fb73cbfaebe6e6c99d308458d17da",
        "name": "Longgang, Shenzhen, China",
        "state": null
      },
      {
        "city": "Shenzhen Shi",
        "country": "CN",
        "lat": 22.556599,
        "lng": 114.086145,
        "locationId": "05d94c22bb034189ffb84c089c2fa613cf738870",
        "name": "3002 Sungang W Rd, Futian Qu, Shenzhen Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": "nct04276896"
  },
  {
    "brandName": "pathogen-specific aapc",
    "chemicalName": "",
    "conditionOrDisease": "covid 19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "covid-19/aapc vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells",
    "numSites": "3",
    "otherPartners": "shenzhen third people's hospital,shenzhen second people's hospital",
    "phase": "1",
    "preferredName": "pathogenspecific_aapc",
    "productId": 213,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": "nct04299724"
  },
  {
    "brandName": "peptide-based therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptidebased_therapeutic",
    "productId": 214,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "970c9dcb0770cc2be64dd33cbfa88ac640f9e606",
        "sponsorName": "48Hour Discovery Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "pharmetrx therapeutics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "pharmetrx_therapeutics",
    "productId": 215,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f3b4e5e84c266ea60771ec2883e82c2204ec2f04",
        "sponsorName": "Afecta Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "active agent",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "active_agent",
    "productId": 216,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f2b34e7e5c8d41cfa0c7e4ca7543514b6c633fe9",
        "sponsorName": "Aicuris Antiinfective Cures GmbH"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviral",
    "productId": 217,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "39b3f1f3677b274c50b99d83330f4862d0b8f6a8",
        "sponsorName": "Aikido Pharma Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "adx-629,reproxalap",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "adx629_reproxalap",
    "productId": 218,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5525922d920320b60e93d8e039b662d088125b7d",
        "sponsorName": "Aldeyra Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "soliris",
    "chemicalName": "eculizumab",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "eculizumab",
    "productId": 219,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "41794d8c7643f99fc7895546d19147d1b41daf20",
        "sponsorName": "Alexion Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "das-181",
    "chemicalName": "recombinant sialidase",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "recombinant_sialidase",
    "productId": 220,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5e79a7dfd885e0baf118378ff6d6ac832c4a44f3",
        "sponsorName": "Ansun Biopharma Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "sars-cov-2 targeting recombinant methioninase",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sarscov2_targeting_recombinant_methioninase",
    "productId": 221,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "84e8fc3396832ade5506a951a3b3ebbaebd87cde",
        "sponsorName": "Anticancer Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "solnatide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "solnatide",
    "productId": 222,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f8b9528ccb10701b24f862db161ec27fbc4847fd",
        "sponsorName": "Apeptico Forschung und Entwicklung GmbH"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cannabinoid-based therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cannabinoidbased_therapy",
    "productId": 223,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "30a0bfe60f04ff11e51d1901a52fbea2c76f2b5d",
        "sponsorName": "Applied Biology Inc"
      },
      {
        "sponsorId": "0112e7fffc5a7da4b036b0306729e2a12720f796",
        "sponsorName": "Applied Bonanics LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "at-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "aldose reductase inhibitor,new york hospital investigator initiated studies used under an emergency ind",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "at001",
    "productId": 224,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3304021f998972cba57fa873b78bbbcda69f3122",
        "sponsorName": "Applied Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "small molecules",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "3 molecules targeting two viral replication enzymes- 3cl-protease and rna dependent rna polymerase,pre-clinical studies will be taken over by the university of hong kong,covar pharmaceuticals is another collaborator",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "small_molecules",
    "productId": 225,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "552bb9ce9d50b56342d0722bdf6a2e671ba4796e",
        "sponsorName": "Aptorum Group Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "alt-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 26 Aug 2019 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "enamptor is a platform of three products which includes alt-100",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "alt100",
    "productId": 226,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4e3c43064be49069b8902b88fe3a123622091b1f",
        "sponsorName": "Aqualung Therapeutics Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "asc-09,ritonavir",
    "chemicalName": "tmc-310911,ritonavir",
    "conditionOrDisease": "covid19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "hiv-1 protease inhibitor,another clinical trial with oseltamivir retracted due to insufficient patients,asc09-ritonavir vs lopinavir-ritonavir trial sponsor is first affiliated hospital of zhejiang university and ascletis is collaborator",
    "numSites": "",
    "otherPartners": "",
    "phase": "0",
    "preferredName": "tmc310911_ritonavir",
    "productId": 227,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9c77c2ee252590839e7e90f484ab0c46df479dbb",
        "sponsorName": "Ascletis Pharma Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other antiviral drugs",
    "trialId": "nct04261907"
  },
  {
    "brandName": "calquence",
    "chemicalName": "acalabrutinib",
    "conditionOrDisease": "covid19",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "acerta pharma b.v. discovered acalabrutinib and is a collaborator on the clinical trial",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "acalabrutinib",
    "productId": 228,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Barcelona",
        "country": "ES",
        "lat": 41.3850639,
        "lng": 2.1734035,
        "locationId": "70a829504a0622fedd88390c9e8562268db5bd1d",
        "name": "Barcelona, Spain",
        "state": "CT"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2c75b2d91db07786aabe9dcac98ed68f752804f1",
        "sponsorName": "AstraZeneca plc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": "nct04346199"
  },
  {
    "brandName": "virazole",
    "chemicalName": "ribavirin inhalation solution",
    "conditionOrDisease": "covid19",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "control # 238007 for canadian clinical trial website - works best with internet explorer,first posted on clinicaltrials.gov 04/22/2020",
    "numSites": "",
    "otherPartners": "hospira inc.",
    "phase": "1",
    "preferredName": "ribavirin_inhalation_solution",
    "productId": 229,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a88af720747218a96a8aad641b4265d2da310f54",
        "sponsorName": "Bausch Health Cos Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": "nct04356677"
  },
  {
    "brandName": "niclocide",
    "chemicalName": "niclosamide",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "voluntarily withdrawn from market by bayer in 1996,another brand name is yomesan",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "niclosamide",
    "productId": 230,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "67da3aa3718d35ed721af558ab42d840a58dfdbe",
        "sponsorName": "Bayer AG"
      },
      {
        "sponsorId": "541210ab7a6daa7079e19f753dbf3002c81ab5a8",
        "sponsorName": "Union Therapeutics AS"
      },
      {
        "sponsorId": "3f0f11935fb0a109bff465cc279e3b68c954fede",
        "sponsorName": "Ana Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "nanobody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "beroni group submitted emergency use authorization for covid-19 rapid test detection kit to fda in march",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nanobody",
    "productId": 231,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b738e5214e4eac0d75fea1d6f1cfdd47e57c0e9b",
        "sponsorName": "Beroni Group"
      },
      {
        "sponsorId": "28bd9f926647c0b6e60a19fd1317a5fdb10635eb",
        "sponsorName": "Tianjin University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "rhu-pgsn",
    "chemicalName": "recombinant human plasma gelsolin",
    "conditionOrDisease": "community-acquired pneumonia",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 28 Aug 2018 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 28 Aug 2018 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "next step is to move into phase 2b",
    "numSites": "8",
    "otherPartners": "",
    "phase": "1b/2a",
    "preferredName": "recombinant_human_plasma_gelsolin",
    "productId": 232,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": null,
        "country": "AU",
        "lat": -20.9175738,
        "lng": 142.7027956,
        "locationId": "1c7b6b80983f8dc14f931d17ced737c94dfa1490",
        "name": "Queensland, Australia",
        "state": "QLD"
      },
      {
        "city": null,
        "country": "AU",
        "lat": -37.4713077,
        "lng": 144.7851531,
        "locationId": "b91ff92c3b671635203ac915a778cf9927169d18",
        "name": "Victoria, Australia",
        "state": "VIC"
      },
      {
        "city": "Mtskheta",
        "country": "GE",
        "lat": 41.8411674,
        "lng": 44.7073864,
        "locationId": "d3728c2ea9168c7ce50b4bfd0eea8b75467cf889",
        "name": "Mtskheta, Georgia",
        "state": "Mtskheta-Mtianeti"
      },
      {
        "city": "Rustavi",
        "country": "GE",
        "lat": 41.5225612,
        "lng": 45.0430369,
        "locationId": "77ce7b8d617a25024400d73d282d1077bded2015",
        "name": "Rustavi, Georgia",
        "state": "Kvemo Kartli"
      },
      {
        "city": "Tbilisi",
        "country": "GE",
        "lat": 41.7151377,
        "lng": 44.827096,
        "locationId": "432200551c749ea7d8878666a321c88b7392797f",
        "name": "Tbilisi, Georgia",
        "state": "Tbilisi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a6c2d1473eb80756c87eca409671a57e3947b727",
        "sponsorName": "Bioaegis Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct03466073"
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "final product aim is a nanobody-an antibody but contains only a single very small unit needed for recognition and disruption of the covid-19 targets",
    "numSites": "",
    "otherPartners": "wuxi-jiangsu local government",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 233,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "69fd255e06de9b1173c6fdf9c2a593c7a7784d3e",
        "sponsorName": "Bioduro LLC"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "vazegepant",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vazegepant",
    "productId": 234,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9416a898d6c70803634f7f9d56ed68eda301ff71",
        "sponsorName": "Biohaven Pharmaceutical Holding Co Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "anti-viroporin therapeutics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviroporin_therapeutics",
    "productId": 235,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b9c81254affc60230c18ca7f16da8eb9fd4cc3e6",
        "sponsorName": "Biotron Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "bold-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "bold100",
    "productId": 236,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d66e29eb51e46ebb67035da91e045d8c5ced9d8d",
        "sponsorName": "Bold Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 237,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a635c9162245b5b265427b6b347bf36ec00ab510",
        "sponsorName": "Brii Biosciences"
      },
      {
        "sponsorId": "597be3ec42623eb2b339b165717d84c7c3137601",
        "sponsorName": "Columbia University"
      },
      {
        "sponsorId": "bfce396095503d26f651c5dad224c79f44d87649",
        "sponsorName": "Tsinghua University"
      },
      {
        "sponsorId": "8bdecc942a48de24772aedb84f5bd52bc0737054",
        "sponsorName": "3rd Peoples Hospital of Shenzhen"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cm-4620-ie",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cm4620ie",
    "productId": 238,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "878b8442cb543076e452c2d646f57de1f361f6f6",
        "sponsorName": "Calcimedica Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cap-1002",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cap1002",
    "productId": 239,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2488a9c05ed2f222808e0d9c70595368ed86a7a6",
        "sponsorName": "Capricor Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 240,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ef5993e2d91aec68e38a7180d305dc11099e9ba5",
        "sponsorName": "Carterra Inc"
      },
      {
        "sponsorId": "c4a8ae6729d9974f1941051e2956e64de583ec66",
        "sponsorName": "La Jolla Institute for Immunology"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ck-0802",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ck0802",
    "productId": 241,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "92d27d31ee16c9150c4ce4a2d09f18d71707dba3",
        "sponsorName": "Cellenkos Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mesenchymal stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mesenchymal_stem_cells",
    "productId": 242,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e2adf519c2fb405939c957dd6389845849f22ca",
        "sponsorName": "CellTex Therapeutics Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "light",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "light",
    "productId": 243,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96d364e5af844fa0968bbd605a149ba3cfd69ca8",
        "sponsorName": "Cerecor Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "not a treatment or a vaccine but tecnology. the tecnology is called chromovert and is used to accelerate drug discovery against hard-to-express biological target.  it has been successfully used to identify a novel non-addictive pain blocker that is in clinical development and it has identified a number of compounds in its pipeline that may help address covid-19-related disease",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chromocell_corp-244",
    "productId": 244,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4f6dba72f4ca74bcc6cb4c053fcddbbd0605b4a8",
        "sponsorName": "Chromocell Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "2-dg",
    "chemicalName": "2-deoxy-d-glucose",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "research was done by university of frankfurt",
    "numSites": "",
    "otherPartners": "wpd pharmaceuticals inc.",
    "phase": "",
    "preferredName": "2deoxydglucose",
    "productId": 245,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b843740e853ec52aa48f7c4d941b036355d61f11",
        "sponsorName": "CNS Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "protase inhibtors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "the compouds are protase inhibitors with a novel mechanism of action",
    "numSites": "",
    "otherPartners": "kansas state university research foundation",
    "phase": "",
    "preferredName": "protase_inhibtors",
    "productId": 246,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "85acfe2552787d1aab27f27a6db39a840956ca36",
        "sponsorName": "Cocrystal Pharma Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "not a treatment or vaccine the intervention is artifical intelligance. cyclica used its proprietary deep learning engine matchmakertm to screen a collection of more than 6700 fda-approved drugs and drug candidates.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cyclica_inc_institute_of_materia_medica-247",
    "productId": 247,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96aa111d21b571477bd2e5134e5c70c2765f72d4",
        "sponsorName": "Cyclica Inc"
      },
      {
        "sponsorId": "90e13d0c6853ec68204942687ed0ccac12474d86",
        "sponsorName": "Institute of Materia Medica"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "nk immunotherapies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "macromoltek",
    "phase": "",
    "preferredName": "nk_immunotherapies",
    "productId": 248,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96da9064b2e31d835251dbc8767057c31f3e37cf",
        "sponsorName": "Cytovia Inc"
      },
      {
        "sponsorId": "f9bfea84937e5d2a1fc4c5dd3aa3872a28df26f8",
        "sponsorName": "Macromoltek Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "ly-3127804",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ly3127804",
    "productId": 250,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3304b2181ddd0c29d7e4e948394439adc182494",
        "sponsorName": "Eli Lilly and Co"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "olumiant",
    "chemicalName": "baricitinib",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "national institute of allergy and infectious diseases",
    "phase": "",
    "preferredName": "baricitinib",
    "productId": 251,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3304b2181ddd0c29d7e4e948394439adc182494",
        "sponsorName": "Eli Lilly and Co"
      },
      {
        "sponsorId": "d70d811c8de3a7e0ae950118837789ce8599f09b",
        "sponsorName": "Incyte Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "covid-hig,covid-eig",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "biomedical advanced research and development authority,emergent and the national institute of allergy and infectious diseases",
    "phase": "",
    "preferredName": "covidhig_covideig",
    "productId": 252,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fb6f2b512443fdfe4d4b85aa2d74466d4ef9bcb4",
        "sponsorName": "Emergent Biosolutions Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "allocetra",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["isreal"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "israel innovation authority",
    "phase": "",
    "preferredName": "allocetra",
    "productId": 253,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "35f03ea5c43e45df3a66c005c91958a6ddad2bc3",
        "sponsorName": "Enlivex Therapeutics Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "enu-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "enu200",
    "productId": 254,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5d1294f0cbab726f6c4136eaea842857641103a9",
        "sponsorName": "Ennaid Therapeutics LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "interferon-beta-1a,traumakine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "interferonbeta1a_traumakine",
    "productId": 255,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a14a930a99f757de7464f323c64a61c4425eeab9",
        "sponsorName": "Faron Pharmaceuticals Oy"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "fw-1022",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fw1022",
    "productId": 256,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cbb02257499f9c2c7d7271d953b3560d56ea08ab",
        "sponsorName": "Firstwave Bio Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "flanders_institute_for_biotechnology-257",
    "productId": 257,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "57edd5513cc69010f620c128c8a4cd203199a017",
        "sponsorName": "Flanders Institute for Biotechnology"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "rcig",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "rcig",
    "productId": 258,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "88873a8fec57e2eafb81051d4b164951b8b32ded",
        "sponsorName": "Gigagen Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "truvada",
    "chemicalName": "emtricitabine,tenofovir",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "emtricitabine_tenofovir",
    "productId": 259,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cbb34f9aed92e21ff89501b842a385faabf9c8c6",
        "sponsorName": "Gilead Sciences Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "trike therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "trike_therapeutic",
    "productId": 260,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "19311beed76e39b72841d55b12b1026f4994706e",
        "sponsorName": "GT Biopharma Inc"
      },
      {
        "sponsorId": "66f07a8584ac1fa31540d4786854faf6c4aa3957",
        "sponsorName": "Cytovance Biologics"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "harrington_discovery_institute-261",
    "productId": 261,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bf94ba6ac350c9a5c8dc12ad79ceb170e893d9a7",
        "sponsorName": "Harrington Discovery Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "hlcm-051",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "hlcm051",
    "productId": 262,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7d37b38fc6903794e0d2745bf6a891faddf43237",
        "sponsorName": "Healios KK"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "hb-admscs",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "hbadmscs",
    "productId": 263,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b6a4863d0716a8f9abb22fd5f19ab102949816cc",
        "sponsorName": "Hope Biosciences LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "lenzilumab",
    "chemicalName": "",
    "conditionOrDisease": "covid 19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "lenzilumab",
    "productId": 264,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a81896aa5b137b226eae204c475800cdbc8c227f",
        "sponsorName": "Humanigen Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04351152"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "considering the use of endonuclease inhibitors that have been proven useful in blocking the sars virus",
    "numSites": "",
    "otherPartners": "iktos sas",
    "phase": "",
    "preferredName": "sri_international-265",
    "productId": 265,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9363c36807614b06638e420a1f2fa93b6641816b",
        "sponsorName": "SRI International"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 19 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "immuncyte_life_sciences_inc_thermogenesis_holdings_inc-266",
    "productId": 266,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c63f55174180d5dacbf95a06be5fab86b51dd9bd",
        "sponsorName": "Immuncyte Life Sciences Inc"
      },
      {
        "sponsorId": "2d735c3d9d663fcc08e98c3576299ec02b7f8090",
        "sponsorName": "Thermogenesis Holdings Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "lodonal - cyto 106,irt-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "initially developed for use in hiv,has shown efficacy in decreasing replication of h1n1 influenza",
    "numSites": "",
    "otherPartners": "immune therapeutics inc.",
    "phase": "",
    "preferredName": "lodonal__cyto_106_irt101",
    "productId": 267,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6ea4d83cf95f6a8d357720443be824816569a0f0",
        "sponsorName": "Cytocom Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "innate_pharma_sa_marseille_immunopole-268",
    "productId": 268,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b337560632de8abae925da303babdc79ea05dadb",
        "sponsorName": "Innate Pharma SA"
      },
      {
        "sponsorId": "587b66a05b02fcac9b73edf0cbb79d9cd55ecd52",
        "sponsorName": "Marseille Immunopole"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "namilumab",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "namilumab",
    "productId": 269,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "62b5112b8c89d1a47c69aa94e5bc89d7166f157b",
        "sponsorName": "Izana Bioscience Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "airuka",
    "chemicalName": "camrelizumab,thymosin",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "camrelizumab_thymosin",
    "productId": 270,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "44eafbed318ddb4f38d794fb4efd9f98455cbe54",
        "sponsorName": "Jingsu HengRui Medicine Co"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "tocilizumab biosimilar",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tocilizumab_biosimilar",
    "productId": 271,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "324d178c669e71e0405a90eac0b5a43232854ad4",
        "sponsorName": "Jinyu Biotechnology Co Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 272,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cf093c3c3034066cc4fc396f460d2433806ea0c3",
        "sponsorName": "Junshi Biosciences Ltd"
      },
      {
        "sponsorId": "e494e00fc769e5a7fbfae8fa40eb4e348fb6dd3b",
        "sponsorName": "Institute of Microbiology of the Chinese Academy of Sciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "selinexor",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "selinexor",
    "productId": 273,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e6cb84b316561809b01b60e49451ae9585f9599e",
        "sponsorName": "Karyopharma Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "arm/nk therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "armnk_therapy",
    "productId": 274,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "65a4395646171957f48b542bb3f8a88cb60f8744",
        "sponsorName": "Kleo Pharmaceuticals Inc"
      },
      {
        "sponsorId": "5d01024199c1e46eb25ce5e44ac99c1bd0431f67",
        "sponsorName": "Green Cross Labcell"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "panaphix",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "panaphix",
    "productId": 275,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "80d5660a048cb4f5f9120ad0ee6693d572076feb",
        "sponsorName": "Komipharm International Co Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "giapreza",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "giapreza",
    "productId": 276,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "eaeb4d2f6090de798cc599bb33c63aece3ea3e59",
        "sponsorName": "La Jolla Pharmaceutical Co"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "lemellosome",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "lemellosome",
    "productId": 277,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a1a954d36a30fd0780c3b830f4faea0c8c2affb2",
        "sponsorName": "Lamellar Biomedical Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "lau-7b",
    "chemicalName": "fenretinide",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fenretinide",
    "productId": 278,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7fccb09ede9fdc5e7fac92574b058cb03352c217",
        "sponsorName": "Laurent Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "lb-1148",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "lb1148",
    "productId": 279,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "939a860ac278db9d975ccb0616222eeeef87f0e8",
        "sponsorName": "Leading Biosciences Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "sanofi sa,amneal pharmaceuticals inc.,rising pharma holdings inc.,university of minnesota,university of oxford,ihu-mÃ©diterranÃ©e infection,sandoz inc.,bayer ag,university of washington,patient-centerede outcomes research institute,world health organization,new york state department of health,national institute or respiratory diseases - mexico,",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sanofi_sa_amneal_pharmaceuticals_inc_rising_pharma_holdings_inc_university_of_minnesota_university_of_oxford_ihumÃ©diterranÃ©e_infection_sandoz_inc_bayer_ag_university_of_washington_patientcenterede_outcomes_research_institute_world_health_organization_new_york_state_department_of_health_national_institute_or_respiratory_diseases__mexico_",
    "productId": 280,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "86b83695165cca282e4f9c439eda39501ae4f0df",
        "sponsorName": "Lupus Therapeutics"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "thiolanox",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "thiolanox",
    "productId": 281,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1bae5c9e81061a3096b953a0c281893f63528dcf",
        "sponsorName": "Mallinckrodt plc"
      },
      {
        "sponsorId": "6911212feb8516a3c67e4d56ab144214fba04e7c",
        "sponsorName": "Novoteris LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "prototype powders",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "prototype_powders",
    "productId": 282,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "98d35ba7fbc9135eb8b0efad1c369b7efd428d50",
        "sponsorName": "Mannkind Corp"
      },
      {
        "sponsorId": "7879cb30e61a74d5398a4ad84131b67c7bdef5e5",
        "sponsorName": "Immix Biopharma Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 283,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3b31ebe3bec88be1939ba82b92fd751109ba63c",
        "sponsorName": "Medicago Inc"
      },
      {
        "sponsorId": "89ce3145e138aa498d0b8624253df8d652b51d01",
        "sponsorName": "Laval University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mn-166",
    "chemicalName": "ibudilast",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ibudilast",
    "productId": 284,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "93b330b91c5cf5de4858a317eb4e5d88f5c33274",
        "sponsorName": "Medicinova Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ivermectin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ivermectin",
    "productId": 285,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "62af02d502c3b46af39cf1393ded764d02cf2dd3",
        "sponsorName": "Medincell SA"
      },
      {
        "sponsorId": "4504468bad51eef6a2ac6172fa89a91614df3c56",
        "sponsorName": "Merck"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "wp-1122",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "wp1122",
    "productId": 286,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bfc86f4330be66b8207ed43b7e662f038bf16e6e",
        "sponsorName": "Moleculin Biotech Inc"
      },
      {
        "sponsorId": "47b17e1c6508ca65a8f74513d8a91bf7fea67bd1",
        "sponsorName": "University of Texas Medical Branch"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "colchicine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "colchicine",
    "productId": 287,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "249179236abc76c285b00f0d0d7abc1e9abfdaa2",
        "sponsorName": "Montreal Heart Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cd-16,n-803,mesenchymal stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "cd-16 off-the-shelf natural killer cells to enhance antibody killing of infected cells given alone or combined with convalescent plasma (cp) in combination with immunitybioâs il-15 superagonist n-803 and avelumab",
    "numSites": "",
    "otherPartners": "nantkwest inc.,immunitybio inc.",
    "phase": "pre-clinical",
    "preferredName": "cd16_n803_mesenchymal_stem_cells",
    "productId": 288,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "13fabd5b14178a13d0539b59d6a9be0b068e4309",
        "sponsorName": "Nantkwest Inc"
      },
      {
        "sponsorId": "8bfec75fcf441b5e6dfde4d8556e152456e80321",
        "sponsorName": "Immunitybio Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "pritumumab",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 03 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "cell therapies",
    "notes": "a natural human igg1 kappa antibody that has been derived from a b cell isolated from regional draining lymph node of a cervical carcinoma patient",
    "numSites": "",
    "otherPartners": "nascent biotech inc.",
    "phase": "pre-clinical",
    "preferredName": "antibody",
    "productId": 289,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b3867b6cd9697e882535adad3e08532327c9d976",
        "sponsorName": "Nascent Biotech Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "vicromax",
    "chemicalName": "merimepodib",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "biosig technologies inc.,coronavirus treatment acceleration program (ctap)",
    "phase": "phase 4",
    "preferredName": "merimepodib",
    "productId": 290,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9dd3cb9d73f8e8a80aadc56ad0d1970eff4f088d",
        "sponsorName": "Neuroclear Technologies INc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "nitricil therapeutic",
    "chemicalName": "nitric oxide",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "wainwright & co. llc",
    "phase": "pre-clinical",
    "preferredName": "nitric_oxide",
    "productId": 291,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ddee329111caa7d96be4e5aea7fa3ccfaccac422",
        "sponsorName": "Novan Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "st-266",
    "chemicalName": "cell-free platform biologic containing hundreds of anti-inflammatory proteins",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 19 Sep 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "noveome biotherapeutics inc.,us government",
    "phase": "pre-clinical",
    "preferredName": "cellfree_platform_biologic_containing_hundreds_of_antiinflammatory_proteins",
    "productId": 292,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8c4038c7c0eddd116fc3688efef61be78abbacb4",
        "sponsorName": "Noveome Biotherapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vyripharm_biopharmaceuticals_llc-444",
    "productId": 444,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "078da56adc71e2a029154078183324f8f351e10a",
        "sponsorName": "Vyripharm Biopharmaceuticals LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "rnai therapeutic",
    "chemicalName": "small interfering rnas",
    "conditionOrDisease": "",
    "countries": ["south korea"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "the sirnas would operate within the rnai pathway where it interferes with the expression of the genes with complementary nucleotide sequences by degrading mrna after transcription resulting in no translation.",
    "numSites": "",
    "otherPartners": "olix pharmaceuticals inc",
    "phase": "pre-clinical",
    "preferredName": "small_interfering_rnas",
    "productId": 293,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96c730a852872cf66c35cb125b2d7d05d8530e76",
        "sponsorName": "Olix Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "cd24fc",
    "chemicalName": "human cd24 and human igg fc fusion protein",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 04 Sep 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 19 May 2021 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "oncoimmune",
    "phase": "phase 3",
    "preferredName": "human_cd24_and_human_igg_fc_fusion_protein",
    "productId": 294,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Baltimore",
        "country": "US",
        "lat": 39.287105,
        "lng": -76.6268034,
        "locationId": "26fbeaeb531f7b0861ba7f0b7cbca0b31ecfaa56",
        "name": "725 W Lombard St, Baltimore, MD 21201, USA",
        "state": "MD"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8cb5dae787770b38be6694d1c973744aa00c391e",
        "sponsorName": "Oncoimmune Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04317040"
  },
  {
    "brandName": "kth-222",
    "chemicalName": "inhibit the mapk pathway by controlling initiation of the signaling cascade while synthetic drugs block only specific parts of the pathway",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "anticancer drug",
    "numSites": "",
    "otherPartners": "kalos therapeutics,oncology pharma inc.",
    "phase": "pre-clinical",
    "preferredName": "inhibit_the_mapk_pathway_by_controlling_initiation_of_the_signaling_cascade_while_synthetic_drugs_block_only_specific_parts_of_the_pathway",
    "productId": 295,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "94591eec9484636deee6e0aa9cf402169c390282",
        "sponsorName": "Oncology Pharma Inc"
      },
      {
        "sponsorId": "eb7a2deb781669d168a882d3eb969a94f3b7b5d9",
        "sponsorName": "Kalos Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "vnar antibodies",
    "chemicalName": "single domain variable new antigen receptor (vnar) antibodies",
    "conditionOrDisease": "",
    "countries": ["usa", "uk"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 04 Aug 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "lundbeck,ossianix inc.",
    "phase": "pre-clinical",
    "preferredName": "single_domain_variable_new_antigen_receptor_vnar_antibodies",
    "productId": 296,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e0168852b1423a84cb2e4cc6a63702915618d555",
        "sponsorName": "Ossianix Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "ostrich antibodies",
    "chemicalName": "ostrich igy antibodies",
    "conditionOrDisease": "",
    "countries": ["usa", "japan"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "ostrich pharma usa",
    "phase": "phase 1",
    "preferredName": "ostrich_igy_antibodies",
    "productId": 297,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Frisco",
        "country": "US",
        "lat": 33.1021814,
        "lng": -96.84083869999999,
        "locationId": "d0fb3b28c617ca0c01dcedc4ef75deaa84591224",
        "name": "2840 Legacy Dr #100, Frisco, TX 75034, USA",
        "state": "TX"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "81131cc14196ec0102f65dd04174c541d8ed0900",
        "sponsorName": "Ostrich Pharma USA Ostrigen"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "leukine",
    "chemicalName": "sargramostim",
    "conditionOrDisease": "covid-19 ards",
    "countries": ["belgium"],
    "countryCodes": ["bel"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Sun, 19 May 1991 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "university hospital ghent,flanders institute of biotechnology",
    "phase": "4",
    "preferredName": "sargramostim",
    "productId": 298,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Gent",
        "country": "BE",
        "lat": 51.0245573,
        "lng": 3.7252219,
        "locationId": "1236f8d79986768ae7f2c179307676a9f546444b",
        "name": "De Pintelaan 185, 9000 Gent, Belgium",
        "state": "Vlaanderen"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8b5205e0d7efb338bddea3c077306518cd3232bc",
        "sponsorName": "Partner Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "eudra ct 2020-001254-22"
  },
  {
    "brandName": "microbiome therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "microbiome_therapeutic",
    "productId": 299,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8a2aaacc01bd11f71c410206ebedcdc6087bc015",
        "sponsorName": "Persephone Biosciences Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "centhaquine",
    "chemicalName": "pmz-2010",
    "conditionOrDisease": "hypovolemic shock",
    "countries": ["india"],
    "countryCodes": ["ind"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Oct 2014 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 29 May 2017 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 23 Jan 2019 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "18",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "pmz2010",
    "productId": 300,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Nagpur",
        "country": "IN",
        "lat": 21.138992,
        "lng": 79.1201063,
        "locationId": "32a11f672798e24249604e0f5233ed7d9871d665",
        "name": "324, 1, Great Nag Rd, Jagnade square, Nandanvan, Nagpur, Maharashtra 440009, India",
        "state": "MH"
      },
      {
        "city": "Ajmer",
        "country": "IN",
        "lat": 26.4672983,
        "lng": 74.63633999999999,
        "locationId": "8f9e5a96ecd1f3833eeee73c2569e5061d360ba9",
        "name": "opp. Patel stadium, Kala Bagh, Ajmer, Rajasthan 305001, India",
        "state": "RJ"
      },
      {
        "city": "Amravati",
        "country": "IN",
        "lat": 20.9205299,
        "lng": 77.7614303,
        "locationId": "2d20c84f6b3664066cdffed3ed5e171f238417af",
        "name": "Sabnis Plot, Near Kalyan Nagar Chowk, Vivekanand Colony, Amravati, Maharashtra 444606, India",
        "state": "MH"
      },
      {
        "city": "Bengaluru",
        "country": "IN",
        "lat": 13.028795,
        "lng": 77.5394651,
        "locationId": "5b24ac33ef3b4b9d90070647ddd79cb360f616ff",
        "name": "Metro Stop, 2, Tumkur Main Rd, Next to, Goraguntepalya, Yeswanthpur, Bengaluru, Karnataka 560022, India",
        "state": "KA"
      },
      {
        "city": "Belgaum",
        "country": "IN",
        "lat": 15.8881346,
        "lng": 74.5196845,
        "locationId": "da0e191506425f751271fdf6b21bc94bb31761ac",
        "name": "NH Service Road, Basava Circle, Chikodi, Nehru Nagar, Belgaum, Karnataka 590010, India",
        "state": "KA"
      },
      {
        "city": "Dehradun",
        "country": "IN",
        "lat": 30.3028453,
        "lng": 78.0215003,
        "locationId": "798f4e63464abde5d2273feb6fdecd5a4b55ce0a",
        "name": "Dehrakhas, Patel Nagar, Dehradun, Uttarakhand 248001, India",
        "state": "UK"
      },
      {
        "city": "Kanpur",
        "country": "IN",
        "lat": 26.4809431,
        "lng": 80.3075733,
        "locationId": "111de104081c1da086cfb9f61177cb002c22abad",
        "name": "Swaroop Nagar, Kanpur, Uttar Pradesh 208002, India",
        "state": "UP"
      },
      {
        "city": "Kolkata",
        "country": "IN",
        "lat": 22.5394793,
        "lng": 88.3418445,
        "locationId": "735c9fd56d2ca3f639946ba48bb4856516ac3806",
        "name": "244, Acharya Jagadish Chandra Bose Rd, Bhowanipore, Kolkata, West Bengal 700020, India",
        "state": "WB"
      },
      {
        "city": "Lucknow",
        "country": "IN",
        "lat": 26.8692591,
        "lng": 80.91624019999999,
        "locationId": "2558ce59c9f150868c72736e3550753ccd2128d0",
        "name": "Shah Mina Rd, Chowk, Lucknow, Uttar Pradesh 226003, India",
        "state": "UP"
      },
      {
        "city": "Ludhiana",
        "country": "IN",
        "lat": 30.9105009,
        "lng": 75.8635015,
        "locationId": "b8bf3d6b13531938d392e65f9ce07ef5bfd3e8d4",
        "name": "Brown Rd, CMC Campus, Ludhiana, Punjab 141008, India",
        "state": "PB"
      },
      {
        "city": "Doraha",
        "country": "IN",
        "lat": 30.7967047,
        "lng": 76.0337859,
        "locationId": "1275aa8efd044aa4a0e72fe2da43db617222f5be",
        "name": "G.T. Road, SBS Nagar, SBS Nagar, Doraha, Punjab 141421, India",
        "state": "PB"
      },
      {
        "city": "Mysuru",
        "country": "IN",
        "lat": 12.296409,
        "lng": 76.65572519999999,
        "locationId": "6709548550e40f80d610e749783347006bd84e47",
        "name": "JSS Hospital Rd, Ramachandra Agrahara, Mysuru, Karnataka 570004, India",
        "state": "KA"
      },
      {
        "city": "Nagpur",
        "country": "IN",
        "lat": 21.1514646,
        "lng": 79.12188929999999,
        "locationId": "e1c2178b419599ad55a1eec082624b002acd4481",
        "name": "Queta Colony, Lakadganj, Nagpur, Maharashtra 440008, India",
        "state": "MH"
      },
      {
        "city": "Nagpur",
        "country": "IN",
        "lat": 21.1491809,
        "lng": 79.1163622,
        "locationId": "f4b6e827fd3656c4b07ce8dcaebc6d9b1f54f0e6",
        "name": "Kolbaswami Chowk, Central Ave, Mangalwari, Lakadganj, Nagpur, Maharashtra 440008, India",
        "state": "MH"
      },
      {
        "city": "Nagpur",
        "country": "IN",
        "lat": 21.1405576,
        "lng": 79.0854809,
        "locationId": "d5985e95bb647eed384c8eb0d17b55787c2a6f2c",
        "name": "4th Floor, Dhanshri Complex, Humpyard Rd, near Hardeo Hotel, Sitabuldi, Nagpur, Maharashtra 440012, India",
        "state": "MH"
      },
      {
        "city": "NLR",
        "country": "IN",
        "lat": 14.4261617,
        "lng": 79.96336219999999,
        "locationId": "cc0af6f885b6b81db60c33c09d15dcaa440cae02",
        "name": "Nellore, Andhra Pradesh 524004, India",
        "state": "AP"
      },
      {
        "city": "New Delhi",
        "country": "IN",
        "lat": 28.6382666,
        "lng": 77.2385937,
        "locationId": "570f55dd3d752c960dd07268e08c32cbdec70fe1",
        "name": "metro Station Central, near, Jawaharlal Nehru Marg, Delhi Gate, New Delhi, Delhi 110002, India",
        "state": "DL"
      },
      {
        "city": "Varanasi",
        "country": "IN",
        "lat": 25.2744547,
        "lng": 82.9995254,
        "locationId": "a274393d99e99fac7caf2ab6875b7c9f804eab33",
        "name": "Aurobindo Colony, Banaras Hindu University Campus, Varanasi, Uttar Pradesh 221005, India",
        "state": "UP"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ccbaab96d082b74ca31a6f4f904d47ead69db5d3",
        "sponsorName": "Pharmazz INc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04045327"
  },
  {
    "brandName": "multiple repurposed therapeutics - pharnext",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["france"],
    "countryCodes": ["fra"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "university hospital institute mÃ©diterranÃ©e infection",
    "phase": "",
    "preferredName": "multiple_repurposed_therapeutics__pharnext",
    "productId": 301,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8ef7261cae683e2f3ccfe5dbf762a36c5ef48adb",
        "sponsorName": "Pharnext SA"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "neumifil",
    "chemicalName": "sp2cbmtd",
    "conditionOrDisease": "",
    "countries": ["scotland"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 30 Sep 2014 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Sep 2019 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 29 Apr 2014 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "carbohydrate bonding module (cbm40) blocks sialic acid receptors in respiratory tract and prevents virus from entering host cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "pre-clinical",
    "preferredName": "sp2cbmtd",
    "productId": 302,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "983efe23794f5ea689b6644c79f8581943a74fe3",
        "sponsorName": "Pneumagen Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "corecyte",
    "chemicalName": "umbilical cord mesenchymal stem cells",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "umbilical cord mesenchymal stem cells isolated from wharton's jelly,applied for fda approval for immediate use for covid-19 on 04/09/2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "umbilical_cord_mesenchymal_stem_cells",
    "productId": 303,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "761c8b0485e032a24d29f63f18726bb53f50bdc1",
        "sponsorName": "Predictive Biotech"
      },
      {
        "sponsorId": "0a520daf69e8730cf20a260e53d5354fd23003aa",
        "sponsorName": "Predictive Technology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "prtx-007",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "activates tlr7 to stimulate innate immune system",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "prtx007",
    "productId": 304,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "59184ad543e6f439787b2e2ac1527ea53b1e5ac1",
        "sponsorName": "Primmune Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["singapore"],
    "countryCodes": ["sgp"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "heidelberg university hospital,tÃ¼bingen university hospital,the german cancer research center (dkfz),the nmi natural and medical sciences institute,nus enterprise,10x genomics,novogeneait",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 305,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "245b051b6523c597e8560495815affabbbd6151f",
        "sponsorName": "Proteona Pte Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "yeliva",
    "chemicalName": "opaganib",
    "conditionOrDisease": "covid-19",
    "countries": ["israel"],
    "countryCodes": ["isr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Tue, 08 Jun 2010 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 14 Sep 2010 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Aug 2011 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 07 Mar 2018 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "phase 2 trial ind application made",
    "numSites": "uknown",
    "otherPartners": "",
    "phase": "2a",
    "preferredName": "opaganib",
    "productId": 306,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Charlotte",
        "country": "US",
        "lat": 35.2205194,
        "lng": -80.8575444,
        "locationId": "ba7a7840a2a3e1f06da465a5b31bf75410f05a11",
        "name": "1327 S Mint St, Charlotte, NC 28203, USA",
        "state": "NC"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e8c8185248be3a1b2daf8211acc52922e6293844",
        "sponsorName": "Redhill Biopharma Ltd"
      },
      {
        "sponsorId": "f01ab327db3d24c889ea79c039140f87ed85ab74",
        "sponsorName": "Apogee Biotechnology Group Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "unknown"
  },
  {
    "brandName": "upamostat",
    "chemicalName": "rhb-107",
    "conditionOrDisease": "",
    "countries": ["israel"],
    "countryCodes": ["isr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 27 Sep 2004 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 01 Jul 2008 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "passed phase 1 and 2 clinical trials for other diseases currently being tested in-vitro for covid-19",
    "numSites": "",
    "otherPartners": "niaid",
    "phase": "pre-clinical",
    "preferredName": "rhb107",
    "productId": 307,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e8c8185248be3a1b2daf8211acc52922e6293844",
        "sponsorName": "Redhill Biopharma Ltd"
      },
      {
        "sponsorId": "4f42e3229651f0892787042619eb74da72a1a688",
        "sponsorName": "Link Health Group"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "apabetalone",
    "chemicalName": "2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1,4-dihydroquinazolin-4-one",
    "conditionOrDisease": "covid19",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 15 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "private,nihr",
    "phase": "3",
    "preferredName": "242hydroxyethoxy35dimethylphenyl57dimethoxy14dihydroquinazolin4one",
    "productId": 308,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e60afe62e3596c8891ede53bfdc0f1c2a71320a",
        "sponsorName": "Resverlogix Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "bucillamine",
    "chemicalName": "",
    "conditionOrDisease": "covid19",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "antirheumatic",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "bucillamine",
    "productId": 309,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "df3723439d2a920860a172a5dd962f7ec0f7cc36",
        "sponsorName": "Revive Therapeutics Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "eidd-2801",
    "chemicalName": "",
    "conditionOrDisease": "covd19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 07 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 10 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "oral antiviral",
    "numSites": "",
    "otherPartners": "wayne and wendy holman",
    "phase": "1",
    "preferredName": "eidd2801",
    "productId": 310,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4086aa4aca201f3493eee784dbab92ad400778f",
        "sponsorName": "Ridgeback Biotherapeutics LP"
      },
      {
        "sponsorId": "490f2c2447baa96b61de933f67b94a46fd87a097",
        "sponsorName": "Drug Innovations at Emory LLC"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "gimsilumab",
    "chemicalName": "morab-022",
    "conditionOrDisease": "covid19",
    "countries": ["switzerland"],
    "countryCodes": ["che"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 19 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "morab022",
    "productId": 311,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c0cd5a7a71a7a2120e0b79f29aacd606755aff2a",
        "sponsorName": "Roivant Sciences Ltd"
      },
      {
        "sponsorId": "f062e8029186acd42f78d91ab787d4579d4c5484",
        "sponsorName": "Altasciences Co Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "sab-185",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "barda",
    "phase": "",
    "preferredName": "sab185",
    "productId": 312,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "21fe6f5f8237968ddc20622797f630647c872671",
        "sponsorName": "Sab Biotherapeutics"
      },
      {
        "sponsorId": "586353dc7d3f7de1b8b0aaf247aaacaa7293cc9f",
        "sponsorName": "CSL Behring LLC"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "s-protein/ace2 targeted prohylactic polypeptide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "apeiron biologics",
    "phase": "",
    "preferredName": "sproteinace2_targeted_prohylactic_polypeptide",
    "productId": 313,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": null,
        "country": "AT",
        "lat": 47.516231,
        "lng": 14.550072,
        "locationId": "b7ab5670f84eb378a1b9ebc4257d3849a51967ee",
        "name": "Austria",
        "state": null
      },
      {
        "city": null,
        "country": "DE",
        "lat": 51.165691,
        "lng": 10.451526,
        "locationId": "e4e8b7f5d82eede366bf08f9b6edda3b04b70329",
        "name": "Germany",
        "state": null
      },
      {
        "city": null,
        "country": "DK",
        "lat": 56.26392,
        "lng": 9.501785,
        "locationId": "2c77a425556d9bee3e2650be8a5e920bcd092916",
        "name": "Denmark",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8812b6d8e3894f01681250e96efa2ff723ccf680",
        "sponsorName": "Sichuan Kelun Pharmaceutical Co Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "lipocurc",
    "chemicalName": "liposomal curcumin",
    "conditionOrDisease": "covid19",
    "countries": ["usa"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 07 Nov 2012 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "cancer treatment",
    "numSites": "",
    "otherPartners": "paracelsus medical university,discretionary research fund",
    "phase": "2",
    "preferredName": "liposomal_curcumin",
    "productId": 314,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "US",
        "lat": 41.2033216,
        "lng": -77.1945247,
        "locationId": "8291079da3bf3e28936c7d4f2921601ac8dfe351",
        "name": "Pennsylvania, USA",
        "state": "PA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3a23c78238689fa6d8b86e48413a0fbe0d9d35c1",
        "sponsorName": "Signpath Pharma Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "antiviral",
    "chemicalName": "interferon alpha",
    "conditionOrDisease": "covid19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "nihr",
    "phase": "1/2",
    "preferredName": "interferon_alpha",
    "productId": 315,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "9b3e8d92191f31e85098a84b7579330bfe16e99d",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "74c3cd3bc3fa22bf3900e0d4e84bb19508cb9132",
        "sponsorName": "Sinopharm Group"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "antiviral",
    "chemicalName": "glycosides",
    "conditionOrDisease": "covid19",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "private",
    "phase": "",
    "preferredName": "glycosides",
    "productId": 316,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Val-de-Reuil",
        "country": "FR",
        "lat": 49.258212,
        "lng": 1.187725,
        "locationId": "4ae46b685b0445caf55b2aff16630c79e4543ab6",
        "name": "Voie de l Innovation, PharmaParc 2, 27100 Val-de-Reuil, France",
        "state": "Normandie"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b943d0928f25a94239b30d1f795032375383033f",
        "sponsorName": "Sirona Biotechem Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "therapeutic",
    "chemicalName": "compounds that block the activity of the sars-cov-2 mpro protease",
    "conditionOrDisease": "covid19",
    "countries": ["japan"],
    "countryCodes": ["jpn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "compounds_that_block_the_activity_of_the_sarscov2_mpro_protease",
    "productId": 317,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a116938a80ab1812d2085339b93325c5e6a0805b",
        "sponsorName": "Sosei Group Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "lung airway cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["canada", "china"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "neither a treatment nor a prophylactic,mainly used to propagate the sars-cov-2 which allowed scientists at china's cdc to isolate the virus and obtain the gene sequence,clinical milestones and studies will not be filled out for this reason,development was finished before 03/25/2020 (which is when article about this breakthrough was published)",
    "numSites": "",
    "otherPartners": "cdc - china",
    "phase": "",
    "preferredName": "lung_airway_cells",
    "productId": 318,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "49edcacef773406a08e3a11e32fb4caf84388c84",
        "sponsorName": "Stemcell Technologies Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "epaspire",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "purified epa in a capsule currently in a phase 3 clinical trial in europe for treatment of fap,well established safety profile and observed suppression of inflammatory cytokines that may contribute to covid-19 progression,this allowed the quick initiation of phase 3 covid-19 trials and led to the goal of using epaspire to reduce the complications of covid-19",
    "numSites": "undisclosed",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "epaspire",
    "productId": 319,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "06ec5df840715222bbeb972210bfa28ff5aceb2c",
        "sponsorName": "The KD Pharma Group SA"
      },
      {
        "sponsorId": "b47bc7cc175c3bb7640659ad687ac2f480ba8fd6",
        "sponsorName": "SLA Pharma AG"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct04335032"
  },
  {
    "brandName": "td-0903",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "lung-selective inhaled jak inhibitor that has the potential to block cytokines and chemokines associated with ali and ards,shown to have effective and broad inhibition of jak-stat signaling in rodent models,cta was submitted in the uk on 04/09/2020 - approval pending and phase 1 will begin immediately after",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "td0903",
    "productId": 320,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Manchester",
        "country": "GB",
        "lat": 53.4807593,
        "lng": -2.2426305,
        "locationId": "d3588aaf836af72456a8642d1e8d57d2d0f1ed96",
        "name": "Manchester, UK",
        "state": "England"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "262d9fad81968c24466a839589f81bece22471db",
        "sponsorName": "Theravance"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": "nct04350736"
  },
  {
    "brandName": "arms-i",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "other",
    "notes": "arms-i is a microbe-impermeable barrier with anti-viral action designed to prevent upper respiratory infections,currently holds an ind as a potential flu prophylaxis,clinical trial (unspecified phase but characteristics inmply phase 2) to investigate whether arms-i will help protect against covid-19 in frontline health workers,no entry in clinicaltrials.gov yet",
    "numSites": "unspecified",
    "otherPartners": "arms pharmaceutical llc,cleveland foundation,case western reserve university",
    "phase": "2",
    "preferredName": "armsi",
    "productId": 321,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Cleveland",
        "country": "US",
        "lat": 41.5050672,
        "lng": -81.605476,
        "locationId": "67cc958abc539e90d1303fdd5424609888d58180",
        "name": "University Hospitals, 2101 Adelbert Rd, Cleveland, OH 44106, USA",
        "state": "OH"
      },
      {
        "city": "Warren",
        "country": "US",
        "lat": 41.2221809,
        "lng": -80.7967887,
        "locationId": "b15bcb64fcb5b84095b9c810309dc4e969315732",
        "name": "1977 Niles Rd SE, Warren, OH 44484, USA",
        "state": "OH"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "081649a78e8f049d5576bf2c9694fd3841668997",
        "sponsorName": "Cleveland University Hospitals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "tradipitant",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "tradipitant is currently undergoing clinical trials for other conditions such as gastroparesis,tradipitant is an nk-1r antagonist that is being tested to see if it can treat inflammatory lung injury associated with covid-19",
    "numSites": "1",
    "otherPartners": "university of illinois at chicago",
    "phase": "3",
    "preferredName": "tradipitant",
    "productId": 322,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7736341,
        "lng": -73.9608549,
        "locationId": "cd5f6752cfb9c26f0acd5391534ad58b10f879d7",
        "name": "130 E 77th St, New York, NY 10075, USA",
        "state": "NY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d2734c3b72bd97da45e8be5b00151cb1c2fe5838",
        "sponsorName": "Vanda Pharmaceuticals Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04326426"
  },
  {
    "brandName": "monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "$14 million contract from us department of defense for ology bioservices and vanderbilt to collaborate on antibody discovery against covid-19,twist to build a synthetic antibody discovery library based on sequences from a recovered covid-19 patient from vandebilt",
    "numSites": "",
    "otherPartners": "twist bioscience corp.",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 323,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3505691a86b3a9dacf9bb0dd76bfd49b7cd40e83",
        "sponsorName": "Vanderbilt University"
      },
      {
        "sponsorId": "8b02e4cb59e0603882788f6b09eece49a6f530e2",
        "sponsorName": "Ology Bioservices Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "genosyl ds",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 20 Dec 2019 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "genosyl ds is a tankless nitric oxide delivery system that obtained fda approval on 12/20/19,fda recently granted expanded access emergency use on 03/26/20 for the genosyl ds to be used in treating cardiopulmonary symptoms associated with covid-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "genosyl_ds",
    "productId": 324,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9ec0b02ebf735a301023bce110203311a36cbe28",
        "sponsorName": "Vero Biotech"
      }
    ],
    "status": "on market",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "vir-7832",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "vir-7831 and vir-7832 are leading antibody candidates that have demonstrated high affinity for the sars-cov-2 spike protein,companies aim to directly enter phase 2 clinical trial within the next three to five months,currently still in the development phase",
    "numSites": "",
    "otherPartners": "wuxi biologics,national institute of allergy and infectious diseases,xencor inc.,glaxosmithkline plc,samsung biologics co. ltd.",
    "phase": "",
    "preferredName": "vir7832",
    "productId": 325,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c32fa743ed510db10e7c97fd975d2a2a5700a4a",
        "sponsorName": "Vir Biotechnology Inc"
      },
      {
        "sponsorId": "7b6f419a075a9d4cfc1742367fdc3d11cc35f994",
        "sponsorName": "Biogen Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "elpida",
    "chemicalName": "elsafavirine",
    "conditionOrDisease": "covid-19",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "elpida is a non-nucleoside reverse transcriptase inhibitor that received market approval from the russian ministry of health to treat hiv on 06/30/2017,initated phase 2 clinical study to evaluate efficacy of elpida in adults with covid-19 on 04/08/2020 but currently has no entry on clinicaltrials.gov",
    "numSites": "unspecified",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "elsafavirine",
    "productId": 326,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "RU",
        "lat": 61.52401,
        "lng": 105.318756,
        "locationId": "a6574bb02b2758b53e8848e85092463c59609785",
        "name": "Russia",
        "state": null
      },
      {
        "city": null,
        "country": "PL",
        "lat": 51.919438,
        "lng": 19.145136,
        "locationId": "0f979d5a0c95f8f28213febfaef9e1c8aa04da88",
        "name": "Poland",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3e65bda0e3a4586a7154c208c474b7fc79f60ab1",
        "sponsorName": "Viriom Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "viscient is using 3d bioprinting tech to create lung tissue to support research efforts on finding and testing covid-19 therapies - clinical trial in a dish, as of 04/20/2020 - still working on a way to develop infected lung tissue",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "viscient_biosciences_inc-327",
    "productId": 327,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8d59671a4747cb2aa6f2acfa1c51b5de8644ae5b",
        "sponsorName": "Viscient Biosciences Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "cb1 antagonist",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cb1_antagonist",
    "productId": 328,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96dc8ffb76c357cda9bf1ea512a6b3faedc50ed5",
        "sponsorName": "Viripharm Biopharmaceuticals LLC"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "kl4 surfactant",
    "chemicalName": "sinapultide",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sinapultide",
    "productId": 329,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b9d4687e32bd1665b98b110c465c991959943db7",
        "sponsorName": "Windtree Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "mesenchymal stem cells",
    "chemicalName": "uc-mscs",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ucmscs",
    "productId": 330,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.583826,
        "lng": 114.273585,
        "locationId": "b61e7ae470bcf8405dc81aaf08d8533cf08494ce",
        "name": "Jiefang Ave, Xi Bei Hu, Jianghan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14038d17d9fa18917792c69af98837142687f2af",
        "sponsorName": "Wuhan Hamilton Biotechnology Co Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04273646"
  },
  {
    "brandName": "antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["belgium"],
    "countryCodes": ["bel"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibody",
    "productId": 331,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "aceff18e5b0594f0ed960779ae931d91cbc7fa9f",
        "sponsorName": "VIBUGent Center for Medical Biotechnology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "plasma treatment",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "plasma_treatment",
    "productId": 332,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d1a873903a92cac9d889e8f9ff8977b7f9e100ce",
        "sponsorName": "Xbiotech Inc"
      },
      {
        "sponsorId": "96240c6492e03d5753e52d4da6fa236a7e4dc6f2",
        "sponsorName": "Biobridge Global"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "xrx-101",
    "chemicalName": "oxypurinol",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "oxypurinol",
    "productId": 333,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3942d9eba6d7c598d2d7548e1f99237e337f7f56",
        "sponsorName": "Xortx Therapeutics Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviral",
    "productId": 334,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "40539840e055053cf646a7a6c2d6f01184a9f4a3",
        "sponsorName": "Xphyto Therapeutics Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["slovakia"],
    "countryCodes": ["svk"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaccine",
    "productId": 335,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0fc1c2eb025301d74761cfdaad2e702a05e14ea7",
        "sponsorName": "Axon Neuroscience SE"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "dendritic cell vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "dendritic_cell_vaccine",
    "productId": 336,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "08a21a27c82e51464712adac2679fb2dc228d69b",
        "sponsorName": "Betta Pharmaceuticals Co Ltd"
      },
      {
        "sponsorId": "5971cf2c808d095d9d239606be69759cc12a3ff5",
        "sponsorName": "Beijing Dingcheng Taiyuan Biotechnology"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaccine",
    "productId": 337,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "61c10d4a8a5dee7e9c508ca4cf94e5fb4aedf2a3",
        "sponsorName": "Chongqing Zhifei Biological Products Co Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "fusogenix dna vaccine",
    "chemicalName": "",
    "conditionOrDisease": "disease",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "direct introduction of a plasmid encoding the antigen(s) against which an immune response is sought and relies on the production of the target antigen in the patientâs own cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "discovery",
    "preferredName": "fusogenix_dna_vaccine",
    "productId": 338,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "792d66b4f6751aa1d3eabedb66b4e1a4b26c759b",
        "sponsorName": "Entos Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "ercâs sars-cov-2 vaccine",
    "chemicalName": "",
    "conditionOrDisease": "condition,disease",
    "countries": ["belgium"],
    "countryCodes": ["bel"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "other",
    "notes": "vaccine containing virions,viral proteins at different stages of viral replication,whole human cells and cellular fragments,composing all elements of viral replication",
    "numSites": "",
    "otherPartners": "",
    "phase": "discovery",
    "preferredName": "ercâs_sarscov2_vaccine",
    "productId": 339,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2bae05a8f1ef431f06f3f32e8a5b62ac2088a4e7",
        "sponsorName": "Epitopoietic Research Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "coroflu",
    "chemicalName": "",
    "conditionOrDisease": "disease",
    "countries": ["india", "united states"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "modification of m2sr by adding part of the coding region for the coronavirus spike protein",
    "numSites": "",
    "otherPartners": "flugen inc,bharat biotech international ltd - india,university of wisconsin-madison",
    "phase": "discovery",
    "preferredName": "coroflu",
    "productId": 340,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d0615a827003e8423ac0ea3c03f9fbd824fc52b3",
        "sponsorName": "Flugen Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "ii-key-sars 2 peptide vaccine",
    "chemicalName": "",
    "conditionOrDisease": "disease",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "china technology exchange,beijing zhonghua investment fund management co. ltd,biology institute of shandong academy of sciences,sinotek-advocates international industry development (shenzhen) co. ltd",
    "phase": "discovery",
    "preferredName": "iikeysars_2_peptide_vaccine",
    "productId": 341,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bd241b032c9ac50523b8215691176cc94b2966b6",
        "sponsorName": "Generex Biotechnology Group"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "z-vaccirna",
    "chemicalName": "",
    "conditionOrDisease": "disease",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "discovery",
    "preferredName": "zvaccirna",
    "productId": 342,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de3c929194d9aac1196f6a1b8c9e5983cfa58911",
        "sponsorName": "Guanhao Biotech Co Ltd"
      },
      {
        "sponsorId": "f12c99eed6736f965feb517d2d827d893d1cd2b0",
        "sponsorName": "Zy Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaccine",
    "productId": 343,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "344b517c43ad6d6219c6a66b35a3d655b2918e54",
        "sponsorName": "Hualan Biological Engineering"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaccine",
    "productId": 344,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "07b42758a4b70d9b70f8e828e2488a0d0c69160d",
        "sponsorName": "ID Pharma Co Ltd"
      },
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "virus suppressing factor",
    "chemicalName": "hzvsfv13",
    "conditionOrDisease": "condition",
    "countries": ["korea"],
    "countryCodes": ["prk"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 28 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "phase 1",
    "preferredName": "hzvsfv13",
    "productId": 345,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": null,
        "country": "KR",
        "lat": 37.5795356,
        "lng": 126.9990276,
        "locationId": "1e8c2237a8af42367cefdae2295cd356b686f09b",
        "name": "101 Daehak-ro, Yeongeon-dong, Jongno-gu, Seoul, South Korea",
        "state": "Seoul"
      },
      {
        "city": null,
        "country": "KR",
        "lat": 35.8473237,
        "lng": 128.5848209,
        "locationId": "d823a4703f28f810095f6435f865596d42d8f09d",
        "name": "170 Hyeonchung-ro, Daemyeong 5(o)-dong, Nam-gu, Daegu, South Korea",
        "state": "Daegu"
      },
      {
        "city": null,
        "country": "KR",
        "lat": 36.31695,
        "lng": 127.4157208,
        "locationId": "ede28bf505518a0432e813815ecd30daf5ae114c",
        "name": "282 Munhwa-ro, Daesa-dong, Jung-gu, Daejeon, South Korea",
        "state": "Daejeon"
      },
      {
        "city": null,
        "country": "KR",
        "lat": 37.5622702,
        "lng": 126.941068,
        "locationId": "8fde4e298dbeb3a4546ae6c86cb1e3a3639f3f91",
        "name": "50-1 Yonsei-ro, Sinchon-dong, Seodaemun-gu, Seoul, South Korea",
        "state": "Seoul"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1b6935230a67257c55ec98d018cd779af0ce72b1",
        "sponsorName": "Immunemed"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "nucleic acid vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nucleic_acid_vaccine",
    "productId": 346,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "32698ef58730c0db442e4711afe4d8872c1122fa",
        "sponsorName": "Immunomic Therapeutics Inc"
      },
      {
        "sponsorId": "668459853f4364a918946339a776e7b4d8542169",
        "sponsorName": "Epivax Inc"
      },
      {
        "sponsorId": "4a67621b1cdb93f9e5a800f34f028cee1e42d049",
        "sponsorName": "Pharmajet"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "mesencure",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mesencure",
    "productId": 445,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "21fffcbea9a29011a432f5076a9bf80e04b86566",
        "sponsorName": "Wize Pharma Inc"
      },
      {
        "sponsorId": "33a0699dc37b7638ed3184d943514267306a6b62",
        "sponsorName": "Bonus Biogroup Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "maps vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "maps_vaccine",
    "productId": 446,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4c4eaf123ba9a0ed44f528ea27f445b3ebffc82",
        "sponsorName": "Affinivax Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "dpx-covid-19",
    "chemicalName": "",
    "conditionOrDisease": "disease",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "subunit vaccines",
    "notes": "epitope based vaccine,design of a phase 1 clinical study in 48 healthy subjects completed,clinical sites identified in nova scotia and quebec",
    "numSites": "",
    "otherPartners": "",
    "phase": "discovery",
    "preferredName": "dpxcovid19",
    "productId": 347,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "48214836aaae1d030dc63fd584ec75a89c69a299",
        "sponsorName": "IMV Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ipt-001",
    "chemicalName": "peptide vaccine",
    "conditionOrDisease": "",
    "countries": ["canada"],
    "countryCodes": ["can"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptide_vaccine",
    "productId": 348,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e307a242cd4a80ef8961828e2bd56978153ba4c4",
        "sponsorName": "Intellistem Technologies Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "polypeptide vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "polypeptide_vaccine",
    "productId": 349,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e01b4e370f661002ed37476bd661968f309a64db",
        "sponsorName": "Liaoning Chengda Biotechnology"
      },
      {
        "sponsorId": "bfce396095503d26f651c5dad224c79f44d87649",
        "sponsorName": "Tsinghua University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "peptide mini-scaffold",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "high-affinity peptide scaffold that blocks interactions of sars-cov-2 to ace2 receptor",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptide_miniscaffold",
    "productId": 350,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4f3b270f3c1a96d8081041d6786e25d3ccc38629",
        "sponsorName": "Ligandal Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["taiwan"],
    "countryCodes": ["twn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "national institutes of health",
    "phase": "",
    "preferredName": "medigen_biotechnology_corp-351",
    "productId": 351,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c76c86ae23d07fd42bbc979f6877c5fb8af70eb6",
        "sponsorName": "Medigen Biotechnology Corp"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "uk government covid-19 research funding package",
    "phase": "",
    "preferredName": "mologic_ltd-352",
    "productId": 352,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dd2867855c9bba29ec1a2f9db4b0e7896eb33b42",
        "sponsorName": "Mologic Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "unknown",
    "trialId": ""
  },
  {
    "brandName": "nantkwest vaccine",
    "chemicalName": "second-generation ad5 platform",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "clinical trials expected to start this quarter",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "secondgeneration_ad5_platform",
    "productId": 353,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "13fabd5b14178a13d0539b59d6a9be0b068e4309",
        "sponsorName": "Nantkwest Inc"
      },
      {
        "sponsorId": "8bfec75fcf441b5e6dfde4d8556e152456e80321",
        "sponsorName": "Immunitybio Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "university if hawai'i at manoa",
    "phase": "",
    "preferredName": "soligenix_inc-354",
    "productId": 354,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7795392453455f76046eb84a28aa370b14026e0c",
        "sponsorName": "Soligenix Inc"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "s protein vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "s_protein_vaccine",
    "productId": 355,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8badc8865679f144a1d2fbf604740245348ebc8e",
        "sponsorName": "US Army Medical Research and Development Command"
      },
      {
        "sponsorId": "5dfde89cd058e25942ead74f974aa75a0b3ed04c",
        "sponsorName": "Walter Reed Army Institute of Research"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "covid-19 xwg-03",
    "chemicalName": "truncated s-protein",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "originally started being developed to treat hpv",
    "numSites": "",
    "otherPartners": "glaxosmithkline",
    "phase": "",
    "preferredName": "truncated_sprotein",
    "productId": 356,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f3e18d1badc8e3e140a4e145313f20f56e471293",
        "sponsorName": "Xiamen Innovax Biotech Co Ltd"
      },
      {
        "sponsorId": "bf45296df9f69d118ce8ad2b5fd20dcd2bb45568",
        "sponsorName": "Xiamen University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "zip-1642",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["belgium"],
    "countryCodes": ["bel"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "zip1642",
    "productId": 357,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "12f2c56c2a8c8e754b73a3d0736ac5246e1fc2ca",
        "sponsorName": "Ziphius Therapeutics NV"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "dna plasmid vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["japan"],
    "countryCodes": ["jpn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "takara bio inc.",
    "phase": "",
    "preferredName": "dna_plasmid_vaccine",
    "productId": 358,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      },
      {
        "sponsorId": "17be17f24c77c426a72f3b040131c995834c2be1",
        "sponsorName": "AnGes"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "ilaris",
    "chemicalName": "canakinumab",
    "conditionOrDisease": "covid-19 pneumonia",
    "countries": ["switzerland"],
    "countryCodes": ["che"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "not yet recruiting for observational study,very limited information on novartis website about using ilaris for covid,just listed as one of numerous drugs under investigation for people with covid infection",
    "numSites": "",
    "otherPartners": "",
    "phase": "observational",
    "preferredName": "canakinumab",
    "productId": 359,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b08c1310d27c7a8b020bed114122bccabe38726f",
        "sponsorName": "Novartis"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "nct04348448"
  },
  {
    "brandName": "gamifant",
    "chemicalName": "emapalumab",
    "conditionOrDisease": "hyperinflammation and respiratory distress in covid-19 patients",
    "countries": ["sweden"],
    "countryCodes": ["swe"],
    "currentStatus": "",
    "indication": "other",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "emapalumab",
    "productId": 360,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Brescia",
        "country": "IT",
        "lat": 45.5564352,
        "lng": 10.2310468,
        "locationId": "5427c20e836a322a5e00669fc5a1754352abd6dc",
        "name": "Piazzale Spedali Civili, 1, 25123 Brescia BS, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Milano",
        "country": "IT",
        "lat": 45.458872,
        "lng": 9.1950515,
        "locationId": "7b3c57d27329094629517acfc0362cab9df5b726",
        "name": "Via Francesco Sforza, 35, 20122 Milano MI, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Parma",
        "country": "IT",
        "lat": 44.8016341,
        "lng": 10.3083481,
        "locationId": "f3501923afde644616f875d0ea5a39e8605a69d5",
        "name": "Viale Antonio Gramsci, 14, 43126 Parma PR, Italy",
        "state": "Emilia-Romagna"
      },
      {
        "city": "Roma",
        "country": "IT",
        "lat": 41.866501,
        "lng": 12.4564793,
        "locationId": "ccead0d9e9e21feca25adb5c762f8fc37d48b712",
        "name": "Via Portuense, 292, 00149 Roma RM, Italy",
        "state": "Lazio"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4be4dbabdaa77091d49b0c6b38bd5a8ef5b04a9d",
        "sponsorName": "Swedish Orphan Biovitrum Sobi"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "nct04324021"
  },
  {
    "brandName": "antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "crowdsourcing",
    "phase": "",
    "preferredName": "antibody",
    "productId": 361,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9ceaf8fbcb1950d5b4df0acbe1671777bd9893a0",
        "sponsorName": "Distributed Bio"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "uk government,university of kent,hong kong university,national institute for biological standards and control",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 362,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a",
        "sponsorName": "Chelsea and Westminster Hospital"
      },
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "antibody therapeutic innovent biologics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibody_therapeutic_innovent_biologics",
    "productId": 363,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d6b2121d955a97b23570b0c2284d3d758aca0355",
        "sponsorName": "Innovent Biologics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "recombinant chimeric monoclonal antibody",
    "chemicalName": "ic14",
    "conditionOrDisease": "covid-19,ards",
    "countries": ["australia"],
    "countryCodes": ["aus"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "expanded access available",
    "numSites": "1",
    "otherPartners": "",
    "phase": "expanded access",
    "preferredName": "ic14",
    "productId": 364,
    "repurposed": "repurposed-not approved",
    "siteLocations": [
      {
        "city": "Milano",
        "country": "IT",
        "lat": 45.5069106,
        "lng": 9.267293800000001,
        "locationId": "b27fc8b41a80e83595192f9e7f58e3dfeda43f52",
        "name": "Via Olgettina Milano, 58, 20132 Milano MI, Italy",
        "state": "Lombardia"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9676cb2db18bbea317e9ea9e591807187950be72",
        "sponsorName": "Implicit Bioscience"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": "nct04346277"
  },
  {
    "brandName": "vicromax",
    "chemicalName": "merimepodib",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "submitted ind to fda for phase 2 trial for covid-19 patients,three phase 2 trials completed in other idications,completed animal testing and phase 1 trials for other indications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "merimepodib",
    "productId": 365,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4bcc018e9e747cb03d0973b36b6b83c2276aa48c",
        "sponsorName": "ViralClear Pharmaceuticals  subsidiary of BioSig Technologies"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "isr-50",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["sweden"],
    "countryCodes": ["swe"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "hope to have animal testing done in 2nd quarter and human testing complete in 4th quarter",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "isr50",
    "productId": 366,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "987e067b08e440461ef8fc126e195d7d57d749c7",
        "sponsorName": "ISR Immune System Regulation"
      },
      {
        "sponsorId": "5dcd0fc710b300f98746062aff74be3806516be0",
        "sponsorName": "TCER AB"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "antiviral fc conjugates",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "uses antiviaral fc conjugates (avcs)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviral_fc_conjugates",
    "productId": 367,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "124c17c54d9555bc7787cea6f6043207f25479ba",
        "sponsorName": "Cidara Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "antiviral combination",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["netherlands"],
    "countryCodes": ["nld"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "unknown",
    "notes": "it is indicted that combinations of fda-approved drugs will be teste but unknown as to which ones.",
    "numSites": "",
    "otherPartners": "european union's horizon 2020 program",
    "phase": "",
    "preferredName": "antiviral_combination",
    "productId": 368,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3ca1363324c98b475983319168e4c05919716630",
        "sponsorName": "SCORE Consortium"
      },
      {
        "sponsorId": "8717ea76eb52afd496f981afcc95aa693b0fbbd9",
        "sponsorName": "Helmholtz Centre for Infection Research"
      },
      {
        "sponsorId": "da5d8fe85f181501e049f3e20e8e1e2e438b9267",
        "sponsorName": "Janssen Pharmaceutica NV"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "multistem",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "cell therapies",
    "notes": "the multistem cells express a range of therapeutically-relevant proteins that act like drugs,planning to start phase 2/3 clinical trial by 06/30/2020,completed phase 1/2 clinical trial on july 2019,fast-track designation by the fda",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "multistem",
    "productId": 369,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a3a12b6d931e87c4b8d0d2273853f647cf3c65f",
        "sponsorName": "Athersys"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "inhalded mrna",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["switzerland", "germany"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "nucleic acid based therapies/vaccines",
    "notes": "manufacturing intended to initiate summer 2020,expected clinical testing in 4th quarter of 2020 pending regulatory approval",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "inhalded_mrna",
    "productId": 370,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1d194ed49d10f544c68a1c9d4116020692ba8b5b",
        "sponsorName": "Neurimmune"
      },
      {
        "sponsorId": "c6ddaeaa6ff1e400a4d8f29afd9415df2398bd02",
        "sponsorName": "Ethris"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "novaferon",
    "chemicalName": "",
    "conditionOrDisease": "covid-19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "currently licensed in china for treatment of hepatitis b,started recruiting for phase 4 clinical trial(hu'nan) for covid-19 patients,also in testing in another phase 4 clinical trail (zhejiang) for covid-19 patients",
    "numSites": "2",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "novaferon",
    "productId": 371,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Changsha",
        "country": "CN",
        "lat": 28.301619,
        "lng": 113.005226,
        "locationId": "7d74876fa86db5e0515db8ea5fddc1e6c0e94db9",
        "name": "Kaifu District, Changsha, Changsha, Hunan, China",
        "state": "Hunan"
      },
      {
        "city": "Changsha Shi",
        "country": "CN",
        "lat": 28.187002,
        "lng": 112.993998,
        "locationId": "fe1810e08ea511e10cee133f11f445d51f8ef85d",
        "name": "139 Renmin Middle Rd, Yuan Jia Ling Shang Quan, Furong Qu, Changsha Shi, Hunan Sheng, China",
        "state": "Hunan Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "818e1de4129b2f52a53d8da808ff6c036588610d",
        "sponsorName": "The First Hospital of Changsha"
      },
      {
        "sponsorId": "815809b19bd18eae88cb00c73fd9f3bbc9764dd3",
        "sponsorName": "The Second Xiangya Hospital of Central South University"
      },
      {
        "sponsorId": "9e8c8e9d300f14660fbd928824d2e2e27fbba9ce",
        "sponsorName": "First Affiliated Hospital of Zhejiang University Medical School"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": "chictr2000029496"
  },
  {
    "brandName": "bio-11006",
    "chemicalName": "",
    "conditionOrDisease": "ards",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 05 Aug 2017 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "currently tested in a pilot phase 2a clinical trial",
    "numSites": "5",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "bio11006",
    "productId": 372,
    "repurposed": "new",
    "siteLocations": [
      {
        "city": "Chicago",
        "country": "US",
        "lat": 41.8952146,
        "lng": -87.623156,
        "locationId": "0864353e5fd81f680fa36519372b36c12c883411",
        "name": "150 E Huron St #900, Chicago, IL 60611, USA",
        "state": "IL"
      },
      {
        "city": "Chapel Hill",
        "country": "US",
        "lat": 35.906058,
        "lng": -79.052199,
        "locationId": "4bc3f5efa1b8e2f249aebefc75115670eaeb7736",
        "name": "321 S Columbia St, Chapel Hill, NC 27516, USA",
        "state": "NC"
      },
      {
        "city": "Winston-Salem",
        "country": "US",
        "lat": 36.1355052,
        "lng": -80.2791958,
        "locationId": "c9a1e80ffa11c3206da6ac5680ccea9e55d5877b",
        "name": "1834 Wake Forest Rd, Winston-Salem, NC 27109, USA",
        "state": "NC"
      },
      {
        "city": "Philadelphia",
        "country": "US",
        "lat": 39.9522188,
        "lng": -75.1932137,
        "locationId": "fd50de0b19383601201bf3bce226675c64801250",
        "name": "Philadelphia, PA 19104, USA",
        "state": "PA"
      },
      {
        "city": "Nashville",
        "country": "US",
        "lat": 36.1447034,
        "lng": -86.8026551,
        "locationId": "687ff5c6a8fb09ad52f79b7400975131eba3498e",
        "name": "2201 West End Ave, Nashville, TN 37235, USA",
        "state": "TN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ee0168c868efcb79c99cceb1ad9c4b367356e247",
        "sponsorName": "Biomarck Pharmaceuticals"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": "nct03202394"
  },
  {
    "brandName": "nafamostat",
    "chemicalName": "nafamostat mesylate",
    "conditionOrDisease": "covid-19",
    "countries": ["japan"],
    "countryCodes": ["jpn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "currently recruiting for phase 2/3 clinical trial in padova-italy,set to start a unknown phase clinical trial at national center for global health and medicine in april 2020,requested eua from fda with planned phase 1/2 clinical trial in united states at unknown start time",
    "numSites": "",
    "otherPartners": "",
    "phase": "2/3",
    "preferredName": "nafamostat_mesylate",
    "productId": 373,
    "repurposed": "repurposed-approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ab1e8ad3d379bcd134e4e3f47f828591f21bca7b",
        "sponsorName": "University of Tokyo"
      },
      {
        "sponsorId": "e5fd2e305fd3cf838a58fa49356e6a687de59229",
        "sponsorName": "Ensysce Biosciences"
      },
      {
        "sponsorId": "e22bdba3cbf2ef89fffeee543c2f866f142cd77f",
        "sponsorName": "National Center for Global Health Medicine"
      },
      {
        "sponsorId": "fee8ee418bcb93a56059c6670596e6c18214fd42",
        "sponsorName": "University Hospital Padova"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-antiretrovirals",
    "trialId": "nct04352400"
  },
  {
    "brandName": "activase",
    "chemicalName": "alteplase",
    "conditionOrDisease": "ards",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "ards",
    "interventionType": "therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "fda-approved for treating blood clots but currently in phase 2 clinical trial for covid-19 patients,therapeutic approach is human tissue plasminogen activator",
    "numSites": "3",
    "otherPartners": "national institutes of health,department of defense peer reviewed medical research program",
    "phase": "2",
    "preferredName": "alteplase",
    "productId": 374,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Aurora",
        "country": "US",
        "lat": 39.7427323,
        "lng": -104.8391914,
        "locationId": "917d2169ec93c3a7fdd8c6b39f395ded56173605",
        "name": "1665 Aurora Ct, Aurora, CO 80045, USA",
        "state": "CO"
      },
      {
        "city": "Denver",
        "country": "US",
        "lat": 39.7282404,
        "lng": -104.9910801,
        "locationId": "ef49a55526a0940a015e8051a6cdf6f6acfec1e0",
        "name": "777 Bannock St, Denver, CO 80204, USA",
        "state": "CO"
      },
      {
        "city": "Boston",
        "country": "US",
        "lat": 42.3397365,
        "lng": -71.1049051,
        "locationId": "2555602f9d5c4ca55c835a0a2a105736a64a6664",
        "name": "330 Brookline Ave, Boston, MA 02215, USA",
        "state": "MA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b03aa77c14c56ff5b4f5d3426dfb679c28ea44f9",
        "sponsorName": "Beth Israel Deaconess"
      },
      {
        "sponsorId": "4c60ee4e3a2c0a8b5e660916048f460f70033ae3",
        "sponsorName": "University of Colorado Anschultz Medical Campus"
      },
      {
        "sponsorId": "aeb9a00ace7546f0b60499cf3dd4a85be50b4e0d",
        "sponsorName": "Denver Health"
      },
      {
        "sponsorId": "3ef65938333d443798d2043926bf988ac4c3c305",
        "sponsorName": "Genentech"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": "nct04357730"
  },
  {
    "brandName": "chimigen vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chimigen_vaccine",
    "productId": 447,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8f43d7087cc0c2a8d9687603029d4f8c7c3e6446",
        "sponsorName": "Akshaya Bio Inc"
      },
      {
        "sponsorId": "66f07a8584ac1fa31540d4786854faf6c4aa3957",
        "sponsorName": "Cytovance Biologics"
      },
      {
        "sponsorId": "979bfa8ba62f21bb1e1f2b82b0e6aeb823504607",
        "sponsorName": "Shenzhen Hepalink Pharmaceutical Group Co Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "brilacidin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "brilacidin",
    "productId": 448,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1d734ed76d96923533eb179ad68641d15e10b3a1",
        "sponsorName": "Innovation Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "kineret",
    "chemicalName": "anakinra",
    "conditionOrDisease": "covid-19",
    "countries": ["netherlands"],
    "countryCodes": ["nld"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "protein-based (including monoclonal antibodies)",
    "notes": "currently testing in phase 4 clinical trial named remap-cap that was updated to include a sub-platform  remap-covid for covid-19 patients,also testing in numerous other phase 2/3 clinical trials",
    "numSites": "89",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "anakinra",
    "productId": 375,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": null,
        "country": "AU",
        "lat": -25.274398,
        "lng": 133.775136,
        "locationId": "a61170b4619aea108d7986ecaae599eebf2b646d",
        "name": "Australia",
        "state": null
      },
      {
        "city": null,
        "country": "BE",
        "lat": 50.503887,
        "lng": 4.469936,
        "locationId": "bbe199a56d414e6702a21b3bbff9c6096750ddb1",
        "name": "Belgium",
        "state": null
      },
      {
        "city": null,
        "country": "CA",
        "lat": 56.130366,
        "lng": -106.346771,
        "locationId": "5669aed945a834dee5d6a60ed16f15d827dc6d59",
        "name": "Canada",
        "state": null
      },
      {
        "city": null,
        "country": "HR",
        "lat": 45.1,
        "lng": 15.2000001,
        "locationId": "8960113254097ba5b5cb9501075534fa8a567bef",
        "name": "Croatia",
        "state": null
      },
      {
        "city": null,
        "country": "DE",
        "lat": 51.165691,
        "lng": 10.451526,
        "locationId": "84f52327e64ffd1f8ee2c03456a1d11cfbd079dd",
        "name": "Germany",
        "state": null
      },
      {
        "city": null,
        "country": "HU",
        "lat": 47.162494,
        "lng": 19.5033041,
        "locationId": "dca59f29cb5be9c52fad5708938952c46b32b328",
        "name": "Hungary",
        "state": null
      },
      {
        "city": null,
        "country": null,
        "lat": 53.1423672,
        "lng": -7.692053599999999,
        "locationId": "814c0330d8f6e33f6a76889e94c1dc3a6676e2c2",
        "name": "Ireland",
        "state": null
      },
      {
        "city": null,
        "country": "NL",
        "lat": 52.132633,
        "lng": 5.291265999999999,
        "locationId": "e247f73b20232bb614b9c54a15dba283dc8f36fa",
        "name": "Netherlands",
        "state": null
      },
      {
        "city": null,
        "country": "NZ",
        "lat": -40.900557,
        "lng": 174.885971,
        "locationId": "93880e9b5562e686a1dc8e3b75456c48624e81cb",
        "name": "New Zealand",
        "state": null
      },
      {
        "city": null,
        "country": "PT",
        "lat": 39.39987199999999,
        "lng": -8.224454,
        "locationId": "3fa665f31954b25a72aafcdca7d93a5c8188d26d",
        "name": "Portugal",
        "state": null
      },
      {
        "city": null,
        "country": "RO",
        "lat": 45.943161,
        "lng": 24.96676,
        "locationId": "463d640868e7f7e932a6dda80eb7cf4050cb4e92",
        "name": "Romania",
        "state": null
      },
      {
        "city": null,
        "country": "ES",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "c5ca8a1f2d70b076740f0a00d8bbbf04473a220a",
        "name": "Spain",
        "state": null
      },
      {
        "city": null,
        "country": "GB",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "2277e7e5c959e1fe18d001ee5083d2e32a8ca8b5",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "584eb38a0c9689f77c37d2ae76a472d221834c3c",
        "sponsorName": "Swedish Orphan Biovitrum"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "nct02735707"
  },
  {
    "brandName": "pp-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["austria"],
    "countryCodes": ["aut"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "drug has just completed a phase 2 clinical trial for treatment of severe eye disesases,article states that clinical trials for covid-19 could begin shortly.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "pp001",
    "productId": 376,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d84536309abcf2b1a75abfa06c2300e2a5917cb8",
        "sponsorName": "Panoptes Pharma GmbH"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "xeljanz",
    "chemicalName": "tofacitinib",
    "conditionOrDisease": "pneumonia",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "pneumonia",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "fda approved to treat arthritis and colitis,currently testing in phase 2 clinical trial for covid-19 related pneuomia",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "tofacitinib",
    "productId": 377,
    "repurposed": "repurposed-approved",
    "siteLocations": [
      {
        "city": "Torrette, Ancona",
        "country": "IT",
        "lat": 43.6026491,
        "lng": 13.4538759,
        "locationId": "a0e456e124d18bf658cdcb309469fdc71c745333",
        "name": "Via Conca, 71, 60030 Torrette, Ancona AN, Italy",
        "state": "Marche"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "kinase inhibitors",
    "trialId": "nct04332042"
  },
  {
    "brandName": "bld-2660",
    "chemicalName": "",
    "conditionOrDisease": "sars-cov2",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "caplain (protease) inhibitor,used to be a drug to treat fibrosis",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "bld2660",
    "productId": 378,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "89667736796d6828f9626bcd8b0fbb2b3f0c30ba",
        "sponsorName": "Blade Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": "nct04334460"
  },
  {
    "brandName": "aplidin",
    "chemicalName": "plitidepsin",
    "conditionOrDisease": "",
    "countries": ["spain"],
    "countryCodes": ["esp"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "small molecule",
    "notes": "previously approved in australia to treat multiple myeloma",
    "numSites": "",
    "otherPartners": "pharmamar",
    "phase": "2",
    "preferredName": "plitidepsin",
    "productId": 379,
    "repurposed": "repurposed-not approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "880c99550c8a42deeaff83ad0902af0b020c8848",
        "sponsorName": "Centro Nacional Biotecnologia"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "this consortium includes many different groups that are making different drugs,one main group involved is adaptvac (line 79)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "preventncov_consortium-380",
    "productId": 380,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "af0e9043938d3ffd18d4aa4f263c303abe7a87c1",
        "sponsorName": "PREVENTnCoV consortium"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["india"],
    "countryCodes": ["ind"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "biological_e_ltd-381",
    "productId": 381,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "18d359f3a6a2fc44b7f04abc4ab8baad62117955",
        "sponsorName": "Biological E Ltd"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["australia"],
    "countryCodes": ["aus"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaxine_pty_ltd_flinders_university-382",
    "productId": 382,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b103c316060fe38a9bb6cb32740cba7009ff4993",
        "sponsorName": "Vaxine Pty Ltd"
      },
      {
        "sponsorId": "5b15122e16efd5040af4ad925335499c22697ac0",
        "sponsorName": "Flinders University"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united kingdom"],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "university_of_cambridge_diosynvax-383",
    "productId": 383,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "83c94185cc09e66de46b286461805b6666ee47e1",
        "sponsorName": "University of Cambridge"
      },
      {
        "sponsorId": "7d21b3cf2e2c033e713858c5883640d91677f72e",
        "sponsorName": "DIOSynVax"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["russia"],
    "countryCodes": ["rus"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "st_petersburg_scientific_research_institute_of_vaccines_and_serums-384",
    "productId": 384,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1c450dbef9738d9b66fe108c2438eedf9206b820",
        "sponsorName": "St Petersburg Scientific Research Institute of Vaccines and Serums"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "in collaboration with the national research council of canada (nrc),advances on vbi's enveloped virus-like particle vaccines (evlp vaccines)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vbi_vaccines-385",
    "productId": 385,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ccba56f09bfbe72461df11aa67398b87f33bc6a5",
        "sponsorName": "VBI Vaccines"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["russia"],
    "countryCodes": ["rus"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "biocad_iem-386",
    "productId": 386,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7a849d71160735d95f7cfb3ca259e2bb33ed4fb8",
        "sponsorName": "BIOCAD"
      },
      {
        "sponsorId": "05fc10448e3ccf081b100a8e2f7113e804fec492",
        "sponsorName": "IEM"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "intends to help lower the cost for producing vaccines for covid-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "iavi_batavia-387",
    "productId": 387,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "44d1bb59e8c48cd0b43da165d6d9606f2583b5fe",
        "sponsorName": "IAVI"
      },
      {
        "sponsorId": "f2e8788350358421b65552cc2679a931104ad1ab",
        "sponsorName": "Batavia"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "saiba_gmbh-388",
    "productId": 388,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a558e81d8b75a91096450dac109735d6cb004a49",
        "sponsorName": "Saiba GmbH"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "imophoron_ltd-389",
    "productId": 389,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "47418e382f699611afcc07ba422a212ac3cd258e",
        "sponsorName": "Imophoron Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "niclosamide",
    "chemicalName": "duplicate?",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "duplicate",
    "productId": 390,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3f0f11935fb0a109bff465cc279e3b68c954fede",
        "sponsorName": "Ana Therapeutics"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "prtx-007",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["united states"],
    "countryCodes": ["usa"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "small molecule",
    "notes": "activates tlr7 to stimulate innate immune system",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "prtx007",
    "productId": 391,
    "repurposed": "new",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "59184ad543e6f439787b2e2ac1527ea53b1e5ac1",
        "sponsorName": "Primmune Therapeutics"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "other",
    "trialId": ""
  },
  {
    "brandName": "ab00-1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ab001",
    "productId": 392,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "939b55ffb6ce9f4b830c8776c83f2f2116fd16d3",
        "sponsorName": "Agastiya Biotech LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ultomiris",
    "chemicalName": "ravulizumab-cwvz",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ravulizumabcwvz",
    "productId": 393,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "41794d8c7643f99fc7895546d19147d1b41daf20",
        "sponsorName": "Alexion Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "metablok",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "metablok",
    "productId": 394,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6ae7877eca7b978170ddee9d611fbce51b4868f7",
        "sponsorName": "Arch Biopartners Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "medi-3506",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "medi3506",
    "productId": 395,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e4db405906dfdb58ac2ee1ccf9877fc1ad52116d",
        "sponsorName": "Aztrazeneca plc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "farxiga",
    "chemicalName": "dapagliflozin",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "dapagliflozin",
    "productId": 396,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e4db405906dfdb58ac2ee1ccf9877fc1ad52116d",
        "sponsorName": "Aztrazeneca plc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "igm antibodies,iga antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "igm_antibodies_iga_antibodies",
    "productId": 397,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "300c03c87517131e06a725327908570fd8798f8b",
        "sponsorName": "Atreca Inc"
      },
      {
        "sponsorId": "5a19a0834e482d0229a397f62492ab8dfcd271d9",
        "sponsorName": "Beigene Ltd"
      },
      {
        "sponsorId": "4852c490222a54deb2d41b655f588096c92cb6ad",
        "sponsorName": "IGM Biosciences Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "audax_medical_inc-398",
    "productId": 398,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "06fe14bef7ae50a2f1a152d1eba019ce4b0b33bf",
        "sponsorName": "Audax Medical Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "bemcentinib",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "bemcentinib",
    "productId": 399,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e99b1e4fd130967b98ec911ffe343851949fc17b",
        "sponsorName": "Bergenbio ASA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "anti-viroporin therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviroporin_therapeutic",
    "productId": 400,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8ff2bf908543da634f6c955434fd59ba86816e6d",
        "sponsorName": "Biovista Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "clbs-119",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "clbs119",
    "productId": 401,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "28d929d86c67592db08f4897b313d80028476e9e",
        "sponsorName": "Caladrius Biosciences Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "dociparstat sodium",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "dociparstat_sodium",
    "productId": 402,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b205baf63638325039ee5a5cb8163c92032c7373",
        "sponsorName": "Chimerix Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "itanapraced",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "itanapraced",
    "productId": 403,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b3fae6fd4eeae1f99462dfff0a75d2eab3c4253a",
        "sponsorName": "Cerespir Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "niagen",
    "chemicalName": "nicotinamide riboside",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nicotinamide_riboside",
    "productId": 404,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e44b4742cbdb4c8802c4d11e460311b5195d0a43",
        "sponsorName": "Chromadex Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "pacritinib",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "pacritinib",
    "productId": 405,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9f40c9583b5968ab1adbdf1d8a099bc79d1c1c88",
        "sponsorName": "CTI Biopharma Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cyc-065",
    "chemicalName": "fadraciclib",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fadraciclib",
    "productId": 406,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae",
        "sponsorName": "Cyclacel Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cyc-202,r-roscovitine",
    "chemicalName": "seliciclib",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "seliciclib",
    "productId": 407,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae",
        "sponsorName": "Cyclacel Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ryanodex",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ryanodex",
    "productId": 408,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6bd89fd19b2baf31fb93f1a63de6b53953ee9577",
        "sponsorName": "Eagle Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "edesa_biotech_inc_light_chain_bioscience_novimmune_sa-409",
    "productId": 409,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "df7336e82b3ee964918b55e0124c5c863386b59e",
        "sponsorName": "Edesa Biotech Inc"
      },
      {
        "sponsorId": "9898e6e8a31d2229ba186cbe74951fc0875a5ae1",
        "sponsorName": "Light Chain Bioscience"
      },
      {
        "sponsorId": "18504c03801e154a688184f061e282ba41d0c0e4",
        "sponsorName": "Novimmune SA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "zotatifin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "zotatifin",
    "productId": 410,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d2b4445d416dbf8501b919b961f16cb45cf218d9",
        "sponsorName": "Effector Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 411,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "09467ddba3462cd3be13db3493e74a1cd13ee832",
        "sponsorName": "Fairjourney Biologics SA"
      },
      {
        "sponsorId": "e461e3fcff3dfbf264418228bb2872ec75a77d64",
        "sponsorName": "Iontas Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fusion_antibodies_plc-412",
    "productId": 412,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4c15e115bbf73c231a08f5b902eca1c36dbc7fe1",
        "sponsorName": "Fusion Antibodies plc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 413,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3f5e70ee0770a61cea95a52724b629ed752e8d50",
        "sponsorName": "Hemogenyx Pharmaceuticals plc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "imu-838",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "imu838",
    "productId": 414,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8ebeaa89bdf967acb860530de89f2bf521947797",
        "sponsorName": "Immunic Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "tnf inhibitor",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tnf_inhibitor",
    "productId": 415,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8f0e3543fdf32bd70090945d74cdf9d835d0edcb",
        "sponsorName": "Immune Bio Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cannabidiol-loaded exosomes",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cannabidiolloaded_exosomes",
    "productId": 416,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f5509fdc8d977098de524cfe1324119bca44d958",
        "sponsorName": "Innocan Pharma Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ins-1007",
    "chemicalName": "brensocatib",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "brensocatib",
    "productId": 417,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e97f167fe7a9cdf40d469f7fe1f8fc68fcce2030",
        "sponsorName": "Insmed Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "sonlicromanol",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sonlicromanol",
    "productId": 418,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "515553435142eb535852e295f3bd6c501327f36b",
        "sponsorName": "Khondrion BV"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vap-1 inhibitors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vap1_inhibitors",
    "productId": 419,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e738bf6a692bdb6a103840a21c304833dc861452",
        "sponsorName": "Kubota Vision Inc"
      },
      {
        "sponsorId": "267bf8e98b940f881544a2ce9ccf3dca31f50926",
        "sponsorName": "Leo Pharma AS"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "xav-19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "xav19",
    "productId": 420,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e051009634417c8e337feeb1e73c8c03b2ff106c",
        "sponsorName": "LFB SA"
      },
      {
        "sponsorId": "39f19090c785e55de80ad34b54bc88b1ea610d27",
        "sponsorName": "Kenothera SAS"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "carragelose inhalation therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "carragelose_inhalation_therapy",
    "productId": 421,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b76c240d33285d07cee07c91c6542ec704092b3e",
        "sponsorName": "Marinomed Biotech AG"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviral",
    "productId": 422,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "156f730ad2e8e71aaec7362be122a0c821d51c14",
        "sponsorName": "Molecular Partners AG"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "veyonda",
    "chemicalName": "idronoxil",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "idronoxil",
    "productId": 423,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "98fbd4c7c935e48e7246ffa9696377e27973373d",
        "sponsorName": "Noxopharm Co"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "peptides",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptides",
    "productId": 424,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de93cb0c4a3bc024e5f42b0cf2117729b320a781",
        "sponsorName": "Nuritas Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "2x-121",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "2x121",
    "productId": 425,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7c3734e76aa183a3eb2e24a57c0009a112b44055",
        "sponsorName": "Oncology Ventures AS"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "camostat mesylate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "camostat_mesylate",
    "productId": 426,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4c42301126ac99d75b7be429df5e77830bc45d8b",
        "sponsorName": "Ono Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vafidemstat",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vafidemstat",
    "productId": 427,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "54df2e1eb201b7a6fc15d098af3042d22ffa6dde",
        "sponsorName": "Oryzon Genomics SA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "q_biomed_inc_mannin_research-428",
    "productId": 428,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b275b8324ed9b360015738d5c52283b783d3e511",
        "sponsorName": "Q Biomed Inc"
      },
      {
        "sponsorId": "6369487c22ff53cc21139097558058341e98e631",
        "sponsorName": "Mannin Research"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "recursion_pharmaceuticals_inc-429",
    "productId": 429,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "11fe98d508be31415b00d71b9e4504f2beb1ee7a",
        "sponsorName": "Recursion Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "rtb-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "rtb101",
    "productId": 430,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2afef1b9b3945cdfc232fc3cd9fc8ed8d184003f",
        "sponsorName": "Restorbio Inc"
      },
      {
        "sponsorId": "b284e0fd16c925a93e4f38c453f4c70e7636b223",
        "sponsorName": "Adicet Bio Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "rt-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "rt001",
    "productId": 431,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "db62040470630e8a5c0d95e03ff88dcb0d440132",
        "sponsorName": "Retrotope Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "nt-300",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nt300",
    "productId": 432,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1a4907ea590dbc75efbbb16b2e8f00a1c68f3cf6",
        "sponsorName": "Romark Laboratories LC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "olokizumab,rph-104",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "olokizumab_rph104",
    "productId": 433,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "101d14f6d9ef50bd326177b2fd9683e6cfe02662",
        "sponsorName": "RPharm JSC"
      },
      {
        "sponsorId": "1e8c65f7ae6e1857da235f503ee96eecdfc212b5",
        "sponsorName": "Cromos Pharma LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "pol-6014",
    "chemicalName": "ionodelestat",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ionodelestat",
    "productId": 434,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6e39bc194deb64616e841179d70de0e3e8f6e7ad",
        "sponsorName": "Santhera Pharmaceuticals Holding AG"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "antisense oligonucleotides",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antisense_oligonucleotides",
    "productId": 435,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "318a3819bc03871596e0a772e1caa9643afd627c",
        "sponsorName": "Sarepta Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "shionogi__co_ltd-436",
    "productId": 436,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "49af49978e8b9f02c1384c21ddd1c7526817f753",
        "sponsorName": "Shionogi  Co Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "cynarine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "cynarine",
    "productId": 437,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "prexasertib",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "prexasertib",
    "productId": 438,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "xerava",
    "chemicalName": "eravacycline",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "eravacycline",
    "productId": 439,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      },
      {
        "sponsorId": "83cfc31290e69df07985c4197a3d92ab4c6b2d1c",
        "sponsorName": "Tetraphase Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "llama-derived antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "llamaderived_antibodies",
    "productId": 440,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "94b9fb08c2b9a96fe640774a647230d6d7a7b34c",
        "sponsorName": "Sysvax Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ppp-003",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ppp003",
    "productId": 441,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d64052c9fc506bd796cd3404142772d1197adf54",
        "sponsorName": "Tetra BioPharma Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "allorx stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "allorx_stem_cells",
    "productId": 442,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2a124d615112a39893fb8a499cdb57c08486b0e4",
        "sponsorName": "Vitro Diagnostics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vbi-s",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vbis",
    "productId": 443,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96b4ec30be2b8b138d6a097ca033241b0479fed5",
        "sponsorName": "Vivacelle Bio Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "pathogen-specific aapc",
    "chemicalName": "",
    "conditionOrDisease": "covid 19",
    "countries": ["china"],
    "countryCodes": ["chn"],
    "currentStatus": "",
    "indication": "covid-19",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "subunit vaccines",
    "notes": "covid-19/aapc vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells",
    "numSites": "3",
    "otherPartners": "shenzhen third people's hospital,shenzhen second people's hospital",
    "phase": "1",
    "preferredName": "pathogenspecific_aapc",
    "productId": 452,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "ongoing",
    "therapeuticApproach": "vaccine",
    "trialId": "nct04299724"
  },
  {
    "brandName": "orapro-covid-19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "oraprocovid19",
    "productId": 453,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d3558ec7487260af8eeda161f466322bb598e734",
        "sponsorName": "Stabilitech Biopharma Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vivagel,spl-7013",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vivagel_spl7013",
    "productId": 454,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8d39bbb89598527ce93987da7ed5e69cefec828b",
        "sponsorName": "Starpharma Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vlp vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vlp_vaccine",
    "productId": 455,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "94b9fb08c2b9a96fe640774a647230d6d7a7b34c",
        "sponsorName": "Sysvax Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "baculovirus expression vector system vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "baculovirus_expression_vector_system_vaccine",
    "productId": 456,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "85a7bc9d8e40313776bed1f5693ea229f6014f09",
        "sponsorName": "UMN Pharma Inc"
      },
      {
        "sponsorId": "2a31f723919cc93c85ccb5d42e4a9fb7445136d2",
        "sponsorName": "Shinogi  Co Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ixiaro",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ixiaro",
    "productId": 457,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "059f2a3d5a1e49d84849751adc693a806e10964c",
        "sponsorName": "Valneva SE"
      },
      {
        "sponsorId": "8e7b2da49f08d6b67425d83fea0307211169ec91",
        "sponsorName": "Dynavax Technologies Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "pepticrad vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "pepticrad_vaccine",
    "productId": 458,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "647f2087ef04f50197602c4a93c8cd00e43f1216",
        "sponsorName": "Valo Therapeutics Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "vaxipatch vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "vaxipatch_vaccine",
    "productId": 459,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d55c14eadb5f58261f7259e0d7eeaa8926742a23",
        "sponsorName": "Verndari Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["gbr"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "vaccine - prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "viravaxx_ag-460",
    "productId": 460,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b49bbd5f20c2dcea7a6b4e32bbe73978f88a8fce",
        "sponsorName": "Viravaxx AG"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  }
]
